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Abstract 
The phosphodiesterase 4 (PDE4) family are cAMP specific phosphodiesterases 
that play an important role in the inflammatory response and is the major PDE 
type found in inflammatory cells. A significant number of PDE4 specific inhibitors 
have been developed and are currently being investigated for use as therapeutic 
agents. Apremilast, a small molecule inhibitor of PDE 4 is in development for 
chronic inflammatory disorders and has shown promise for the treatment of 
psoriasis, psoriatic arthritis as well as other inflammatory diseases. It has been 
found to be safe and well tolerated in humans and in March 2014 it was 
approved by the US food and drug administration for the treatment of adult 
patients with active psoriatic arthritis. The only other PDE4 inhibitor on the 
market is Roflumilast and it is used for treatment of respiratory disease. 
Roflumilast is approved in the EU for the treatment of COPD and was recently 
approved in the US for treatment to reduce the risk of COPD exacerbations. 
Roflumilast is also a selective PDE4 inhibitor, administered as an oral tablet once 
daily, and is thought to act by increasing cAMP within lung cells. As both 
(Apremilast and Roflumilast) compounds selectively inhibit PDE4 but are 
targeted at different diseases, there is a need for a clear understanding of their 
mechanism of action (MOA). Differences and similarity of MOA should be defined 
for the purposes of labelling, for communication to the scientific community, 
physicians, and patients, and for an extension of utility to other diseases and 
therapeutic areas.  In order to obtain a complete comparative picture of the 
MOA of both inhibitors, additional molecular and cellular biology studies are 
required to more fully elucidate the signalling mediators downstream of PDE4 
inhibition which result in alterations in pro- and anti-inflammatory gene 
expression. My studies were conducted to directly compare Apremilast with 
Roflumilast, in order to substantiate the differences observed in the molecular 
and cellular effects of these compounds, and to search for other possible 
differentiating effects. Therefore the main aim of this thesis was to utilise 
cutting-edge biochemical techniques to discover whether Apremilast and 
Roflumilast work with different modes of action.   
In the first part of my thesis I used novel genetically encoded FRET based cAMP 
sensors targeted to different intracellular compartments, in order to monitor 
cAMP levels within specific microdomains of cells as a consequence of challenge 
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with Apremilast and Roflumilast, which revealed that Apremilast and Roflumilast 
do regulate different pools of cAMP in cells.  
In the second part of my thesis I focussed on assessing whether Apremilast and 
Roflumilast cause differential effects on the PKA phosphorylation state of 
proteins in cells. I used various biochemical techniques (Western blotting, 
Substrate kinase arrays and Reverse Phase Protein array and found that 
Apremilast and Roflumilast do lead to differential PKA substrate 
phosphorylation. For example I found that Apremilast increases the 
phosphorylation of Ribosomal Protein S6 at Ser240/244 and Fyn Y530 in the S6 
Ribosomal pathway of Rheumatoid Arthritis Synovial fibroblast and HEK293 cells, 
whereas Roflumilast does not. This data suggests that Apremilast has distinct 
biological effects from that of Roflumilast and could represent a new 
therapeutic role for Apremilast in other diseases.  
In the final part of my thesis, Phage display technology was employed in order to 
identify any novel binding motifs that associate with PDE4 and to identify 
sequences that were differentially regulated by the inhibitors in an attempt to 
find binding motifs that may exist in previously characterised signalling proteins. 
Petide array technology was then used to confirm binding of specific peptide 
sequences or motifs. Results showed that Apremilast and Roflumilast can either 
enhance or decrease the binding of PDE4A4 to specific peptide sequences or 
motifs that are found in a variety of proteins in the human proteome, most 
interestingly Ubiquitin-related proteins. The data from this chapter is 
preliminary but may be used in the discovery of novel binding partners for PDE4 
or to provide a new role for PDE inhibition in disease.   
Therefore the work in this thesis provides a unique snapshot of the complexity of 
the cAMP signalling system and is the first to directly compare action of the two 
approved PDE4 inhibitors in a detailed way. 
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Definitions/Abbreviations 
 
aa   amino acid 
Ab   Antibody 
AC   Adenylyl cyclase 
AKAP    A-kinase anchoring protein 
AKAR   A-kinase activity reporter 
AMP   Adenosine monophosphate 
AR     Adrenergic receptor 
ATP     Adenosine triphosphate 
AC    adenylyl cyclases 
AKAP    A Kinase anchoring protein 
ANOVA   analysis of variance 
ATP   adenosine triphosphate 
-AR    β-adrenergic receptor 
BSA     Bovine serum albumin 
C    PKA catalytic subunit 
cAMP    3’, 5’ cyclic adenosine monophosphate 
cGMP   3’, 5’ cyclic guanosine monophosphate 
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 CCD    charged-coupled device 
 CFP   cyan fluorescent protein  
cGMP   3’, 5’ cyclic guanosine monophosphate  
CBD    cyclic nucleotide binding domains 
 CNB   Cyclic nucleotide-binding domains  
CNG    Cyclic nucleotide-Gated Channels 
 CRE    cAMP response element 
 CREB   CRE binding protein  
COPD    Chronic obstructive pulmonary disease 
DAG    diacylglycerol 
 DEP   Dishevelled, Egl-10, and Pleckstrin 
DMEM   Dulbecco’s modified Eagle’s medium  
DMSO   Dimethylsulfoxide 
 ECC    excitation-contraction coupling 
ECL    Enhanced chemiluminescence 
 E.coli   Escherichia coli  
EPAC    exchange proteins directly activated by cAMP 
Epac    Exchange protein directly activated by cAMP  
ERK    Extracellular signal regulated kinase 
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FRET    fluorescence resonance energy transfer 
FSK     Forskolin 
GDP   guanosine diphosphate 
GEF     Guanine nucleotide exchange factor 
GFP    Green fluorescent protein 
Gi     Inhibitory G protein 
GPCR   G protein-coupled receptor 
Gs     Stimulatory G protein 
GTP   guanosine triphosphate 
HEK    Human embryonic kidney 
IBMX   3-isobutyl-1-methylxantine 
IC50   Half maximal inhibitor concentration 
IP3   inositol-triphosphate 
ISO    isoproterenol 
Makap   Muscle-specific A-kinase anchoring protein 
MAPK   Mitogen-activated protein kinase 
MEF    Myocyte enhancer factor 
mRNA   Messenger RNA 
OD   optical density 
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PDE    phosphodiesterase 
PPi   Inorganic Pyrophosphate  
PGE1    prostaglandin E1  
PIP3    Phosphatidylinositol-trisphosphate 
PKA    cAMP-dependent protein kinase 
PKG    cGMP-dependent protein kinase 
PKC    Protein kinase C  
PKD    Protein kinase D  
PKI    Protein kinase inhibitor  
PP1   proteins phosphatase 1  
PP2A    protein phosphatase 2A 
 PPi    inorganic pyrophosphate  
PsA    Psoriatic Arthritis 
RA    Ras-association domain  
RASF `  Rheumatoid Arthritis Synovial Fibroblasts 
RPPA  Reverse Phase Protein Array 
SEM    standard error of measurement or mean  
TNF    Tumour necrosis factor 
UCR   upstream conserved region 
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YFP    yellow fluorescent protein
 1 Introduction 
1.1 Cyclic 3’ 5’- adenosine monophosphate (cAMP) 
signalling. 
Signal transduction can be defined as the process by which an extracellular 
ligand binds to and activates a cell surface receptor and this in turn initiates a 
series of intracellular signalling cascades. Extracellular ligands are thought of as 
‘first messengers’ in this context and are usually neurotransmitters, hormones, 
chemokines, lipid mediators or drugs which cannot cross the plasma membrane. 
When they interact with a membrane receptor their signals are transduced 
which causes a change in the level of an intracellular second messenger. Second 
messengers are small chemical molecules, gases, ions or lipids which bind to and 
activate protein kinases, channels or other proteins thereby continuing the 
signalling cascade and mediating intracellular responses that are specific to the 
receptor that was activated. 
The first second messenger to be discovered was Cyclic nucleotide3’5’- 
adenosine monophosphate (cAMP) (figure1-1)(Sutherland and Rall 1958). cAMP  is 
a ubiquitous second messenger involved in a variety of cellular responses such as 
inflammation, apoptosis, lipid metabolism, learning and memory, gene 
regulation, immune response, insulin secretion, cell growth, proliferation and 
differentiation(Beavo and Brunton 2002) (Suzuki, J et al. 2002). cAMP was 
discovered by Dr Earl W. Sutherland during his studies into the mechanisms of 
hormone action (Sutherland and Rall 1958). Other second messengers include the 
nucleotide cyclic 3’5’-guanine monophosphate (cGMP), calcium and the 
phosphatidylinositol derivatives inositol phosphate (IP3) and diacylglycerol (DAG) 
and Nitric Oxide (NO) (Berridge 1984). 
 25 
 
Figure 1-1 Structure of the second messenger cyclic adenosine 3’5’-monophoosphate 
(cAMP). The 3’ bond is hydrolysed by phosphodiesterase (PDE) enzymes indicated by the 
arrow (Bender and Beavo 2006). 
 
1.1.1 cAMP generation 
The level of intracellular cAMP is tightly regulated by the balance of two 
enzymes: Adenelyl cyclase (AC)(Sutherland and Rall 1958) and the super family 
of cyclic nucleotide phosphodiesterase (PDEs). The generation of cAMP is 
initiated following ligand binding to a seven transmembrane –spanning G protein 
coupled receptor (GPCR) that is coupled to a stimulatory G protein α subunit 
(Gαs). Ligand binding to the GPCR results in the exchange of GDP for GTP on the 
Gαs protein, which results in the dissociation from the βγ subunit complex 
(Landry, Niederhoffer et al. 2006). The free Gαs subunit then activates adenelyl 
cyclase, the enzyme which catalyses the
 
 
 
cyclisation of adenosine triphosphate (ATP) to generate cAMP and pyrophosphate 
(Sunahara and Taussig 2002, Kamenetsky, Middelhaufe et al. 2006)(figure 1-3). 
There are 10 known AC isoforms that are differentially expressed in various 
tissue types (Sunahara and Taussig 2002) see table 1-1 and 1-2. Some of the best 
characterised Gαs coupled GPCR ligands include epinephrine and 
norepinephrine, histamine and serotonin. cAMP exerts its effects by the 
activation of a limited number of effectors. These are the cAMP dependent 
protein kinase A (PKA), the exchange proteins directly activated by cAMP (Epac 1 
and Epac 2) and the cAMP-gated ion channels (CNG) (figure 1-2). 
Termination of the cAMP signal is mediated by the action of phosphodiesterases 
(PDEs), which hydrolyse 3’5’-cyclic adenosine monophosphate (cAMP) to the 
inactive 5’-adenosine monophosphate (AMP). This action represents the sole 
route for termination of cAMP signals. Therefore intracellular levels of cAMP are 
determined by the balance between generation by adenylyl cyclases (ACs) and 
degradation by phosphodiesterases (PDEs). 
 
 
Table 1-1  Regulatory properties of membrane-bound ACs. (Sadana and Dessauer 2009). 
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Table 1-2  Tissue distribution of ACs. Adapted from (Sadana and Dessauer 2009) 
 
 
 28 
 
Figure 1-2  Overview of cAMP signalling in cells.  cAMP is produced following stimulation of 
7-transmembrane domain receptors (GPCRs) at the plasma membrane. These receptors 
couple to G-proteins, which activate adenylyl cyclases leading to the conversion of ATP into 
cAMP. The effects of cAMP within the cell are mediated by three distinct effector proteins: 
PKA, EPAC and Cyclic nucleotide-channels. cAMP is degraded by phosphodiesterase 
enzymes. 7-TM, 7-transmembrane domain receptor; G, G-protein; AC, adenylyl cyclase; 
PKA, cAMP dependent protein kinase A; PDE, phosphodiesterase. 
. 
 
 
Figure 1-3 Conversion of ATP to cylic adenosine 3’5’-monophosphate (cAMP) by adenylyl 
cyclase enzymes. Adenylyl cyclases catalyse the conversion of ATP to pyrophosphate (PPi) 
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and 3’5-cAMP, which acts as a second messenger in cells. PDE hydrolyse the catalytic 
cleavage of cAMP to 5’AMP, terminating the cAMP signal (Section 1.3, (figure 1-1). 
 
1.1.2 cAMP Compartmentalisation 
Levels of cAMP do not rise and fall uniformly in cells and in fact are 
compartmentalised into microdomains controlled by proximity to the generating 
adenylyl cyclases and the phosphodiesterases that degrade it to 5’AMP.  Such 
sculpting of cAMP pools underpins the specificity of receptor function. 
Compartmentalisation is a key feature of cyclic nucleotide signalling with 
phosphodiesterases playing a pivotal role in achieving spatial control of cAMP, 
since phosphodiesterases are the only known route of cAMP degradation.  
Once cAMP is synthesised it interacts with several spatially restricted effector 
proteins, primarily the cAMP-dependent serine-threonine protein kinase A (PKA) 
and exchange protein activated by cAMP (EPAC) (Tasken and Aandahl 2004, Bos 
2006). 
1.1.2.1 Protein Kinase A (PKA) 
The primary target of cAMP is Protein Kinase A (PKA), which is a heterotetramer 
composed of two cAMP binding regulatory (R) subunits, together with 2 catalytic 
(C) subunits. There are two major subtypes of the regulatory subunits known as 
type I and type II R subunits (Lee, Carmichael et al. 1983, Takio, Smith et al. 
1984). Depending on whether a type I or type II regulatory subunit is present, 
PKA holoenzymes are classified as either type I or type II. Each R subunit 
contains two cAMP binding sites, which when occupied by cAMP, leads to a 
conformational change in the enzyme releasing the active C subunits which can 
then phosphorylate their substrate protein (Taylor, Kim et al. 2005). PKA C 
subunits phosphorylate their target proteins on serine-threonine residues which 
are typically found in a consensus sequence of R-R-X-S/T-X (Kemp, Graves et al. 
1977) (Figure 1-4). 
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Figure 1-4 Activation of the cAMP-dependent protein kinase (PKA) in response to increased 
cAMP levels. When cAMP is low, PKA exists as an inactive heterotetramer with and R2C2 
conformation. The two catalytic subunits are maintained in an inhibited state by the 
regulatory subunits. When cAMP levels are raised, cAMP binds to the R-subunits with 2:1 
stoichometry. Active C-subunits are then released to go on to phosphorylate their 
downstream targets which are involved in a diverse range of biological processes. 
 
 
1.1.2.2 Exchange Protein activated by cAMP (EPAC) 
Epacs are guanine nucleotide exchange factors (GEFs) for Rap 1 and Rap 2 (de 
Rooij, Zwartkruis et al. 1998). These Rap GTPases cycle between an inactive 
GDP-bound state and an active GTP-bound state with GEFs mediating this 
exchange of GDP for GTP. The N terminus of Epac 1 contains a regulatory 
domain, which houses a cAMP-binding site, which is similar to those present in 
the R subunit of PKA. In addition to this site, there is also a Disheveled, Egl-10 
and pleckstrin homology (DEP) domain which mediates membrane attachment 
(de Rooij, Zwartkruis et al. 1998). The C-terminal region consists of a catalytic 
domain that is characteristic of exchange factors for the Ras family of GTPases. 
At low levels of cAMP, Epac folds into an inactive state conformation, and steric 
hindrance prevents the binding of Rap. When cAMP binds to the protein, Epac 
unfolds, allowing Rap to bind (Rehmann, Prakash et al. 2003). 
PKA and Epac are intrinsically soluble proteins and subpopulations of each are 
present in the cytosol. However, for compartmentalisation to occur, it is critical 
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that subpopulations of these cAMP effectors are sequestered to specific 
intracellular complexes, whether located at the membrane or in the cytosol 
along with their downstream targets. At different locations, the cAMP effectors 
“sample” the cAMP concentration and drive signalling only when the cAMP 
concentration breaches the threshold of activation of these proteins. 
1.1.2.3 A Kinase Anchoring Proteins (AKAPs) 
The discovery of a family of anchor proteins called AKAPs (A kinase anchoring 
proteins), have been fundamental in establishing the concept of 
compartmentalised cAMP signalling. AKAPs specifically sequester PKA (Tasken 
and Aandahl 2004) (Carnegie, Means et al. 2009) via a short α helical structure 
which interacts with a groove formed by the N-terminal dimerisation domain of 
PKA R- subunits. PKA RII provides the majority of membrane associated PKA 
(Wong and Scott 2004) whereas the majority of R I is generally considered to be 
located in the cytosol (Miki and Eddy 1998, Gronholm, Vossebein et al. 2003). 
Originally it was thought that only PKA R II was able to bind AKAPs, but recent 
evidence suggests that AKAPs can interact specifically with PKA RI (Miki and Eddy 
1998, Gronholm, Vossebein et al. 2003) or with both PKA type RI and II (Huang, 
Durick et al. 1997, Huang, Durick et al. 1997).  
AKAPs not only act as scaffolds for PKA, but also bind additional proteins of the 
cAMP signalling pathway. For example, Phosphodiesterases (PDEs), protein 
phosphatases,a variety of kinases and substrates of PKA (Gronholm, Vossebein et 
al. 2003).   
By hydrolysing cAMP, PDEs act as “sinks” for the otherwise freely diffusible 
cAMP, and this action creates distinct pools of cAMP in the cytoplasm.  Basically 
cAMP only exists in high concentration in areas that are devoid of PDE activity or 
following receptor activation where cAMP can “swamp” the PDE pool in one 
location. So PDEs along with protein phosphatases, which counteract PKA 
mediated phosphorylation, serve to efficiently terminate cAMP signals.  
Some AKAPs can bind both GPCRs and adenylyl cyclases, which therefore directs 
PKA functionality to targets associated with cAMP production. For example 
mAKAP, which is muscle specific, can provide dual output of the cAMP signalling 
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system as it sequesters both Epac and PKA (Dodge-Kafka, Soughayer et al. 2005). 
Therefore sequestered and spatially constrained PKA and Epac subpopulations 
provide the machinery to interpret intracellular cAMP gradients formed by PDEs.  
In the past however, the idea of cAMP being compartmentalised was hard to 
envisage as it was generally considered to be freely diffusible in the cytosol with 
a calculated diffusion constant of – 150-700µm
2
 s-1 (Bacskai, Hochner et al. 1993, 
Kasai and Petersen 1994, Nikolaev, Gambaryan et al. 2005). The traditional 
approach for the measurement of  cAMP was by radioimmunoassay (RIA) which 
utilised anti- cAMP antibodies and radio-labelled cAMP as a tracer, which is 
displaced by the endogenous cAMP present in the sample (Steiner, Kipnis et al. 
1969) resulting in a concentration dependent signal decrease. However, antibody 
based methods can only detect cAMP accumulation at defined time points and so 
only determine total steady state cAMP levels in a cell population, not in a single 
cell which would be desirable in many applications. Therefore RIA failed to 
provide quantitative information required to visualise cAMP gradients in real 
time. Recently this has been solved by the development of genetically encoded 
optical probes that are able to visualise formation of cAMP gradients within 
living cells in real time. 
1.2 Measurement of cAMP gradients using FRET 
Fluorescence Resonance Energy Transfer (FRET) is a method for visualising cAMP 
levels in intact living cells. FRET is a quantum-mechanical event that occurs 
when two flourophores are placed in close proximity to each other (< 100 Å) 
provided that the emission spectrum of the flourophore that acts as the “donor” 
overlaps the excitation spectrum of the acceptor fluorophore. Under these 
conditions, part of the vibrational energy of the excited state of the “donor” is 
transferred to the acceptor that emits its own wavelength. This process results 
in a reduction in the emission of the FRET donor, along with an increase in the 
emission of the FRET acceptor.  The ratio of acceptor/donor emissions can 
therefore be used as a measure of resonance energy transfer.  
The dipole-dipole interactions underlying the FRET phenomenon are highly 
sensitive to distance and orientation of the flourophores. Generally, 
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flourophores must be within 1-10nm of each other for FRET to occur, while at 
the same time maintaining an appropriate spatial orientation.  
The efficiency of this process (E) depends on the distance (R) between the donor 
and acceptor with an inverse sixth power law, as described by Försters  
equation: E=1 /(1+R/R◦)6 (Förster 1948) where R◦ is the distance at which half of 
the energy is transferred. According to the Försters equation, the doubling of 
the distance between the two flourophores, for example, from R◦ to 2 R◦ 
decreases the efficiency of transfer from E=50% to E= 1.5%. Therefore FRET can 
provide a highly sensitive approach to measure intermolecular distance. If the 
two flourophores are held together by proteins that undergo a conformational 
change upon binding to cAMP, FRET can be used to measure cAMP concentration. 
In general, a FRET-based cAMP probe will comprises of two essential 
components: 1) a cAMP sensor, which consists of either two separate interacting 
protein domains or a single protein domain that will undergo a conformational 
change upon cAMP binding and 2) a donor and acceptor fluorophore fused to the 
cAMP sensor. A cAMP induced conformational change will affect the distance or 
the orientation of the two flourophores, and therefore the efficiency of energy 
transfer. Variations in this energy transfer then correlate with changes in cAMP 
concentration. 
A number of FRET biosensors have been developed (figure1-5) (Nikolaev and 
Lohse 2006, Berrera, Dodoni et al. 2008, Willoughby and Cooper 2008).These 
sensors measure relative fluorescence of two fluorescent proteins used as donor 
and acceptor fluorophores, typically cyan (CFP) and yellow fluorescent proteins 
(YFP). These fluorophores are genetically fused to the regulatory and catalytic 
subunits of the cAMP-dependent protein kinase (PKA) (Zaccolo and Pozzan 2002), 
to full length or partially truncated EPAC (DiPilato, Cheng et al. 2004, Nikolaev, 
Bunemann et al. 2004, Ponsioen, Zhao et al. 2004), or to a single cAMP binding 
domain from a cyclic nucleotide-gated channel. The sensors can be expressed in 
the cytoplasm or targeted to specific sub-cellular locations. With such sensors, 
changes in cAMP concentration ([cAMP]i) can be estimated by changes in FRET 
measured as changes in the CFP-to-YFP emissions ratio (480 nm/545 nm), a value 
that is proportional to ([cAMP]i). 
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Many studies have been performed utilising the different PKA and EPAC 
biosensors, which have resulted in data that suggest cAMP has the ability to form 
discrete and often minute gradients within cells as it diffuses from the 
membrane after receptor stimulation. Compartmentalised phosphodiesterases 
play a vital role in this as they control the magnitude and duration of cAMP 
dependent events.(Houslay, Baillie et al. 2007) 
 
Figure 1-5 Genetic engineering of different FRET sensors to monitor real time changes in 
cAMP levels within cells.  
A. FRET sensor based on PKA, with CFP and YFP linked to the R and C subunits of PKA 
respectively. In basal conditions, cAMP is low and PKA is in its inactive conformation. 
Excitation of CFP at 440nm will result in FRET, as CFP and YFP are in close proximity, and 
YFP emission at 545nm. In stimulated cells, cAMP rises. Two molecules of cAMP bind to 
each PKA-R subunit, leading to the dissociation of the active catalytic units. CFP and YFP 
then diffuse further apart and FRET is reduced, leading to detection of CFP emission at 
480nm. Changes in FRET ratio (480/545nm) are directly proportional to R/C subunit 
dissociation, and therefore to cAMP levels (Zaccolo and Pozzan 2002). B. FRET sensor with 
CFP and YFP linked to the cAMP-binding domain of Epac1. Binding of cAMP leads to a 
conformational change in the sensor that moves the fluorophores apart, abolishing FRET 
(Nikolaev, Bunemann et al. 2004). 
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1.3 cAMP degradation by Phosphodiesterases 
cAMP signalling  plays a critical role in a variety of biologic responses within cells 
such as inflammation, apoptosis and lipid metabolism (Tasken and Aandahl 
2004). Phosphodiesterases (PDEs) are the only enzymes that degrade cAMP (Conti 
and Beavo 2007). They belong to a group of 11 families of 
metallophosphohydralases which hydrolyse the cyclic nucleotides, cyclic 
adenosine 3’-5’ monophosphate (cAMP) and cyclic guanine-3’-5’ monophosphate 
(cGMP) to their inactive 5’ monophosphate 5’AMP and 5’GMP respectively (Beavo 
and Brunton 2002)  
Each of family of PDE differ in their selectivity for cAMP and cGMP and are 
characterised by their regulatory and kinetic properties (Beavo, Hansen et al. 
1982) Twenty one genes encoding PDEs have been identified in the human 
genome, and these have been grouped into 11 PDE families based on their amino 
acid sequence, structure, enzyme kinetics, modes of regulation and tissue 
distributions (Conti and Beavo 2007, Houslay 2010) (table1-3). 
Each family of PDE differ in their selectivity for cAMP and cGMP. PDEs 3,4,7 and 
8 selectively hydrolyse cAMP, while PDEs 5,6 and 9 are selective for cGMP. PDEs 
1,2,10 and 11 hydrolyse both cyclic nucleotides with varying efficiencies (Conti 
and Beavo 2007). Within each family multiple isoforms are expressed and over 
50 are known to date. These are generated via alternative mRNA splicing and 
the use of multiple promoter sites (Houslay, Baillie et al. 2007). 
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Family  Genes  Substrate  
(cAMP, cGMP)  
Regulation  Tissue 
distribution  
Inhibitors  
PDE1  A, B, C  Both; cGMP 
preferentially  
Ca2+/CaM;  
PKA 
phosphorylation  
Heart, vascular 
smooth 
muscle, CNS  
Vinpocetine  
PDE2  A  Both; equal 
kMs  
cGMP via GAF 
domains  
Adrenal, heart, 
liver, brain  
EHNA, BAY 
60-7550  
PDE3  A, B  cAMP  Inhibited by 
cGMP. Activated 
by PKA/Akt 
phosphorylation  
Cardiovascular 
system, lung, 
liver, adipose 
tissue  
Cilostamide, 
Cilostazol, 
Milrinone  
PDE4  A, B, C, D  cAMP  UCR1 and UCR2; 
phosphorylation 
by PKA and 
ERK1/2  
                                
 
Rolipram,                              
Roflumilast , 
Apremilast, 
Cilomilast 
PDE5  A  cGMP  cGMP via GAF 
domains; PKA and 
PKG  
Lung, heart, 
smooth 
muscle, brain, 
kidney  
Sildenafil, 
Tadalafil, 
Zaprinast,  
Dipyridamole  
PDE6  A, B, C  cGMP  Rhodopsin, 
transducin;  
cGMP via GAFs  
Retinal photo- 
receptors  
PDE5 
inhibitors  
PDE7  A, B  cAMP  Pancreas, brain, 
heart, immune 
system  
 ASB16165 
PDE8  A, B  cAMP  PAS domain, 
Phosphorylation 
by PKA 
Heart, 
reproductive 
tissue, bowel, 
thyroid  
Dipyridamole  
PDE9  A  cGMP   Brain Zaprinast, 
BAY 73-6691  
PDE10  A  Both; cAMP 
preferentially  
GAF domains; 
PKA  
Brain  Novel agents 
(see text), 
IBMX, 
Zaprinast  
PDE11  A  Both; similar 
Km and Vmax 
values  
GAF domains  Skeletal 
muscle, 
kidney, liver, 
prostate, testis  
IBMX, 
Dipyridamole
Tadalafil  
 
Table 1-3 Summary of the characteristics of the 11 PDE families. 
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1.3.1 PDE Catalytic and Regulatory Domains 
PDEs have a modular structure consisting of catalytic, regulatory and cell 
localisation domains. Although they do not share a high sequence identity, 
structural information shows that the catalytic domain structure is highly 
conserved across all 11 PDE families (Xu, Hassell et al. 2000, Zhang, Card et al. 
2004).  
The catalytic domain of PDEs contains 16 α helices which are grouped into 3 
subdomains, forming a deep binding pocket for either cAMP, cGMP or inhibitors. 
Many of the amino acid residues which are conserved across all PDEs are found 
within this active site pocket (Zhang, Card et al. 2004). The catalytic domain 
also contains one Zn2+ ion and one Mg2+ ion (Xu, Hassell et al. 2000), which are 
essential to catalysis. The position of an invariant glutamine residue that 
stabilises the purine ring of the cyclic nucleotide in the binding pocket is thought 
to determine substrate selectivity and depending on the orientation of this 
residue in the pocket, the enzyme will have specificity for either cAMP, cGMP or 
both (Zhang, Card et al. 2004). Other amino acids conserved across PDE families 
are thought to contribute to substrate and inhibitor specificities by altering the 
shape and size of the binding pocket (Wang, Liu et al. 2005). 
PDEs differ markedly at their N and C termini and contain a number of different 
regulatory domains.  These include regions for ligand binding, inhibition of the 
catalytic domain, kinase phosphorylation sites and domains, which mediate 
oligomerisation and cell localisation (Conti and Beavo 2007). The characteristics 
of the 11 PDE families are summarised in table 1-1 and domain structures 
illustrated in figure 1-6. 
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Figure 1-6 Domain structures of PDE families 1-11. Adapted from (Conti and Beavo 2007). 
The 11 PDE families shown are grouped according to their differing structures, kinetics, 
tissue distributions and modes of regulation 
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1.4 Phosphodiesterase 4 (PDE4) 
PDE 4 enzymes are cAMP-specific phosphodiesterases. The family of PDE4 
enzymes is encoded by four genes (PDE4A, PDE4B, PDE4C, PDE4D) and each 
exhibit distinct functional and regulatory properties (Torphy 1998). Each of 
these genes can produce multiple protein products due to mRNA splice variants, 
which results in approximately 20 different PDE4 isoforms, each of which are 
characterised by a unique N-terminal region (NTR) encoded by 1 or 2 exons 
under the control of a specific promoter (Torphy 1998, Conti and Beavo 2007). 
PDE4 isoforms have a modular structure, consisting of an isoform specific N 
terminus, regulatory domains known as upstream conserved regions (UCRs), the 
conserved catalytic domain common to all PDE families, and a subfamily specific 
C terminal region (Lynch, Baillie et al. 2007). 
1.4.1  N-terminal Region 
The N terminal region of PDE4 is unique to each isoform, and plays an important 
role in protein-protein interactions and intracellular targeting of the enzyme 
(Houslay and Adams 2010). For example, PDE4D5 isoforms are targeted to the 
signalling scaffold protein β-arrestin at the plasma membrane to modulate β - 
adrenergic signalling (Bolger, McCahill et al. 2003, Bolger, Baillie et al. 2006). 
 
1.4.2 Upstream conserved regions (UCRs) 
Different PDE4 isoforms can be classified as long, short, supershort and dead 
short isoforms see figure 1-7 and table 1-4 below. 
PDE4s are classified based on the presence of the two regulatory domains UCR1 
and UCR2 (Houslay and Adams 2003).The long isoforms can be differentiated 
from the short isoforms by an upstream conserved regions or UCRs. Long forms 
possess both UCR1 and UCR2, as well as two linker regions (LRs) which join them 
to the catalytic domain. Short forms lack UCR1 and the first linker region, and 
supershort forms lack UCR1 and LR1, and also have an N terminal truncation of 
UCR2. Finally, dead short isoforms such as PDE4A7 lack UCR1 and UCR2, and 
have a truncated catalytic domain which renders them catalytically inactive 
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(Houslay, Baillie et al. 2007).The UCR sequences play a key role in the regulation 
of PDE4 via phosphorylation in UCR1 by Protein kinase A (PKA) and in the C-
terminal region by the extracellular signal-regulated kinase(ERK) (Houslay and 
Adams 2003). For example, the catalytic domain of all PDE4 subfamilies with the 
exception of PDE4A, possess a serine residue that can be phosphorylated by ERK 
(Baillie, MacKenzie et al. 2000). Phosphorylation of the long form PDE4 enzymes 
at this site results in its inhibition, whereas phosphorylation of this site in 
shortform PDE4s such as PDE4B2 isoform results in activation. Inactivation of 
PDE4 shortforms by ERK leads to the accumulation of cAMP which in turn 
activates PKA. PKA phosphorylation of PDE4 longforms within UCR1 can activate 
the enzyme which overrides the effect of ERK phosphorylation-dependent 
inhibition (Hoffmann, Baillie et al. 1999, Hill, Sheppard et al. 2006). Therefore 
UCRs can determine the functional outcome of ERK phosphorylation. 
 
Class  Truncations  Isoforms  
Long  None  4A4/5, 8, 10, 11  
4B1, 3, 4  
4C1, 2, 3  
4D3, 4, 5, 7, 8, 9  
Short  Lack UCR1  4B2  
4D1, 2  
Super short  Lack UCR1, LR1, N 
terminus of UCR2  
4A1  
4B5  
4D6  
Dead short  Lack UCR1 and UCR2; 
truncated catalytic unit  
4A7  
 
 
 
 
Table 1-4 Classification of PDE4 isoforms 
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Figure 1-7 Domain structures of PDE4 isoforms (Houslay 2010). 
 The four genes of PDE4 encode over 20 distinct isoforms which can be classified into 
categories of long, short, supershort and dead-short as indicated. Different splicing 
mechanisms endow these isoforms with different combinations of the UCR1 (grey) and 
UCR2 (blue) regulatory components. Sites for PKA-mediated phosphorylation of UCR1 (red 
circle) and ERK-mediated phosphorylation of the catalytic unit (black circle) are shown. 
LR1, Linker Region 1 and LR2, Linker Region 2, are stretches of sequence that differ 
markedly in all four PDE4 subfamilies. CTR, C-terminal region is a stretch of sequence that 
differs markedly in all four PDE4 subfamilies. NTR (red), is the N-terminal region encoded by 
distinct exon(s) and defines each isoform. The chromosome localisation of all four genes is 
shown, together with the known number of isoforms generated by each gene (Houslay 
2010). 
 
1.4.3 Conserved Catalytic Domain 
The catalytic domain of PDE4 is common to all PDE families, previously discussed 
in section 1.3.1. 
1.4.4 Unique C terminal Region 
The final exon of PDE4 genes encodes a sub-family specific C terminal region. 
The significance of this region is not yet fully understood, but may involve a 
regulatory function, as recent structural studies of PDE4 isoforms bound to 
inhibitors have revealed. 
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1.5 PDE4 and the Inflammatory Response 
PDE4 plays a particularly important role in inflammatory and immunomodulatory 
cells and is ubiquitously found in inflammatory cells including mast cells, 
eosinophils, neutrophils, T cells, macrophages as well as structural cells such as 
sensory nerves, epithelial , smooth muscle cells and keratinocytes (Torphy 
1998). Three PDE4 subtypes, PDE4A, PDE4B and PDE4D are expressed in these 
cells, while PDE4C is minimal or absent (Press and Banner 2009, Page and Spina 
2011). PDE4 promotes production of proinflammatory mediators and decreases 
production of anti-inflammatory mediators (Schafer, Parton et al. 2010). PDE4 
promotes inflammation by degrading cAMP that normally helps maintain immune 
homeostasis. PDE4 degradation of cAMP can cause immune cell activation and 
release of proinflammatory mediators such as TNFα, IL-17 and IFN-γ (Liu, Chen 
et al. 2000, Jimenez, Punzon et al. 2001, Sheibanie, Tadmori et al. 2004). By 
degrading cAMP PDE4 indirectly decreases the production of anti-inflammatory 
mediators such as IL-10. PDE4 has been implicated in a number of inflammatory 
diseases, including Psoriasis, psoriatic arthritis, Ankylosing spondylitis, Chronic 
Obstructive Pulmonary disease (COPD) and Rheumatoid Arthritis (Lipworth 2005) 
(Pathan E , McCann, Palfreeman et al. 2010) 
1.5.1 The PDE4/PKA signalling Pathway 
Non Clinical studies show that cAMP/PKA pathway plays an important regulatory 
role in several cell types involved in the pathophysiology of inflammatory 
diseases (Tasken and Aandahl 2004).Tumour Necrosis Factor – α (TNFα) is a pro-
inflammatory cytokine produced mainly by monocytes and macrophages. Its 
levels were found to be decreased upon inhibition of PDE4 (Houslay, Schafer et 
al. 2005). Elevation of cAMP via inhibition of PDE4, triggers the Protein Kinase A 
pathway, inhibits TNFα production and suppresses the immune response.  
Therefore a number of PDE4 inhibitors are currently under development for the 
treatment of inflammatory diseases such as asthma, chronic obstructive 
pulmonary disease (COPD), rheumatoid arthritis, psoriasis and cancer (Calverley, 
Rabe et al. 2009, Sengupta, Sun et al. 2011, Schett G and Stevens R 2012, Papp, 
Kaufmann et al. 2013).  
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An increase in cAMP signalling via a PDE4 inhibitor results in the activation of the 
downstream effecter PKA, which directly phosphorylates and enhances gene 
transcription driven by CREB (cAMP response element binding protein). Figure 1-
8 below shows the effect of PDE4 inhibition on signal transduction and cytokine 
gene transcription in monocytes and macrophages. 
Activation of PKA results in extensive regulation of gene transcription in the cell, 
including a primary group of CRE-containing genes (Zambon, Zhang et al. 2005). 
The major transcription factor directly responsible for these primary changes in 
gene transcription is CREB. However, transcription driven primarily by NFκB 
tends to be inhibited by cAMP elevation due to the competition between CREB 
and the NFκB p65 subunit for binding the co-activator CREB binding protein 
(CBP), which directly binds to the TATA box and initiates transcription (Ollivier, 
Parry et al. 1996).  
In human peripheral blood mononuclear cells, TNFα production induced by the 
lipopolysaccharide (LPS), a bacterial endotoxin, is inhibited by a variety of 
agents that activate the PKA pathway. These include β2-adrenoceptor agonists, 
8-bromo-camp, cholera toxin, prostaglandin E2 as well as various PDE4 inhibitors 
such as Rolipram (Seldon, Barnes et al. 1995).  This inhibition is accompanied by 
the elevation of intracellular cAMP and the activation of PKA in both monocytes 
and macrophages. Treatment with the adenylate cyclase activator forskolin or 
with the PKA activator dibutyryl cAMP inhibits transactivation of p65 NFκB 
subunit, which is required for TNFα transcription (Parry and Mackman 1997). 
Conversely, in monocytes, PKA directly phosphorylates and activates CREB 
leading to production of IL-10 an anti-inflammatory cytokine (Platzer, Fritsch et 
al. 1999, Brenner, Prosch et al. 2003). Ultimately there is a positive effect on 
CREB and negative effects on NFκB upon cAMP elevation. 
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Figure 1-8 The PDE4/PKA signalling pathway. Adapted from (Schafer, Parton et al. 2010). 
 
 
1.5.2 Role of PDE4 in Psoriasis and Psoriatic Arthritis 
Psoriasis is a chronic inflammatory disease of the skin and affects more than 125 
million people worldwide. Inflammation is normally tightly regulated and is part 
of the body’s protective response to injury or infection. It prevents damage to 
surrounding tissue and in response to inflammation, several mechanisms work to 
regulate this immune response and establish homeostasis  (Van Parijs and Abbas 
1998). 
The most common type of Psoriasis is plaque psoriasis and it manifests as raised, 
scaly, erythematous skin lesions (Mason, Mason et al. 2013). These lesions can be 
found anywhere on the body but are most commonly found to be on the scalp, 
elbows, nails, lower back and knees (Mason, Mason et al. 2013). 
The formation of Psoriasis plaques is thought to be caused by dysregulated 
immune activity within the skin (Lowes, Bowcock et al. 2007, Mason, Mason et 
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al. 2013). This leads to an imbalance and overproduction of proinflammatory 
cytokines such as TNFα, IL-17 and IL-23 from immune cells (Nestle, Kaplan et al. 
2009, Mason, Mason et al. 2013). The increase in production of these cytokines 
promotes chronic inflammation of the epidermis which leads to keratinocyte 
hyperproliferation (Perera, Di Meglio et al. 2012). These changes then cause the 
redness, itching, epidermal thickening and scaly plaques found in psoriasis 
(Menter, Gottlieb et al. 2008, Nestle, Kaplan et al. 2009). Since PDE4 is the 
predominant phosphodiesterase in a variety of inflammatory cells, its 
degradation of cAMP allows immune cells to produce elevated levels of the pro-
inflammatory cytokines and decreased levels of anti-inflammatory cytokines 
(Souness, Griffin et al. 1996, Baumer, Hoppmann et al. 2007). Therefore this 
overproduction of pro-inflammatory cytokines is thought to drive the hyper 
proliferation and altered differentiation of keratinocytes. 
Psoriatic arthritis (PsA) is an inflammatory arthritis associated with psoriasis and 
is characterised by stiffness, pain, swelling and tenderness of the joints and 
surrounding ligaments and tissue tendons (Gottlieb, Korman et al. 2008). Studies 
have confirmed that increased levels of proinflammatory mediators are found in 
psoriatic lesions and synovium of patients with PsA (van Kuijk, Reinders-Blankert 
et al. 2006, Boniface, Guignouard et al. 2007). In psoriatic arthritis, abnormal 
levels of multiple pro-inflammatory and anti inflammatory mediators have been 
observed in B cells, chondrocytes and synovial cells (Ritchlin, Haas-Smith et al. 
1998).  
It is known that PDE4 plays an important role in the regulation of pro and anti-
inflammatory mediators involved in both psoriasis and psoriatic arthritis. 
 
1.6 PDE4 inhibitors and their use in Inflammatory 
Disease 
Inhibition of PDE4 has been shown to suppress a diverse range of inflammatory 
responses in vitro and in vivo (Torphy 1998, Press and Banner 2009, Page and 
Spina 2011). A significant number of PDE4 inhibitors have been developed and 
are currently being investigated for their use in inflammatory disorders such as 
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asthma, chronic obstructive pulmonary disease (COPD), psoriasis, inflammatory 
bowel disease and rheumatoid arthritis (Souness, Aldous et al. 2000, Page and 
Spina 2011). 
The multiple isoforms of PDE4 and their widespread expression pattern has made 
PDE4 a good target for therapeutic intervention. A major challenge in the 
development of these inhibitors however, is their propensity to promote nausea 
and emesis. The recent development of PDE4 inhibitors with low emotogenic 
potential has proved successful, for example the recent approval of Roflumilast 
for COPD and the ongoing studies involving Apremilast for the treatment of 
Psoriasis and other inflammatory diseases(Gottlieb A, open-label et al. 2008) 
(Pathan E , Schett G 2009, McCann, Palfreeman et al. 2010, Baughman, Judson 
et al. 2012). 
1.6.1 Structural basis of Inhibitor binding to PDE4 
Each PDE4 sub-family contains a highly conserved catalytic unit containing 17 α 
helices, which are organised into 3 sub-domains: a bivalent metal binding pocket 
(Zn2+, Mg2+) which is thought to form a complex with the phosphate moiety of 
cAMP, a pocket containing an invariant glutamine (Q pocket), which forms 
hydrogen bonds with the nucleotide moiety of cAMP, and a solvent pocket. PDE4 
inhibitors occupy this active site via a number of key interactions and prevent 
degradation of cAMP (Zhang, Card et al. 2004). 
Co-crystal structures of many inhibitors in complex with various PDEs have 
identified two common features of inhibitors binding to PDEs (Figure1-9) (Card, 
England et al. 2004). 1) Direct binding to the metal ions by hydrogen bonds to 
water, while hydrophobic interactions between the planar ring structure of 
inhibitors and hydrophobic amino acid residues such as phenylalanine and 
isoleucine act to “clamp” the inhibitor within their active site. 2) Hydrogen 
bonding interactions between the aromatic structure of inhibitors and the Q 
pocket, which is normally occupied by the nucleotide moiety of cAMP (Xu, 
Hassell et al. 2000, Card, England et al. 2004, Wang, Peng et al. 2007). 
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Figure 1-9 Classification of the Active Site of PDEs  
(A) The active site of PDEs is divided into three pockets: the metal binding pocket (M) 
shown in blue, the purine-selective glutamine and hydrophobic clamp pocket (Q) shown in 
red (which is further divided into Q1 and Q2 subpockets), and the solvent-filled side pocket 
(S) shown in green. This colour coding of the active site pocket is mapped on the surface of 
PDE4B in complex with cilomilast, which is shown as a stick model bound at the active site. 
The cocrystal structure of PDE4B in complex with cilomilast has also been used to display 
the surfaces in (B)–(D). (B) Same as (A), but a view of the PDE active site looking toward the 
S pocket. This view is a clockwise rotation of about 90 along the length of cilomilast from 
the view in Figure 1A. The subpockets that subdivide the Q pocket are also labelled: Q1 is 
the small subpocket, and Q2 is the large subpocket. (C) Same as (A), but a view of the PDE 
active site looking away from the S pocket. This view is a counter clockwise rotation of 
about 90 along the length of cilomilast from the view in Figure 1-9A. All the subpockets are 
labelled. (D) Residues lining the three active site pockets. The active site surface is 
semitransparent to reveal residues that make up the active site. The absolutely conserved 
residues in all PDEs are coloured blue. Residues conserved in both cAMP- and cGMP-
specific PDEs are coloured green. The other variable residues are coloured red. (Card, 
England et al. 2004) 
 
1.6.2 The main chemical classes of PDE 4 inhibitors 
All the reported inhibitors that bind PDE4 can be divided into four scaffold 
classes based on the structural motifs present: catechol, xanthine, pyrazole and 
purine analogs.  These can then be further divided into three main chemical 
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classes: 1. Catechol ethers belong to the most widely represented class of 
inhibitors and are structurally related to Rolipram. Many examples of catechol 
diether- containing compounds are reported as PDE4 inhibitors for example, 
Mesopram (daxalipram was discovered as an improved rolipram analogue by 
Schering as a potential treatment for MS. However, Schering discontinued any 
further development of Mesopram. Other examples would be Zardaverine, a dual 
PDE3 and PDE4 inhibitor (Schudt, Winder et al. 1991) and Piclamilast which was 
developed as a treatment for arthritis and was a very potent inhibitor of PDE4 
(0.7Nm) (Souness, Maslen et al. 1995). However, its development was 
discontinued due to toxic side effects. Cilomilast, Roflumilast and Apremilast 
discussed in sections 1.6.4, 5, and 6 are also Catechol diether containing 
compounds. These agents are characterised by the presence of the substructure 
(A) (figure 1-10) in which R1 is generally a methyl and R2 a cyclopentyl group; 
alternatively highly lipophilic groups are present at R2. 2. Quinazolinediones, in 
which are classified the PDE 4 inhibitors structurally related to Nitraquazone, 
which was developed by Syntex as a PDE4 inhibitor for the treatment of 
inflammatory diseases in the 1980s (Glaser and Traber 1984) (B) (figure 1-10). 3. 
Xanthines, which are generally non selective for PDE4 and have clear structural 
similarities to cAMP. Examples of Xanthines would be Theophyline which 
represents the natural product class of xanthines and 3-isobutyl-1-
methylxanthine (IBMX) which was discovered through medicinal chemistry and 
developed specifically as a PDE inhibitor structure (C) (figure1-10). IBMX binds at 
the common core of the active- site pocket shared by all the PDEs and interacts 
with highly conserved residues. IBMX will flip its orientation when bound to 
cAMP-specific PDEs versus cGMP-specific PDEs so it can adapt to the H-bond 
characteristics of the nucleotide recognition glutamine (Huai, Liu et al. 2004). 
These features contribute to IBMX being a relatively weak and non selective PDE 
inhibitor compared to newer generation inhibitors.  However, according to the 
pharmacophoric model proposed by Polimeropoulous et al (Polymeropoulos 1997) 
for PDE4 inhibitors, Classes 2 and 3 could be referred to the unique general 
structure in (D) (figure1-10) in which X= N, CO,CH, Y = bulky akyl or aryl Z = N,C, 
and W = N, CH. Inside this class, two subclasses can be distinguished, namely 
quinazolindiones and xanthines (Figure 1-10). 
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Figure 1-10 Structures of A) General structure of Catechol diethers, B) Nitraquazone, C) 
IBMX and D) general structure of quinazolindiones and xanthines   (modified from (Dal Piaz 
and Giovannoni 2000). 
 
1.6.3 Rolipram 
Among the first generation of selective PDE4 inhibitors was Rolipram (4-[3-
(cyclopentyloxy)-4 methophenyl]- 2-pyrrolidinone)(figure 1-9), which was 
originally developed as a putative antidepressant agent (Wachtel 1982). This 
compound exhibits at least 100-fold selectivity for PDE4 relative to the other 10 
PDE families. It is directed against the active site of the PDE, binding 
competitively with cAMP, and therefore inhibits all PDE4 family members with 
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similar efficacy (Spina 2008). However, its clinical use was hindered by dose 
limiting gastrointestinal effects (Zeller, Stief et al. 1984). Nausea and emesis are 
also common problems associated with PDE4 inhibition and often limit their 
therapeutic window. It is thought that most of these effects are mediated by the 
central nervous system (CNS) and so it has been difficult to separate the effects 
of emesis from the more desirable effects. Studies in knockout mice have 
suggested that PDE4D is the main isoform that is associated with emesis 
(Robichaud, Stamatiou et al. 2002). While PDE4B appears to be the main isoform 
responsible for mediating release of TNFα (Jin and Conti 2002). Investigations 
found that nearly all PDE4 isoforms exist in two confirmations: a high- affinity 
rolipram binding site and a low-affinity rolipram binding site (Souness, Aldous et 
al. 2000). The adverse effects of rolipram and other compounds were found to 
occur when rolipram inhibited high affinity rolipram binding sites (Souness, 
Aldous et al. 2000). High affinity binding predominates in the central nervous 
system, while low predominates in inflammatory cells. 
In light of this, development of PDE4B specific inhibitors that act on PDE4s in the 
low affinity Rolipram binding sites would be a possible means of maintaining 
anti-inflammatory activity without retention of the emetic side effects of PDE4 
inhibition. Indeed, the development of several, newer generation PDE4 inhibitors 
are thought to have decreased emetic side effects.  These include Cilomilast, 
Roflumilast and Apremilast.     
 
1.6.4 Cilomilast     
Cilomilast (figure1-9) was the first PDE4 inhibitor to go through extensive clinical 
testing (Rennard, Schachter et al. 2006). It was in phase 1 and 11 studies that 
cilomilast significantly improved lung function and reduced exacerbation rates in 
chronic obstructive pulmomary disease (COPD) (Giembycz 2006). However, its 
development was suspended in phase 111 trials due to its greater selectivity for 
PDE4D and its unfavourable side effects (Lipworth 2005). 
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1.6.5 Roflumilast 
Roflumilast (DAXAS®, Bristol-Myers-Squibb) (3-cyclopropylmethoxy-4-
diflouromethoxy-N- (3,5-dichloropynol-4-yl)-benzamide) (figure1-9) is an oral 
PDE4 inhibitor for the treatment of severe Chronic obstructive pulmonary 
disease (COPD). COPD is a very common, poorly reversible inflammatory disease 
of the airways and is thought to be mainly caused by smoking. It is the fourth 
most common cause of death in the US and is also a major cause of morbidity 
(Mannino 1971). COPD is characterised by lung parenchymal destruction i.e 
emphysema and obstructive bronchitis and is characterised functionally by 
progressive airway obstruction. Roflumilast and its primary metabolite, 
Roflumilast N-oxide are potent and competitive inhibitors of PDE4. It has been 
licensed in the UK for treatment of severe exacerbations of COPD and it is 
thought to act by increasing cAMP in the lung. 
In COPD, blood levels of the pro-inflammatory cytokines (IL-1, IL-6 and tumour 
necrosis factor α (TNFα) are increased. Using PDE4 isolated from human 
neutrophils, which contains a mixture of different PDE4s, Roflumilast and 
Roflumilast N-oxide have IC50 values of 800pM and 2nM respectively 
(Hatzelmann and Schudt 2001). However, there is no discrimination between 
PDE4 gene variants in these compounds; they inhibit all 4 sub-families equally. 
This lack of subtype selectively contributes to its improved therapeutic ratio 
compared with its predecessors. For example Roflumilast has proportionately 
less effect on PDE4D than Cilomilast, is less likely to cause nausea and emesis 
than Cilomilast and is also a more potent anti-inflammatory (Field 2008). 
Roflumilast and Roflumilast N-oxide potently inhibit PDE4B activity. Roflumilast 
is well tolerated in patients with COPD and inhibits mediator release from 
immune and pro-inflammatory cells as well as in structural cells in the lung 
(Rennard, Schachter et al. 2006). It has been found to improve lung function in 
patients with moderate and severe COPD (Lipworth 2005). In phase III clinical 
trials Roflumilast was found to reduce the requirement for steroid and antibiotic 
treatments, and reduce hospitalisations resulting from exacerbations of COPD 
(Calverley, Rabe et al. 2009, Fabbri, Calverley et al. 2009). Therefore 
Roflumilast has become the first in class PDE4 inhibitor for COPD therapy and 
provides physicians with another treatment option for patients with severe 
COPD. 
 52 
1.6.6 Apremilast 
In addition to COPD, PDE4 inhibitors are also being developed for asthma, 
arthritis and psoriasis. Apremilast (Otezla ®) is a novel PDE4 inhibitor with TNFα 
inhibitory activity (Spina 2003) and has recently (January 2015) been approved 
by the European Commission for the treatment of patients with both Psoriasis 
and Psoriatic Arthritis. In Phase III studies Apremilast resulted in significant and 
clinically meaningful improvements in plaque psoriasis as well as having a 
consistent safety and tolerability profile across clinical trials (Papp, Kaufmann et 
al. 2013) (Gottlieb, Strober et al. 2008). The approval of Apremilast was based 
primarily on safety and efficacy results from two multi-centre, randomized, 
double-blind, placebo-controlled studies - ESTEEM 1 and ESTEEM 2 - conducted 
in adult patients with moderate to severe plaque psoriasis: body surface area 
(BSA) involvement of ≥10%, static Physician Global Assessment (sPGA) of ≥3 
(moderate or severe disease), Psoriasis Area and Severity Index (PASI) score ≥12, 
and candidates for phototherapy or systemic therapy(Papp, Kaufmann et al. 
2013). 
Apremilast (figure1-9) (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-
methanesulfonylethyl]-1,3-dioxo-2,3-dihy dro-1H-isoindol-4-yl] also known as CC-
10004 has a molecular weight of 460.5. It binds to the catalytic site of PDE4, 
competitively blocking cAMP degradation. When it was initially screened for 
PDE4 inhibition, Apremilast was found to have an IC50 of approximately 0.074µM 
(Man, Schafer et al. 2009). The Ki value (affinity constant) of Apremilast for 
PDE4 is 68nM. Apremilast is a partial competitive inhibitor of PDE4 based on 
Lineweaver-Burk Analysis (Schafer, Parton et al. 2010). Apremilast is non 
selective within the PDE4 subfamily as demonstrated by cAMP-degradation assays 
for PDE4 A4,B2, C2 and D3 with similar potencies at IC50s ranging from 20 to 
50nM, therefore is not a PDE4 subtype selective inhibitor (Schafer, Parton et al. 
2010). 
Apremilast has pharmacodynamic properties with potential therapeutic benefit 
for treating inflammatory disorders that involve elevated serum cytokine levels. 
Recent work (Schafer, Parton et al. 2010) has demonstrated the broad anti-
inflammatory effects of Apremilast in vitro and in human cellular models (See 
figure 1-12). This included the inhibition of production of multiple mediators 
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including TNFα, IFN-γ, IL-2, IL-12, IL-13,IL23, macrophage inflammatory protein 
(MIP), monocyte chemoattract protein (MCP-1) and granulocyte  macrophage 
colony stimulating factors (GM-CSF) from Peripheral blood monocytes. TNFα 
production by NK cells and keratinocytes was inhibited by Apremilast in vitro, 
which demonstrated that these two cell types, which are involved in the 
pathophysiology of psoriasis, are directly affected by a PDE4 inhibitor. Therefore 
these in vitro anti- inflammatory activities, and in particular the inhibition of 
production of TNFα, IL-12 and IL-23 and the ability of Apremilast to suppress 
psoriasis lesions in vitro  suggested that it may be useful in the treatment of 
psoriasis via a multi-faceted mechanism (Schafer, Parton et al. 2010). 
Additionally, apremilast is known to augment IL-10 production, which is a known 
suppressor of other pro-inflammatory chemokines.    
When comparing Apremilast to for example Cilomilast, Cilomilast is 10 fold more 
selective for PDE4D than Apremilast (Giembycz 2006). This lack of PDE4D 
selectivity in Apremilast may explain its better therapeutic index compared with 
other inhibitors. It has also been shown to have low binding to HARBS and so 
does not induce central nervous system effects such as lethargy, fatigue and 
nausea (McCann, Palfreeman et al. 2010). 
Therefore Apremilast seems to elicit less emetic side effects while also having a 
wider therapeutic window. However, the underlying mechanism for this 
increased tolerability is unknown, although only 10% of the compound passes 
over the blood brain barrier. 
 
Figure 1-11 Chemical structures of the PDE4 inhibitors Apremilast, Rolipram, Cilomilast and 
Roflumilast 
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Figure 1-12 An overview of proposed mechanism of action of Apremilast in various cell 
types derived from in vitro studies. By blocking PDE4 activity, apremilast affects several cell 
types in the immune system including monocytes, dendritic cells , neutrophils, T cells, 
natural killer cells and macrophages (Samrao, Berry et al. 2012). 
 
1.6.7 Comparing Apremilast and Roflumilast  
The latest generation of selective PDE4 inhibitors such as Apremilast and 
Roflumilast seem to have an improved therapeutic index. While Roflumilast has 
been approved for treatment of COPD in 2010, Apremilast was more recently 
approved for Psoriasis and Psoriatic Arthritis. Apremilast may also prove useful in 
the future for other dermatological and Rheumatological conditions for example 
Rheumatoid arthritis and ankylosing spondyltis. Studies by Celgene in Psoriasis 
and Psoriatic Arthritis have demonstrated clinical activity of Apremilast (Papp, 
Kaufmann et al. 2013). 
A number of similarities and differences were found in studies performed by PH 
Schafer et al between Apremilast and Roflumilast (Schafer, Parton et al. 2010). 
For example a direct comparison of cAMP elevation within prostaglandin E2 
(PGE2)-stimulated peripheral blood monocytes was made between Apremilast 
and Roflumilast (figure1-8). Other PDE4 inhibitors Rolipram and Cilomilast were 
also included. Results indicated that while Apremilast elevated cAMP in a 
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manner similar to Cilomilast and Rolipram, Roflumilast elevated cAMP levels 
approximately twice as high as Apremilast, Cilomilast and Rolipram.  
 
Figure 1-13 Intracellular cAMP levels in PGE2-stimulated PBMC treated with various PDE4 
inhibitors (n=3) (data courtesy of Celgene) 
 
 
The data in figure 1-13 suggested that roflumilast might inhibit a cAMP-
hydrolyzing enzyme other than PDE4. Possibilities included PDE1, 2, 3, 7, 8, 10, 
or 11. Therefore roflumilast and apremilast were tested for inhibition of both 
cAMP- and cGMP-hydrolyzing PDE enzymes in recombinant human enzyme assays 
(figure 1-14). 
 
 
Figure 1-14 . Selectivity of apremilast and roflumilast against recombinant human PDE 
enzymes (data courtesy of Celgene) 
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Based on the data in Figure 1-14, both apremilast and roflumilast are highly 
selective for PDE4 over other PDEs. Roflumilast does exhibit some PDE5A1 
inhibition, but this is a cGMP-selective phosphodiesterase. The other cAMP-
hydrolyzing phosphodiesterases (PDE1, 2 3, 7, 8, 10, 11) are not significantly 
inhibited at 10 µM roflumilast. Therefore, lack of PDE selectivity cannot explain 
the very high cAMP levels attained by roflumilast treatment in PGE2-stimulated 
PBMC. Apremilast and roflumilast were then tested against several PDE4 
isozymes to determine if PDE4 subtype selectivity might explain the differences 
in cAMP elevation. Results are shown in Table 1-5. 
Compound  IC50 (nM) for specific PDE4 isoforms 
A1A B1 B2 C1 D2 D3 D7 
apremilast 14 43 27 118 33 28 30 
roflumilast 0.5 0.8 0.3 5.9 0.5 0.5 0.7 
rolipram* 188 418 135 847 858 825 913 
* Rolipram was used as a positive control 
 
Table 1-5 IC50 values of the compounds against example PDE4 isoforms from each of the 
four PDE4 sub-families, A1A,B1,B2,C1,D2,D3,D7 (Study BPS Bioscience 
Celgene_PDE4_1001). 
 
The data in Table 1-3 indicate that roflumilast is 20- to 90-fold more potent in 
inhibiting PDE4 isoforms in vitro than apremilast. However, it is extermely 
unlikely that potency alone can explain the different maximal cAMP elevation 
shown in Figure 1-9 as, for example, a concentration of 100 µM rolipram can be 
expected to inhibit completely all PDE4 isoforms. With the exception of PDE4C1, 
which is poorly expressed in the majority of cell types, apremilast and 
roflumilast are largely non-selective among these isozymes. So it appears that 
there are no major differences in selectivity which could explain the excessive 
cAMP elevation induced by roflumilast.  
Since PDE4 enzymes have the ability to assume conformations that bind certain 
compounds (such as rolipram) with high affinity, it is possible that any 
conformational switch may be triggered by the compound itself, or by the 
association of the enzyme with other proteins. The long isoform PDE4A4 (aka 
PDE4A4B, PDE46, or PDE4A isoform1, Bolger 1993), for example, can assume a 
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high affinity conformation when associated with SH3 domain-containing proteins 
such as the Src-family kinase Lyn. This enzyme has been found to co-localize 
with Lyn when the two proteins are co-expressed in COS7 cells (Figure 1-15) 
(McPhee, Yarwood et al. 1999). 
 
Figure 1-15 Colocalization of PDE4A4B (PDE46) with the kinase Lyn (McPhee, Yarwood et al. 
1999). 
 
The binding of apremilast and roflumilast was tested using the low affinity 
(cytosolic, isolated from cell lysate supernatant) and high affinity (membrane-
associated, isolated from cell lysate pellet) forms of PDE4A4. Results indicated 
that while roflumilast bound to the membrane-associated fraction of PDE4A4 
with 12-fold greater affinity than the cytosolic fraction, apremilast behaved in 
the opposite manner. Apremilast actually exhibited a 7-fold lower affinity for 
the so called high affinity form of PDE4A4 (Table 1-6). This indicates that 
apremilast, unlike roflumilast and rolipram, does not readily bind to the 
membrane-associated fraction of PDE4A4. 
IC50 (µM) 
PDE4A4 low affinity 
(supe 2) 
PDE4A4 high affinity 
(pellet 2) 
PDE4A4 low/high ratio 
apremilast 0.02 0.136 0.15 
roflumilast 0.0005 0.00004 12.5 
rolipram 0.568 0.156 3.64 
 
Table 1-6 . Inhibition of the low affinity and high affinity forms of PDE4A4 expressed in 
COS7 cells. 
 
Due to the differential binding of these inhibitors to the ‘high’ and ‘low’ affinity 
forms of PDE4A4, one would expect there to be a commensurate differential 
effect in cAMP elevation within microdomains, which should be detectable using 
the appropriate cAMP probes, discussed in section 1.2. 
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Therefore in comparing Apremilast and Roflumilast, Celgene found no major 
differences in PDE selectivity or PDE4 isoform selectivity pattern. However, they 
found different cAMP elevation and PDE4A4 conformer inhibition pattern. 
 
1.7  Thesis aims 
Apremilast is a novel, orally available small molecule that specifically inhibits 
phosphodiesterase 4 (PDE4) and thus modulates multiple pro- and anti-
inflammatory mediators and has recently (January 2015) been approved by the 
European Commission for the treatment of patients with both Psoriasis and 
Psoriatic Arthritis. Apremilast may be useful in the future for use in other 
diseases such as Rheumatoid arthritis and Ankylosing Spondylitis for example, 
Apremilast has undergone phase 2 clinical studies in Rheumatoid Arthritis (RA-
002) and a Phase III study (AS-001) (Celgene) is also underway for Ankylosing 
Spondylitis. In the phase III trials in psoriasis and psoriatic arthritis, the clinical 
efficacy of apremilast was within the range of efficacy of low dose etanercept. 
With this biologic-like efficacy, oral route of administration, favourable safety 
and acceptable tolerability profile, apremilast is expected to fill a market niche 
as a new safe oral medication in dermatology and rheumatology that is suitable 
for use prior to the biologics.  
Within the inflammatory disease therapeutic landscape, there are now several 
approved biologics targeting pro-inflammatory cytokines, namely TNF-α, IL-1β, 
IL-6, and IL-12/IL-23 (Gottlieb, Chamian et al. 2005, Krueger, Langley et al. 
2007, Cantarini, Vitale et al. 2015). Novel biologics targeting IL-17, IL-22, and 
oral small molecules targeting JAK3, Syk, and other intracellular targets others 
are in late stage clinical development (Jiang, Ghoreschi et al. 2008) (Chao, Chen 
et al. 2011). Therefore the dermatology and rheumatology space will become 
increasingly crowded with new therapies over the next decade. Furthermore, 
the presence of another PDE4 inhibitor (Roflumilast) on the market for the 
treatment of respiratory disease will further complicate the therapeutic 
landscape. Roflumilast is approved in the EU for the treatment of COPD and was 
recently approved in the US for treatment to reduce the risk of COPD 
exacerbations. Roflumilast is a selective PDE4 inhibitor, administered as an oral 
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tablet once daily, and is thought to act by increasing cAMP within lung cells. 
Therefore, there is a need for a clear understanding of Apremilast’s mechanism 
of action (MOA), and how it compares to that of biologic and other small 
molecule drugs, for the purposes of labelling, for communication to the 
scientific community, physicians, and patients, and for an extension of utility to 
other diseases and therapeutic areas. In order to obtain a complete picture of 
the apremilast MOA, additional molecular and cellular biology studies are 
required to more fully elucidate the signalling mediators downstream of PDE4 
inhibition which result in alterations in pro- and anti-inflammatory gene 
expression. My studies were conducted to directly compare Apremilast with 
Roflumilast, in order to substantiate the differences observed in the molecular 
and cellular effects of these compounds, and to search for other possible 
differentiating effects. Therefore the main aim of this thesis is to utilise 
biochemical techniques to discover whether Apremilast and Roflumilast work 
with different modes of action ie: 
Clarify the Apremilast mechanism of action in comparison to Roflumilast: 
1. Measure differences in cAMP elevation within cellular microdomains 
of cells treated with apremilast and roflumilast, to determine 
where within the cell the cAMP elevation differs between the two 
compounds. 
2. Identify potential differences in PKA substrate phosphorylation 
patterns elicited by the two PDE4 inhibitors.
 
 
 
2 Materials and Methods 
All materials and chemicals were from Sigma-Aldrich (Gillingham, Dorset, UK), 
unless otherwise stated. 
2.1 Mammalian Cell Culture 
All cell culture was performed in a class II tissue culture hood unless otherwise 
stated using an aseptic technique. All reagents were filter-sterilised or 
autoclaved prior to use. 
2.1.1 HEK293 cells 
 
The HEK293 cell line is derived from transformed human embryonic kidney cells 
(Graham, Smiley et al. 1977). HEK293 cells were cultured in Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with10% fetal bovine serum (FBS), 1% 
penicillin (10 000 U/ml)/streptomycin (10mg/ml) and 2mM L-glutamine. Cells 
were maintained in an atmosphere of 37°C and 5% CO2, and passaged at 70-90% 
confluence. To passage, the growth media was removed and 2ml of1x trypsin-
EDTA added per 10cm2 of growth area. Cells were incubated at 37°C until they 
were seen to detach when viewed under a light microscope. 8ml of growth 
media was then added to inactivate trypsin. Cells were collected by 
centrifugation at 150g for 3minutes, and the cell pellet resuspended in 5-10ml 
fresh growth medium to remove the trypsin, then 1ml of suspended cells and 
9ml of complete growth medium was added per10cm dish. Cells were then re-
incubated at 37°C and 5% CO2 until required. Media was changed every 48 hours. 
2.1.2 Jurkat T and U937 cells 
Jurkat Clone E6-1 is a human T lymphoblastoid cell line derived from an acute T 
cell leukemia (Gillis and Watson 1980). The cells are suspension lymphoblasts.  
Cells were maintained in RPMI1640 media supplemented with 5% foetal bovine 
serum, 0.1% Penicillin and Streptomycin (10000U/ml), 2mM Glutamine. Cells 
were generally sub-cultured at 80% confluence and re-seeded at a density of 10% 
confluence. Cultures can be maintained by the addition of fresh medium or 
replacement of medium. 
 61 
Alternatively, cultures can be established by centrifugation with subsequent 
resuspension at 1 to 2 X 105 viable cells/mL.  
The U-937 cell line was derived by (Nilsson and Sundstrom 1974) from malignant 
cells obtained from the pleural effusion of a patient with histiocytic lymphoma. 
The cells are suspension monocytes. Cells were maintained in RPMI1640 media 
supplemented with 5% foetal bovine serum, 0.1% Penicillin and Streptomycin 
(10000U/ml), 2mM Glutamine. Subculture in the same way as Jurkat T cells. 
2.1.3 Rheumatoid Arthritis Synovial Fibroblasts 
Primary Human Rheumatoid Arthritis Synovial Fibroblasts Rheumatoid arthritis 
synovial fibroblasts (RASFs) were purchased from Asterand Bioscience and 
culture was performed according to the manufacturer's instructions. Cells were 
grown in DMEM containing 5% FBS supplemented with 2 mM L-glutamine, 100 
μg/ml penicillin, and 100 μg/ml streptomycin in a humidified atmosphere 
containing 5% CO2.  
 
2.1.4 Transfection of cells for FRET analysis 
HEK 293 cells were transfected using TransIT-LT1 transfection reagent (Mirus 
Bio, Madison, USA). Cells were passaged 24 hours before transfection to ensure 
40-60% confluence on the day of transfection, and maintained as described 
above (Section 2.2.1.) Cells were seeded onto sterilsed 24-mm diameter round 
glass coverslips mounted onto 6-well plates, transfections were performed at 50- 
70% confluence with Mirus transfection reagent according to the manufacturer’s 
instructions using 1–2 μg DNA (sensor) per coverslip. 36µl of Mirus transfection 
reagent was added to 1.5ml Opti-MEM (Invitrogen), and the solution pippetted 
briefly to mix, then incubated at room temperature for 5 minutes. 12μg of 
sensor was then added, the solution pipetted once more to mix, and incubated 
at room temperature for a further 15 minutes. Meanwhile, the cell media was 
replaced with 750µl/well of complete growth medium. The transfection solution 
was then added drop-wise to the coverslips and swirled to mix. Cells were 
incubated at 37°C and 5% CO2 for 24-48 hours to allow protein expression, prior 
to FRET experiments. 
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Transfection of RASFS and Jurkat T cells was performed using Nucleofector™ 
Technology (Lonza). Electroporation is a transfection technology based on the 
momentary creation of small pores in cell membranes by applying an electrical 
pulse. For nucleofection the required numbers of cells were centrifuged at 90xg 
for 10 minutes at room temperature. Supernatant was removed and the cell 
pellet was resuspended in 100μl room temperature Nucleofector® solution per 
sample and then combined with required amount of DNA. The Cell/DNA 
suspension was transferred into a certified cuvette (sample must cover bottom 
of cuvette without air bubbles). Sample was then inserted into nucleofector 
device and appropriate Nucleofector® programme X-001 was selected. 
Immediately after programme was finished the cells were resuspended in 500µl 
of media and gently transferred to a 6 well plate with 24-mm diameter round 
glass coverslips. Fret imaging experiments were performed after 24–48 h.  
2.1.5 PDE4 inhibitor treatments for western blotting analysis 
1 x 107 Jurkat T Cell Leukemia or U937 cells were plated in tissue culture dishes 
(10 x 10 cm) in 10 ml Complete Media (RPMI-1640 + 10% FBS, 2 mM L-glutamine, 
100 units/ml Penicillin and 100 µg/ml Streptomycin) and incubated overnight at 
37oC, 5% CO2.  The next day, the cells were treated with 0.1% DMSO (vehicle), 
0.1, 1 and 10 µM Apremilast (CC-10004), 10 µM Forskolin (Sigma, Cat# 89156-
988) with and without 10 µM Apremilast, 1, 0.1 and 0.01 µM Roflumilast (CC-
14064) for 30 minutes at 37oC. All compounds were prepared in DMSO as a 10 mM 
stock.  After 30 minutes, the cells were collected and centrifuged at 1200 RPM 
for 10 minutes. The supernatant was discarded and the cells were washed twice 
with cold 1X PBS and then PBS removed completely.  The cells were then lysed 
with 100 µl 3T3 lysis buffer (25mM HEPES, 10% w/v glycerol, 50mM NaCl, 1% w/v 
Triton x100, 50mM NaF, 30mM NaPP, 5mM EDTA pH7.4)  supplemented with 
complete EDTA-free Protease Inhibitor Cocktail Tablets (Roche®) . The same 
treatments were used for HEK 293 cells however; lysate preparation was 
performed as described below in section 2.1.6 for adherent cells. 
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2.1.6 Preparation of whole cell lysates 
Lysates for Western blotting were prepared using 3T3 lysis buffer (25mM HEPES, 
10% w/v glycerol, 50mM NaCl, 1% w/v Triton x100, 50mM NaF, 30mM NaPP, 5mM 
EDTA pH7.4). Complete, EDTA-free Protease Inhibitor Cocktail Tablets (Roche®) 
were also added to the lysis buffer prior to use. Adherent cells were detached 
from the tissue culture vessel by vigorous scraping with a scraper. Lysates were 
pipetted up and down to homogeneity and immediately transferred to a 1.5ml 
tube and kept on ice. Lysates were then centrifuged at 14000 x g for 5 minutes 
to remove insoluble material. Suspension cells were lysed as described above in 
(section 2.1.5). Concentration was immediately assessed and cleared lysates 
were either used the same day, or snap frozen on dry ice and stored at -80oC for 
future use. 
2.1.7 Protein Assay 
The concentration of protein in cell lysates was determined using the Bradford 
method (Bradford 1976). Protein assays were performed in clear 96 well plates. 
All samples were prepared in a final volume of 50μl 3T3 lysis buffer, and were 
tested in triplicate. A standard curve of known BSA concentrations between 0 
and 5 μg was prepared. Each protein sample of unknown concentration was then 
diluted 1:50 – 1:200 in 3T3 lysis buffer. Bradford reagent (Bio-Rad) was diluted 
1:5 in sterile dH20, and 200μl of diluted reagent added per well. Samples and 
standards were analysed with a 595nm filter on an Anthos 2010 plate reader 
using ADAP software. Protein concentrations were calculated using a curve 
derived from the BSA standard values, and adjusted for sample dilution. 
2.2 Western Blot 
2.2.1 SDS- PAGE 
Sodium dodecylsulphate polyacrylamide gel electrophoresis (SDS-PAGE) was used 
to separate proteins by molecular weight. Proteins were separated using the 
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Invitrogen NuPage Novex gel system. Protein samples were denatured and 
reduced for gel electrophoresis by diluting in 5x Laemmli protein sample buffer 
(Bio-Rad) and boiling for 5 minutes, then 1-100μg of protein per well was loaded 
directly onto 4-12% Bis-Tris NuPage gels. Gels were immersed in NuPage MES (for 
<50kDa proteins) or MOPS (for >50kDa proteins) running buffer. 3μl of Bio-Rad 
Precision Plus Dual Colour Protein Standard was added to the first well of each 
gel. This is a pre-stained standard protein ladder used to aid analysis of the 
molecular weight of the protein samples. Protein samples were subjected to gel 
electrophoresis at 180V for approximately 1.5 hours, or until protein separation 
was achieved. 
2.2.2 Western Immunoblotting 
Western immunoblotting allows the detection of individual SDS-PAGE separated 
proteins with specific anti-sera. The proteins separated by SDS-PAGE were 
transferred to nitrocellulose membrane using the XCell® blotting apparatus and 
NuPAGE® transfer buffer containing 20% methanol. The proteins were 
transferred with an applied voltage of 30V for 1 hour.  
Following the transfer of the sample proteins, as indicated by successful transfer 
of the pre-stained molecular weight markers, the nitrocellulose membrane was 
washed 3 time with 1xTBST (20mM Tris-Cl pH 7.6, 150mM, NaCl and 0.1% 
Tween20). Nitrocellulose membranes were then incubated with Odyssey blocking 
buffer (LI-COR Biosystems) for 1hour at room temperature on an orbital shaker. 
Primary antibodies were diluted 1:1000 in odyssey block plus 0.1% Tween 20 (see 
table 2-1 for details of primary antibodies used). The blocked nitrocellulose 
membrane was then heat-sealed in an airtight bag containing the primary 
antibody solution. This was incubated overnight at 4°C on an orbital shaker.  The 
membrane was then washed 3 times with TBST. LI-COR Biosystems® fluorophore 
conjugated secondary antibodies raised against the appropriate primary 
immunoglobulin species were diluted 1:10000 in odyssey block plus 0.1% Tween 
20 (see table 2-2 for details of secondary antibodies used). The secondary 
antisera were incubated with primary immunoglobulin bound membranes within 
heat sealed bags for 1hour at room temperature on an orbital shaker (in the 
dark). The blots were washed 4 times for 5 minutes each with 1X TBST and once 
with 1X TBS to remove Tween 20.  LI-COR Biosystems® fluorophore conjugated 
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secondary antibodies were visualised using the LI-COR Biosystems® Odyssey 
infrared western blot scanning visualisation system. Membranes were placed 
face down on the scanner and visualised at medium sensitivity at a resolution of 
100μm at either 680 or 800nm wavelengths according to the secondary 
fluorophore. The resulting Tif files were analysed using LI-COR Biosystems® 
proprietary Odyssey® software.  
 
Primary Antibody Type Dilution Supplier 
Anti-β-Actin Mouse Monoclonal 1:20,000 Sigma Aldrich 
Phospho-CREB (Ser133) Rabbit Polyclonal 1:1000 Cell Signalling 
Phospho-VASP (Ser157) Rabbit Polyclonal 1:1000 Cell signalling 
Phospho-PKA Substrate (RRXS*/T*) Rabbit Polyclonal 1:1000 Cell Signalling 
Phospho- Fyn (Y530) Rabbit Polyclonal 1:1000 Abcam 
Phospho-Src (Y416) Rabbit Polyclonal 1:1000 Cell Signalling 
Phospho-Akt (Thr 308) Rabbit Polyclonal 1:1000 Cell Signalling 
Phospho-Akt (Ser 473) Rabbit Polyclonal 1:1000 Cell Signalling 
S6 Ribosomal Protein Rabbit Monoclonal 1:1000 Cell Signalling 
Phospho-S6 Ribosomal Protein (Ser240/244) Rabbit Polyclonal 1:1000 Cell Signalling 
Phospho-S6 Ribosomal Protein (Ser235/236) Rabbit Polyclonal 1:1000 Cell Signalling 
PI3 Kinase p85  Rabbit Polyclonal 1:1000 Cell Signalling 
p70 S6 Kinase  Rabbit Polyclonal 1:1000 Cell Signalling 
Phospho-p70 S6 Kinase (Thr421/Ser424) Rabbit Polyclonal 1:1000 Cell Signalling 
p44/42 MAPK (Erk1/2)  Rabbit Monoclonal 1:1000 Cell Signalling 
Phospho-p90RSK (Thr359/Ser363) Rabbit Polyclonal 1:1000 Cell Signalling 
p90RSK Rabbit Polyclonal 1:1000 Cell Signalling 
Anti-phosphotyrsoine Rabbit monoclonal 1:1000 Abcam 
Anti- MBP  Rabbit polyclonal 1:1000 Abcam 
 
 
 
 
Table 2-1 List of Primary antibodies, their source and working dilutions. 
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Secondary Antibody Type Dilution Supplier 
Donkey anti Rabbit 
IRDye 800CW 
Donkey Polyclonal 1:10,000 LICOR 
Goat anti- Mouse 
IRDye 680LT  
Goat Polyclonal 1:10,000 LICOR 
Goat anti-Rabbit HRP Rabbit 
 
1:5000 Sigma 
 
 
 
 
 
Table 2-2 List of Secondary antibodies, their source and working dilutions. 
 
2.3 Fluorescence Resonance Energy Transfer (FRET) 
imaging 
2.3.1 FRET based imaging 
Fluorescence Resonance Energy Transfer (FRET) is a non-radiative process of 
energy transfer from an excited donor fluorophore to an acceptor fluorophore. 
This phenomenon can only occur when the two fluorophores are in close 
proximity to one another. This technique has been exploited to generate 
genetically-encoded sensors to visualise cyclic adenosine monophosphate (cAMP) 
dynamics in intact living cells (Zaccolo, De Giorgi et al. 2000). A FRET-based 
indicator of cAMP is usually composed of a cAMP-binding domain and the cyan 
and yellow variants of the green fluorescent protein, CFP and YFP respectively. 
Excitation of CFP (430 nm) results in the transfer of the excited state energy to 
YFP (emitting a signal at 545 nm). Both emissions are collected for analysis. 
Binding of cAMP to the sensor induces a conformational change which alters the 
distance between the two fluorophores thereby affecting the energy transfer 
between them. When this occurs only the CFP emission (480nm) is detected. 
FRET changes can be expressed as changes in the ratio between CFP emission 
(480 nm)/ YFP emission (545 nm) upon illumination at a wavelength that excites 
selectively the donor CFP (430 nm). Changes in FRET can be used in real-time 
imaging experiments as variations in FRET efficiency correlates with changes in 
cyclic nucleotide intracellular concentration.  
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2.3.2 Fret Sensors 
The FRET sensors employed in this study were based on the Epac1-camps sensor 
(Nikolaev et al 2004), which consists of the cAMP-binding domain of Epac1 
sandwiched between CFP and YFP (Figure 3-1) and PKA-RI and PKA-RII localizing 
probes based on the AKAP-binding domain of PKA-RIα or PKA-RIIβ, fused to the 
cAMP-binding domain of EPAC (Di Benedetto, Zoccarato et al. 2008). Binding of 
cAMP to EPAC, results in a conformational change which increases the distance 
between the two fluorophores, reducing the FRET signal. These were kindly 
donated by Manuela Zaccolo. 
 
2.3.3 FRET Imaging Set up 
The set up utilised to perform FRET experiments is generally composed of an 
epiflouresence microscope, a light source that can excite the donor 
flouorophore, a beam splitter, a charge coupled device (CCD) camera and a 
computer. The FRET set up I have used for this thesis is described below: 
Microscope: Olympus 1x71 inverted microscope 
Objective: Olympus PlanApoN, 60X, NA 1.42 oil, 0.17/FN 26.5 
Immersion oil: IMMERSOL 518f Zeiss® 
Illumination Source: Xenon Mercury mixed gas arc burner (MT-ARC/HG LG2076, 
Ushio).  
Excitation Filters: CFP: excitation filter ET436/20x, dichroic mirror T455LP, 
(Chroma Technology). YFP: excitation filter ET500/30x, dichroic mirror T515LP 
(Chroma Technology). 
 Emission Filters: CFP: emission filter ET480/40m; YFP: emission filter 
ET535/30m (Chroma Technology). 
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 Beam Splitter: Dichroic mirror 505DCLP, YFP emission 545 nm, CFP emission 480 
nm (Chroma Technology). Light emitted by the sample comprises both CFP and 
YFP emission wavelengths. The dichroic mirror splits the emitted light in two 
beams. Wavelengths below 505 nm, which include CFP emission at 480 nm, are 
reflected and directed through a series of mirrors towards to the CFP emission 
filter. Wavelengths over 505 nm, which include YFP emission at 545 nm, pass 
through the dichoric and are directed to the YFP filter.  
Objective: Olympus PlanApoN, 60X, NA 1.42 oil, 0.17/FN 26.5 
 Immersion Oil: Immersion oil "IMMERSOL" 518F , Carl Zeiss  
Camera: ORCA AG (model C4742-80-12AG, Hamamatsu Photonics K.K., Japan) 
and HAMAMATSU camera controller. 
Computer: Dell DE6700, 2.66 GHz Intel Core 2 Duo CPU, 3.50 GB RAM, 400 GB 
hard drive, Windows XP Professional version 2002  
Image acquisition and analysis: All devices of this imaging system, such as the 
shutter, the motorised filter wheel and digital camera are controlled by Cell^R 
software (Olympus BioSystems). Offline image analysis was performed using 
ImageJ free software. 
2.3.4 Fret imaging acquisition 
Cells to be investigated were grown on 24mm glass cover-slips. When using 
Jurkat T cells cover slips were coated with Fibronectin (Sigma Aldrich). Targeted 
FRET sensors were transiently transfected 24 hours after seeding. FRET imaging 
experiments were performed 18 h after transfection.  The coverslip was firstly 
placed into a metal slide holder which, when sealed, creates a bath where 
stimuli can be directly added. The bath is filled with 900 μl of Hepes-buffered 
Ringer-modified saline solution containing 125 mM NaCl, 5 mM KCl, 1 mM Na3PO4, 
1 mM MgS04, 5.5 mM glucose, 1mM CaCl2, and 20 mM Hepes, pH 7.5 and 
maintained at room temperature. Cells were stimulated in real time with 10µM 
Apremilast, 10µM Roflumilast, 100μM IBMX (Sigma Aldrich) and 25µM Forskolin 
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(Sigma Aldrich) which were diluted to 10x final concentration in saline before 
addition. 
Before starting the experiment a standard protocol for all experiments was 
designed (detailed explanation of this protocol can be found in (Gesellchen et 
al. 2011). Briefly, the following parameters must be set and remain the same 
throughout each set of experiments:  
Binning: Most of the camera detection systems used for FRET have the ability to 
combine the information in adjacent pixel and make them into one effective 
superpixel. The benefit of binning is that there is a reduced noise in the signal. A 
binning of 1x1 means that each individual pixel is used as such; a binning of 2x2 
means that an area of 4 adjacent pixels is combined into one larger pixel, and so 
on. The drawback of binning is the loss of resolution. In the case of 2x2 binning; 
there is a fourfold increase in signal (the four single pixel contributions), a 
twofold loss in resolution but a twofold improvement in signal-tonoise. All 
experiments in this thesis have been acquired with binning 2x2.  
Exposure Time: The exposure time determines the period of time cells are 
illuminated and photons are collected and converted into charges for each 
channel. Optimal exposure time depends on the expression levels of 
fluorophores as well as the characteristics of the lamp, the optics and the 
camera. Generally an exposure time of 50 – 300 ms should be used, depending 
on the brightness of the sample. Increasing the exposure time allows the photons 
coming from the sample to accumulate and enhance the intensity of the image. 
At the same time this will increase the photobleaching of the fluorophores. 
There is also the risk of saturation of pixel charges and any further change in the 
signal cannot be detected. Experiments in this thesis have been acquired at an 
exposure time of 200 ms. 
Time course and Number of Acquisitions: The frequency of acquisition defines 
the interval between each data recording. This time between acquisitions 
depends on the characteristics of the sensor and the kinetics being investigated, 
but the normal range is 2 – 60 seconds. A short interval between illuminations 
may again result in photo-damaging of the cells and photo-bleaching of the 
signal. All experiments have been acquired with a frequency of 5 seconds. After 
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these parameters have been set, the experiment can be started. A small drop of 
oil is added to the objective lens before mounting the coverslip. A bright (well 
tranfected) cell, which is well attached and not contracting, is selected to 
perform the experiment. Cell^R software allows for a live display of the ratio 
between the mean fluorescence intensity of each channel, so it is possible to 
estimate when the signal has stabilised before adding the stimulus (usually after 
25 acquisitions). Further stimuli can be carefully added after each plateau 
phase. Only once the signal has stabilised after the final stimulus should the 
experiment be concluded.  
The first step in analysing the experiment is to split and align the images taken 
by the CFP and YFP channels (this and the following steps is conducted offline 
using ImageJ) resulting in a perfectly superimposed image.  Alignment, drift of 
the focus or change in the position of the cell is checked. A region of interest 
(ROI) is drawn on the background area and another around the cell of interest. 
Mean intensities for each acquisition is calculated and both CFP and YFP are 
subtracted from the background intensities, reducing any artefacts. cAMP 
changes are expressed as ΔR /R0 %, Where ΔR = Rt2 – Rt1. Rt1 is the average of 
at least 5 ratio (ICFP/IYFP) values calculated before the addition of the stimulus; 
Rt2 is the average of at least 5 ratio values at the plateau phase of reached after 
the addition of the correspondent stimulus. R0 corresponds to ICFP/IYFP at basal 
FRET level.   
Ratiometric measurements correct for unequal probe distribution and, within 
certain limits, for bleaching occurring during the experiment and changes in 
focus. Ratio drift is corrected and calculated on the basis of the baseline drift 
before stimulus is added. However, care must be taken when aligning the two 
channels (to avoid artefacts) and when interpreting ratio values. To assess 
whether the increases in ratio correspond to actual increases in cAMP, CFP and 
YFP intensities are plotted over time and accurately analysed on how 
fluorescence intensity changes in the two channels over time. Ratio changes can 
reliably be considered as FRET changes only when determined by a change in 
donor emission which is paralleled by an opposite change in acceptor emission 
(e.g. an increase in CFP emission must be paralleled by a decrease in YFP 
emission). 
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Compound Mode of Action Company 
Apremilast (CC-10004) PDE4 inhibitor Celgene 
Roflumliast (Daxas) PDE4 inhibitor Selleckchem 
IBMX Non specific PDE inhibitor Sigma-Aldrich 
Forskolin Adenylyl Cyclase Activator Sigma-Aldrich 
 
Table 2-3 Table of agonist and inhibitor treatments used in experiments. 
 
2.4 CelluSpots™ tyrosine kinase substrate arrays  
CelluSpots™ tyrosine kinase substrate arrays were purchased from Intavis 
(described in detail in Chapter 4). RASFs were seeded on 10cm3 plates and after 
24hrs cells were treated with 10μM Apremilast, 10μM Roflumilast, as well as one 
plate with no treatment, for 30 mins at 37°C. After 30 minutes media was 
removed and cells were washed twice in ice cold PBS. The cells were lysed with 
100μl lysis buffer [20mM Tris-Hcl (pH7.5), 150mM NaCl, 1mM Na2 EDTA, 1mM 
EGTA, 1% Triton X-100, 2.5mM sodium pyrophosphate, 1mM beta-
glycerophosphate,1mM Na3V04, 1Mm NaF, (2μg/ml leupeptin and 1mM PMSF 
added fresh before use). Protein concentrations of the cell lysates were 
quantified using the Bradford assay (described in section 2.1.7). The cell lysates 
were then stored in -80°C until use. Slides were blocked in 5% BSA, 50mM Hepes 
pH7.4, 150mM NaCl and 0.05% TX 100. The arrays were then overlaid with 
200μg/ml protein from each lysate in (1%BSA, 1x tyrosine kinase buffer (cell 
signalling) supplemented with 10μM final ATP) for two hours. Slides were washed 
briefly in TBST. Slides were then incubated with phospho-tyrosine antibody in 1% 
BSA/TBST at 1:2000 dilution overnight at 4°C. Slides were washed 5 times in 
TBST. Slides were then incubated with anti-rabbit HRP secondary antibody in 
1%BSA/TBST for one hour and then washed 5 times in TBST. The arrays were 
then subjected to analysis using the enhanced chemi-luminescence (ECL) method 
(Amersham BioSciences, Little Chalfont, UK) to detect antibody complexes 
bound to proteins of interest. Arrays were covered with ECL solution for 5 
minutes and then exposed to light-sensitive autoradiography film, which was 
developed on a Kodak X-Omat Model 2000 processor. Densitometric analysis was 
performed using Quantity One software (Biorad). 
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2.5 Reverse Phase Protein Array preparation of cells 
Cells were prepared for RPPA by seeding RASFs on 10cm3 plates and after 24 
hours either incubating with no treatment, 10μM Apremilast, or 10μM Roflumilast 
for 30 mins at 37°C. After the 30 minutes all media was removed and cells were 
washed twice in ice cold PBS and stored in -80°C. RPPA procedure was 
performed at Edinburgh Cancer Research Unit. Described in more detail in 
Chapter 4. Table 2-4 shows the antibodies tested in RPPA. 
FAK1   Cell Signalling 
Technologies 
3285 rabbit 
FAK1 P Y397 Cell Signalling 
Technologies 
3283 rabbit 
ATM Merck (Calbiochem) PC116 rabbit 
ATM/ATR Substrate P Ser/Thr Cell Signalling 
Technologies 
2851 rabbit 
Aurora A/B/C P Thr288/Thr232/Thr198 Cell Signalling 
Technologies 
2914 rabbit 
Bad P Ser136 Cell Signalling 
Technologies 
9295 rabbit 
Bad P Ser112 Cell Signalling 
Technologies 
9291 rabbit 
Bak Epitomics 1542-1 rabbit 
Met P Tyr1234 Signal way 11227-1 rabbit 
CamKII P Thr286 Cell Signalling 
Technologies 
3361 rabbit 
CrkL P Tyr207 Cell Signalling 3181 rabbit 
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Technologies 
FLT3 P Tyr591 P Tyr591 Cell Signalling 
Technologies 
3461 rabbit 
HSP27 (HSPB1) P Ser78 Cell Signalling 
Technologies 
2405 rabbit 
IkB-alpha Cell Signalling 
Technologies 
4812 rabbit 
IKK alpha/beta P Ser176/Ser177 Cell Signalling 
Technologies 
2078 rabbit 
JAK1 Cell Signalling 
Technologies 
3332 rabbit 
MEK1/2 Cell Signalling 
Technologies 
9122 rabbit 
MEK1/2 P Ser217/221 Cell Signalling 
Technologies 
9154 rabbit 
MNK1 (MKNK) P Thr197,Thr202 Cell Signalling 
Technologies 
2111 rabbit 
MSK1 P Ser376 Cell Signalling 
Technologies 
9591 rabbit 
PARP Cell Signalling 
Technologies 
9542 rabbit 
PI3 Kinase p110-alpha Cell Signalling 
Technologies 
4249 rabbit 
PKA RII P Ser96 Epitomics 1151-1 rabbit 
PKC (pan) P Ser660 (beta-2) Cell Signalling 9371 rabbit 
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Technologies 
PKC substrate P (R/K)X(S*)(Hyd)(R/k) Cell Signalling 
Technologies 
2261 rabbit 
PKC-zeta Cell Signalling 
Technologies 
9372 rabbit 
PKC-zeta/lambda P Thr410/403 Cell Signalling 
Technologies 
9378 rabbit 
Bim Epitomics 1036 rabbit 
GSK-3-beta Cell Signalling 
Technologies 
9315 rabbit 
Met P   11238  
Rap1 Cell Signalling 
Technologies 
4938 rabbit 
IGF-1R beta P Tyr1162,Tyr1163 Invitrogen 
(Biosource) 
44-804G rabbit 
ErbB-1/EGFR Cell Signalling 
Technologies 
2232 rabbit 
ErbB-2/Her2/EGFR P Tyr1248/Tyr1173 Cell Signalling 
Technologies 
2244 rabbit 
ErbB-3/Her3/EGFR Cell Signalling 
Technologies 
4754 rabbit 
ErbB-3/Her3/EGFR P Tyr1289 Cell Signalling 
Technologies 
4791 rabbit 
Stat5 Invitrogen 
(Biosource) 
44-368G rabbit 
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Stat5 Cell Signalling 
Technologies 
9351 rabbit 
EGFR P Tyr1173 Cell Signalling 
Technologies 
4407 rabbit 
Akt P Thr308 Cell Signalling 
Technologies 
2965 rabbit 
Met Cell Signalling 
Technologies 
4560 rabbit 
Stat3 P Tyr705 Cell Signalling 
Technologies 
9131  
IkB-alpha P Ser32 Cell Signalling 
Technologies 
2859 rabbit 
mTOR P Ser2448 Cell Signalling 
Technologies 
2971 rabbit 
S6 Ribosomal Protein Cell Signalling 
Technologies 
2217 rabbit 
S6 Ribosomal protein P Ser235,Ser236 Cell Signalling 
Technologies 
2211 rabbit 
p44/42 MAPK (ERK1/2) Cell Signalling 
Technologies 
9102 rabbit 
p44/42 MAPK (ERK1/2) P 
Thr202/Thr185,Tyr204/Tyr187 
Cell Signalling 
Technologies 
4370 rabbit 
Src Cell Signalling 
Technologies 
2109 rabbit 
Akt Cell Signalling 
Technologies 
9272 rabbit 
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Akt P Ser473 Cell Signalling 
Technologies 
4060 rabbit 
Akt P Ser473 Cell Signalling 
Technologies 
9271 rabbit 
PARP cleaved Asp214 Cell Signalling 
Technologies 
9541 rabbit 
beta-actin Cell Signalling 
Technologies 
4970 rabbit 
NFkB p65 Ser536 Cell Signalling 
Technologies 
3033 rabbit 
cdc25c P Ser216 Cell Signalling 
Technologies 
4901 rabbit 
Chk1 P Ser345 Cell Signalling 
Technologies 
2348 rabbit 
Chk2 P Thr68 Cell Signalling 
Technologies 
2661 rabbit 
c-Jun P Ser73 Cell Signalling 
Technologies 
9164 rabbit 
c-Myc Cell Signalling 
Technologies 
5605 rabbit 
E-Cadherin Cell Signalling 
Technologies 
3195 rabbit 
Rb Epitomics 2655-1 rabbit 
M-CSF P Tyr723 Cell Signalling 
Technologies 
3155 rabbit 
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4E-BP1 P Ser65 Cell Signalling 
Technologies 
9451 rabbit 
4E-BP1 P Thr37,Thr46 Cell Signalling 
Technologies 
2855 rabbit 
beta-Catenin Cell Signalling 
Technologies 
9562 rabbit 
beta-Catenin P Ser33,Ser37,Thr41 Cell Signalling 
Technologies 
9561 rabbit 
beta-Catenin P Thr41,Ser45 Cell Signalling 
Technologies 
9565 rabbit 
cdc25A Cell Signalling 
Technologies 
3652 rabbit 
VEGFR P Tyr1175 Cell Signalling 
Technologies 
3770 rabbit 
PTEN Cell Signalling 
Technologies 
9552 rabbit 
Tyk2 P Tyr1054,Tyr1055 Cell Signalling 
Technologies 
9321 rabbit 
Tsc-2 (Tuberin) P Thr1462 Cell Signalling 
Technologies 
3617 rabbit 
Tsc-2 (Tuberin) Cell Signalling 
Technologies 
3612 rabbit 
Survivin Cell Signalling 
Technologies 
2808 rabbit 
p70 S6 Kinase P Thr389 Epitomics 1175-1 rabbit 
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PTEN P Ser380,Thr382,Thr383 Cell Signalling 
Technologies 
9554 rabbit 
SAPK/JNK Cell Signalling 
Technologies 
9258 rabbit 
p70 S6 Kinase P Thr421,Ser424 Cell Signalling 
Technologies 
9204 rabbit 
LKB1 Cell Signalling 
Technologies 
3047 rabbit 
GSK-3-alpha/beta P Ser21/Ser9 Cell Signalling 
Technologies 
9331 rabbit 
Stat6 P Tyr641 Cell Signalling 
Technologies 
9361 rabbit 
SAPK/JNK P Thr182,Tyr185 Cell Signalling 
Technologies 
4668 rabbit 
p53 P Ser15 Cell Signalling 
Technologies 
9284 rabbit 
p53 Cell Signalling 
Technologies 
9282 rabbit 
p38 MAPK PThr180,Tyr182 Cell Signalling 
Technologies 
9211 rabbit 
p38 MAPK Cell Signalling 
Technologies 
9212 rabbit 
mTOR P Ser2448 Cell Signalling 
Technologies 
2971 rabbit 
mTOR Cell Signalling 
Technologies 
2972 rabbit 
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Stat1 P Ser727 Invitrogen 
(Biosource) 
44-382G rabbit 
Raf P Ser259 Cell Signalling 
Technologies 
9421 rabbit 
PLC-gamma1 P Tyr783 Cell Signalling 
Technologies 
2821 rabbit 
PDK-1 P Ser241 Cell Signalling 
Technologies 
3061 rabbit 
p90 S6 kinase (Rsk1-3) P Thr359,Ser363 Cell Signalling 
Technologies 
9344 rabbit 
PDK-1 Cell Signalling 
Technologies 
3062 rabbit 
p70 S6 Kinase Cell Signalling 
Technologies 
9202 rabbit 
JAK1 P Tyr1022,Thr1023 Invitrogen 
(Biosource) 
44-422G rabbit 
c-Myc P Thr58,Ser62 Epitomics 1203-1 rabbit 
SAPK/JNK P Thr183,Tyr185 Cell Signalling 
Technologies 
9251 rabbit 
S6 Ribosomal protein p Ser240,Ser244 Cell Signalling 
Technologies 
2215 rabbit 
S6 Ribosomal Protein Cell Signalling 
Technologies 
2217 rabbit 
Rb P  Ser807,Ser811 Cell Signalling 
Technologies 
9308 rabbit 
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Rb P Ser780 Cell Signalling 
Technologies 
9307 rabbit 
Raf P Ser338 Cell Signalling 
Technologies 
9427 rabbit 
MAPKAPK-2 P Thr334 Cell Signalling 
Technologies 
3041 rabbit 
Bax   1063.1 rabbit 
Stat6 Cell Signalling 
Technologies 
9362 rabbit 
Stat1 P Tyr701 Cell Signalling 
Technologies 
9171 rabbit 
Src (family) P Tyr416 Cell Signalling 
Technologies 
2101 rabbit 
Smad2/3 P Ser465/Ser423,Ser467/Ser425 Cell Signalling 
Technologies 
9510 rabbit 
Smad1/5 P Ser463/Ser465 Cell Signalling 
Technologies 
9516 rabbit 
Cyclin D1 P Thr286 Cell Signalling 
Technologies 
3300 rabbit 
AMPK alpha Cell Signalling 
Technologies 
2532 rabbit 
AMPK alpha P Thr172 Cell Signalling 
Technologies 
2535 rabbit 
Bax Epitomics 1063 rabbit 
Bcl-2 Epitomics 1017-1 rabbit 
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Bcl-x Epitomics 1018 rabbit 
Bid Epitomics 1008 rabbit 
Bim P Ser69 Cell Signalling 
Technologies 
4585 rabbit 
c-Jun N-term Epitomics 1254-1 rabbit 
Caspase 3 Cell Signaling 
Technologies 
9662 rabbit 
Caspase 3 cleaved Cell Signaling 
Technologies 
9664 rabbit 
CDK1 (p34cdc2)  P Tyr15 Cell Signaling 
Technologies 
9111 rabbit 
CREB P Ser133 Millipore (Upstate) 06-519 rabbit 
CREB Cell Signalling 
Technologies 
9197 rabbit 
EGFR P Tyr1068 Invitrogen 
(Biosource) 
44-788G rabbit 
GSK-3-beta P Ser9 Cell Signalling 
Technologies 
9336 rabbit 
IRS-1 Cell Signalling 
Technologies 
2382 rabbit 
Hexokinase Cell Signalling 
Technologies 
2867 rabbit 
eEF2 Cell Signalling 
Technologies 
2332 rabbit 
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P Myosin light chain Cell Signalling 
Technologies 
3761 rabbit 
Tuberin  P S1387 Cell Signalling 
Technologies 
5584 rabbit 
IRS-1 P S636/639 Cell Signalling 
Technologies 
2388 rabbit 
PKM2  XP(R) Cell Signalling 
Technologies 
4053 rabbit 
YB1 Cell Signalling 
Technologies 
4202 rabbit 
PABP1 Cell Signalling 
Technologies 
4992 rabbit 
SQSTM1 Cell Signalling 
Technologies 
8205 rabbit 
PLC-gamma1 Cell Signalling 
Technologies 
2822 rabbit 
Puma Cell Signalling 
Technologies 
4976 rabbit 
SHP2 P Tyr542 Cell Signalling 
Technologies 
3751 rabbit 
Smad2 P Ser465,Ser467 Cell Signalling 
Technologies 
3108 rabbit 
Tau P Ser396 Epitomics 1178-1 rabbit 
VEGFRP  Tyr1175  Cell Signalling 
Technologies 
2478 rabbit 
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VEGFR P Tyr951 Cell Signalling 
Technologies 
4991 rabbit 
Smad3 P Ser423,Ser425 Cell Signalling 
Technologies 
9520 rabbit 
BRCA1 Cell Signalling 
Technologies 
9010 rabbit 
CDK2  Epitomics 1134-1 rabbit 
MAPKAPK-2 Epitomics 1497-1 rabbit 
Stat3 Cell Signalling 
Technologies 
9132 rabbit 
Tau Epitomics 2368-1 rabbit 
VEGFR P Tyr1059 Cell Signalling 
Technologies 
3817 rabbit 
XIAP Cell Signalling 
Technologies 
2045 rabbit 
Zap70 Cell Signalling 
Technologies 
2705 rabbit 
S6 Ribosomal Protein Cell Signalling 
Technologies 
2211 rabbit 
Rsk2 Pser 227 Cell Signalling 
Technologies 
3556 rabbit 
NFkB p105/p50 GeneTex GTX110
585 
rabbit 
Calmodulin Calbiochem   
 84 
Calpain2 Cell Signalling 
Technologies 
2539 rabbit 
Calpastatin Cell Signalling 
Technologies 
4146 rabbit 
PDGFR P Tyr1021 Cell Signalling 
Technologies 
2227 rabbit 
PDGFR  P Tyr751 Cell Signalling 
Technologies 
4549 rabbit 
ErbB-2/Her2/EGFR Dako A0485 rabbit 
PKA Abcam ab26322 rabbit 
GFAP Abcam ab7260 rabbit 
beta-Tubulin Abcam ab6046 rabbit 
PKC-alpha  P Thr638 Abcam ab32502 rabbit 
Raf1 (C-12) Santa Cruz sc-133 rabbit 
Prohibitin Santa Cruz sc-
28259 
rabbit 
p21 CIP/WAF1 p Thr145 Santa Cruz 20220-R rabbit 
FRA1 (R20) Santa Cruz sc-605 rabbit 
p90 S6 kinase (Rsk1-3) Santa Cruz sc-231 rabbit 
PKC-gamma P Thr514 GeneTex GTX257
78 
rabbit 
mTOR P Ser2481 Millipore (Upstate) 09-
343SP 
rabbit 
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Ubiquitin (P4D1) Cell Signalling 
Technologies 
3936 mouseIg
G1 
Stat3 P Tyr705 Cell Signalling 
Technologies 
9138 mouseIg
G1 
Cyclin D1 Cell Signalling 
Technologies 
2926 mouseIg
G2a 
p21 CIP/WAF1 Cell Signalling 
Technologies 
2946 mouseIg
G2a 
CrkL Cell Signalling 
Technologies 
3182 mouseIg
G1 
HSP27 (HSPB1) Cell Signalling 
Technologies 
2402 mouseIg
G1 
Ki-67 (Annexin II, p36) Beckton Dickinson 610968 mouseIg
G1 
PKC-alpha Beckton Dickinson 610108 mouseIg
G2b 
Ras Beckton Dickinson 8100001 mouseIg
G1 
Stat1 Cell Signalling 
Technologies 
9176 mouseIg
G1 
SirT1 (IF3) Cell Signalling 
Technologies 
8469 mouse 
Histone H2A.X P Ser139 Millipore (Upstate) 05-636 mouseIg
G1 
CamKII alpha (22B1) P  Thr286 Abcam ab2724 mouseIg
G1 
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GAPDH Abcam ab9484 mouseIg
G2b 
 
 
Table 2-4 Table of Antibodies used in RPPA 
 
2.6 Phage Display 
Purified Protein PDE4A4 was provided by Frank Christian (Baillie Lab member) 
along with 10mM stock solutions of Apremilast and Roflumilast to Tedd Hupp 
(Edinburgh Cancer Research Institute) where Phage display technology was 
performed using their in house generated 12mer peptide library. 
2.7 Solid Phase Peptide Array and overlay experiments 
Peptide arrays are generated by direct synthesis of peptides onto Whatman 
cellulose membranes. Arrays were synthesised in-house, using an AutoSpot-Robot 
ASS 222 (Intavis Bioanalyical Instruments, Köhn, Germany). Arrays were stored 
dry at 4°C prior to use. To investigate possible protein-protein interactions, 
peptide arrays were first activated by rinsing for 1 minute in 100% ethanol, then 
washed in 1x TBST for 10 minutes. Non-specific binding was blocked by 
incubating with 5% milk solution for 2 hours at room temperature with gentle 
agitation. The array was then incubated with 10μg/ml of the purified protein of 
interest in 1% milk solution at 4°C overnight. After 16 hours, the array was 
washed 3 times for 10 minutes in TBST and incubated with primary antibody to 
the purified protein of interest at the appropriate dilution for 2 hours at room 
temperature. After a further 3 washes in TBST, the appropriate HRP-conjugated 
secondary antibody was added for 1 hour at room temperature. Finally, the 
array was washed 3 times in TBST. The arrays were then subjected to analysis 
using the enhanced chemi-luminescence (ECL) method (Amersham BioSciences, 
Little Chalfont, UK) to detect antibody complexes bound to proteins of interest. 
Arrays were covered with ECL solution for 5 minutes and then exposed to light-
sensitive autoradiography film, which was developed on a Kodak X-Omat Model 
2000 processor. 
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2.8 Basic Local Alignment Search Tool (BLAST) 
The BLAST algorithms used within this study to search protein databases can be 
found on the NCBI website (blast.ncbi.nlm.nih.gov) (Johnson, Zaretskaya et al. 
2008). 
2.9 Multiple Em for Motif Elicitation (MEME) 
MEME is an online consensus motif tool that discovers novel, ungapped motifs 
(recurring, fixed-length patterns) in nucleotide or protein sequences. 
MEME splits variable-length patterns into two or more separate motifs which can 
be found here: (http://meme.nbcr.net/meme/cgi-bin/meme.cgi 
2.10 Statistical analysis 
In this thesis, all experiments were performed an n of 3 times, unless otherwise 
specified in the figure legend. Statistical significance was calculated using either 
an unpaired two tailed t-test in Microsoft Excel or by one way analysis of 
variance (ANOVA) using Graph Pad Prism software, as stated in the figure 
legend. A P value > 0.05 was considered not significant (ns), P < 0.05 was 
considered significant (*), P < 0.01 was considered very significant (**), and P < 
0.001 was considered extremely significant (***). 
 
 
 
3 FRET imaging for real time cAMP dynamics in 
cells 
3.1 Introduction 
Within the cell, cAMP levels do not rise and fall uniformly throughout the cytosol 
following the activation and desensitization of cell surface receptors. Rather, 
cAMP levels are compartmentalized into microdomains influenced by proximity 
to the adenylyl cyclase enzymes located within the plasma membrane that 
produce cAMP, and by the phosphodiesterases which are associated with 
receptors such as the β1-adrenoceptor or the p75 neurotrophin receptor that 
hydrolyse cAMP (Houslay 2010). When cAMP is elevated, it binds to and activates 
the downstream effectors protein kinase A (PKA) or exchange protein directly 
activated by cAMP (EPAC), a cAMP effector protein that acts as a GTP exchange 
factor to activate the mini G-proteins RAP1 and RAP2. FRET probes based upon 
the structures of both these cAMP-binding proteins have proven to be useful 
tools in real time monitoring of cAMP microdomains. For example, the AKAP-
binding domains from the cytosolic PKA-RIα and the membrane-associated PKA-
RIIβ have been fused to the soluble EPAC cAMP-binding domain to generate two 
probes that reveal spatially distinct activation of PKA-RI and PKA-RII within 
cardiac myocytes (Di Benedetto, Zoccarato et al. 2008) (Figure 3-1). 
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Figure 3-1 PKA-RI and PKA-RII localizing probes based on the AKAP-binding domain of 
PKA-RIα or PKA-RIIβ, fused to the cAMP-binding domain of EPAC. (Di Benedetto, Zoccarato 
et al. 2008) Epac1 camps cytosolic localizing probe and Epac 1-nls nuclear localizing probe 
(Nikolaev, Bunemann et al. 2004).  
 
Using such probes, it is possible to monitor cAMP levels within specific 
microdomains of the cell that depend upon specific cellular activation signals for 
Gs-coupled receptors and PDE4 isoform targeting. My studies employed the use 
of these FRET probes to measure cAMP increases resulting from PDE4 inhibition 
with Apremilast and Roflumilast. The experiments in this chapter are unique as 
it has never been determined whether two different PDE4 inhibitors, which show 
no apparent isoform selectivity, alter cAMP dynamics differently.  
Fluorescence resonance energy transfer (FRET), which occurs when two 
compatible fluorophores are brought into molecular proximity, can be exploited 
to measure cAMP dynamics in real time and in intact cells, thus allowing 
detection of signalling events within the complexity of a three-dimensional cell 
with extremely high resolution in space and time. In my experiments, I used 
FRET reporters of cAMP that are genetically encoded and exploit FRET between 
a donor (CFP) and an acceptor fluorophore (YFP) fused to the amino- and 
carboxy- termini of a cAMP binding domain from Epac, respectively. In the 
absence of cAMP the donor and acceptor fluorophores are close enough for FRET 
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to occur. Upon binding of cAMP the cAMP-binding domain undergoes a 
conformational change that moves CFP and YFP apart, thereby diminishing FRET. 
With such sensors, changes in cAMP concentration ([cAMP]i) can be estimated by 
changes in FRET measured as changes in the CFP-to-YFP emissions ratio (480 
nm/545 nm), a value that is proportional to ([cAMP]i). 
3.2 Specific Aims 
The aim of this chapter was to determine whether Apremilast and Roflumilast 
triggered similar cAMP changes at multiple cellular locations. The experiments 
were performed using genetically encoded, FRET-based cAMP sensors to assess 
dynamic changes in cAMP levels in living cells as a consequence of challenge 
with Apremilast and Roflumilast. In doing this, I employed the use of not only (i) 
a cytosolic sensor but also those targeted to, (ii) the nucleus and (iii) to the RI 
and RII sub-populations of protein kinase A, to determine functionally distinct 
phenotypic outputs in cells. Experiments were conducted in the model cell line 
HEK 293 cells and then in more physiologically relevant cell lines,  Jurkat T 
Leukemia cells and Rheumatoid arthritis synovial fibroblasts (RASFs). The data 
provided here affords a unique opportunity of determining whether there is any 
selectivity of action between Apremilast and Roflumilast in regulating specific 
cAMP pools in cells. This may provide a means of linking changes in particular 
cAMP sub-compartments to specific functional effects and determining the 
relative efficacy of Apremilast and Roflumilast in regulating these.  
 
3.3 Experimental Procedure 
Changes in intracellular [cAMP] can be estimated from changes in FRET. FRET 
can be expressed as the ratio (R) of CFP emission intensity over YFP emission 
intensity following excitation of the cell at 440nm (R = CFP480/YFP545). 
Changes in  FRET ratio were expressed as the increase in CFP/YFP ratio over the 
CFP/YFP ratio at time zero (R0), as described in the Materials and Methods 
Section (Mongillo, McSorley et al. 2004). As [cAMP] rises in the vicinity of the 
FRET sensor, the two fluorophores move further apart, and FRET is diminished, 
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resulting in predominantly CFP emission. The CFP/YFP ratio therefore increases 
in proportion to the rise in [cAMP]i (Mongillo, McSorley et al. 2004). 
Cells were transfected with appropriate probes and FRET experiments were 
performed in resting cells as described in materials and methods section. cAMP 
was generated by real time stimulus of the transfected cells with either 
Apremilast or Roflumilast at a concentration of 10µM. The cells expressing the 
probes were then treated with saturating concentrations of 
isobutylmethylxanthine (IBMX) 100µM followed by forskolin (FSK) 25µM to obtain 
a maximal/saturating response. FSK is an adenylyl cyclase activator and 
stimulates cAMP production by Adenylate cyclases, whereas IBMX is a non-
specific PDE inhibitor that blocks cAMP degradation. 
3.4 Results 
Initial FRET experiments were performed in HEK293 cells using the cytosolic 
FRET based sensor for cAMP Epac1-camps (Nikolaev, Bunemann et al. 2004). As 
shown in figure 3-2 the results obtained show that Apremilast induces 
significantly higher concentrations of cAMP in the cytosol compared to 
Roflumilast in HEK 293 cells. There is no evidence of the “super cAMP” elevation 
caused by Roflumilast, which was shown by Schafer and collegues (Schafer, 
Parton et al. 2014) where Roflumilast elevated cAMP more potently in 
prostaglandin E2 stimulated human peripheral blood monocytes with an IC50 OF 
68nM and to a level approximately 50% higher than that of Apremilast , Rolipram 
and Cilomilast.  Apremilast has an effective half maximal concentration (EC50) 
of 1.4µM. It is possible that HEK cells may need to be stimulated to induce cAMP 
before addition of the inhibitors in order to see this super cAMP by Roflumilast. 
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Figure 3-2 Apremilast stimulation of HEK 293 cells induces higher concentrations of cAMP 
in the cytosol compared to Roflumilast.  (A-B) are representative images of HEK cells 
tranfected with the cytosolic EPAC1-camps sensor. (C) Summary of experiments performed 
n=18.  Error bars represent SEM * P <0.05.  (D-E) Representative kinetics of % FRET 
changes generated in the cytosol upon stimulation of  either 10 µM Apremilast or 10 µM 
Roflumilast followed by 100µM IBMX and 25µM forskolin. Values are normalised to the ratio 
value at time t=0 (Ro) (scale bar 10µm). Data are corrected for bleaching effect as calculated 
on the basis of the baseline drift before the stimulus. 
 
 I subsequently tested cAMP elevation differences in HEK 293 cells using both the 
cytosolic PKA-RIα and the membrane-associated PKA-RIIβ sensors. These 
experiments showed differences in cAMP elevation between Apremilast and 
Roflumilast in the cytosolic and membrane associated compartments. Figure 3-3 
below shows Apremilast elevates higher levels of cAMP in the cytosolic 
associated PKAR1 compartment whereas figure 3-4 showed the opposite where 
Roflumilast elevates higher levels of cAMP in the membrane associated PKAR11 
compartment. This is consistent with information Celgene provided (discussed in 
Chapter 1) where binding of Apremilast and Roflumilast was tested using the low 
affinity (cytosolic, isolated from cell lysate supernatant) and high affinity 
(membrane-associated, isolated from cell lysate pellet) forms of PDE4A4. Results 
indicated that while Roflumilast bound to the membrane-associated fraction of 
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PDE4A4 with 12-fold greater affinity than the cytosolic fraction, Apremilast was 
just the opposite. Apremilast actually exhibited 7-fold lower affinity for the so 
called high affinity form of PDE4A4. This indicated that Apremilast, unlike 
Roflumilast and Rolipram, didn’t readily bind to the membrane-associated 
fraction of PDE4A4. So it was expected that there would be a difference in cAMP 
elevation within micro domains due to this differential binding of these 
inhibitors to the ‘high’ and ‘low’ affinity forms of PDE4A4 (discussed in Chapter 
1). 
 
 
 
Figure 3-3 Apremilast stimulation of HEK 293 cells induces higher concentrations of cAMP 
in the PKA-R1 compartment (cytosolic) compared to Roflumilast.  (A-B) are representative 
images of HEK cells tranfected with the cytosolic associated R1-Epac sensor. (C) Summary 
of experiments performed n=12.  Error bars represent SEM * P <0.05.  (D-E) Representative 
kinetics of % FRET changes generated in the cytosol upon stimulation of  either 10 µM 
Apremilast or 10 µM Roflumilast followed by 100µM IBMX and 25µM forskolin. Values are 
normalised to the ratio value at time t=0 (Ro). (scale bar 10µm). Data are corrected for 
bleaching effect as calculated on the basis of the baseline drift before the stimulus. 
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Figure 3-4 Rofllumilast stimulation of HEK 293 cells induces higher concentrations cAMP in 
the PKA-R11 compartment (membrane associated) compared to Apremilast.  (A-B) are 
representative images of HEK cells tranfected with the membrane associated R11-Epac 
sensor. (C) Summary of experiments performed n=14.  Error bars represent SEM * P <0.05.  
(D-E) Representative kinetics of % FRET changes generated in the cytosol upon stimulation 
of  either 10 µM Apremilast or 10 µM Roflumilast followed by 100µM IBMX and 25µM 
forskolin. Values are normalised to the ratio value at time t=0 (Ro). (scale bar 10µm). Data are 
corrected for bleaching effect as calculated on the basis of the baseline drift before the 
stimulus. 
 
 
 
In a bid to use a more relevant cell line and to perhaps unveil the “super cAMP” 
elevation shown by Celgene, Jurkat T cells were tranfected with the EPAC1-
camps cytosolic sensor. The cells were treated with both Apremilast and  
Roflumilast as before and results are shown below in figure 3-5. The oppossite 
effect was found in these cells (compared with HEK293), Roflumilast induced 
higher levels of cAMP compared to Apremilast. It could perhaps be said the super 
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cAMP elevation shown in peripheral blood monocytes (Schafer, Parton et al. 
2014) is observed in these cells as the levels of cAMP elevation caused by 
Roflumilast appear to be double that of Apremilast in the cytosol. However, 
Jurkat cells proved too difficult to continue with their use in FRET experiments 
as they are suspension cells and so had to be attached to coverslips coated with 
fibronectin. This was very time consuming as several coverslips had to be 
discarded when cells that were not fully attached moved when stimulus was 
added. Therefore it was decided to move onto a primary cell line, Rheumatoid 
Arthrtis synovial fibroblasts (RASFs). These are cells harvested from the synovial 
joints of patients with Rheumatoid arthritis. These were particularly relevant 
and interesting cells to use as Apremilast may prove useful for the treatment of 
this disease in the future (Schett, Sloan et al. 2010). Experiments were 
performed in these cells with both the cytosolic Epac-camps sensor in 
conjunction  with a nuclear localised Epac sensor. Results of FRET experiments 
in these cells (figures 3-6 and 3-7) revealed that there appears to be cell type 
specific differences in cAMP elevation between Apremilast and Roflumilast, as 
Apremilast elevates higher levels of cAMP in the cytosol in RASFs compared to 
Roflumilast, whereas it was the opposite in Jurkat T cells (figure 3-5). 
Interestingly, however when cAMP elevation was measured in the nucleus of 
RASFs (figure 3-7) it revealed Roflumilast significantly elevates cAMP levels 
whereas Apremilast seems to have little or no effect in the nucleus. This major 
difference could perhaps lead to signficant physiological differences in the 
effects produced by these two inhibitors.  
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Figure 3-5 Roflumilast stimulation of Jurkat T cells induces higher concentrations of cAMP 
in the cytosol compared to Apremilast.  (A-B) are representative images of Jurkat T cells 
tranfected with the cytosolic EPAC1-camps sensor. (C) Summary of experiments performed 
n=14.  Error bars represent SEM * P <0.05.  (D-E) Representative kinetics of % FRET 
changes generated in the cytosol upon stimulation of  either 10 µM Apremilast or 10 µM 
Roflumilast followed by 100µM IBMX and 25µM forskolin. Values are normalised to the ratio 
value at time t=0 (Ro). (scale bar 10µm). Data are corrected for bleaching effect as calculated 
on the basis of the baseline drift before the stimulus. 
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Figure 3-6 Apremilast stimulation of Rheumatoid Arthritis Synovial fibroblast cells induces 
higher concentrations of cAMP in the cytosol compared to Roflumilast.  (A-B) are 
representative images of HEK cells tranfected with the cytosolic EPAC1-camps sensor. (C) 
Summary of experiments performed n=18.  Error bars represent SEM ** P <0.005.  (D-E) 
Representative kinetics of % FRET changes generated in the cytosol upon stimulation of  
either 10 µM Apremilast or 10 µM Roflumilast followed by 100µM IBMX and 25µM forskolin. 
Values are normalised to the ratio value at time t=0 (Ro). (scale bar 10µm). Data are 
corrected for bleaching effect as calculated on the basis of the baseline drift before the 
stimulus. 
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Figure 3-7 Apremilast stimulation of Rheumatoid Arthritis Synovial fibroblast (RASF) cells 
has no effect on cAMP production in the nucleus whereas Roflumilast does stimulate cAMP 
production in the nucleus.  (A-B) are representative images of RASF cells transfected with 
the nuclear localised EPAC1-nls camps sensor. (C) Summary of experiments performed 
n=12.  Error bars represent SEM *** P <0.0005.  (D-E) Representative kinetics of % FRET 
changes generated in the cytosol upon stimulation of  either 10 µM Apremilast or 10 µM 
Roflumilast followed by 100µM IBMX and 25µM forskolin. Values are normalised to the ratio 
value at time t=0 (Ro). (scale bar 10µm). Data are corrected for bleaching effect as calculated 
on the basis of the baseline drift before the stimulus. 
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3.5 Discussion 
The FRET experiments performed in this chapter have shown for the first time 
that Apremilast and Roflumilast do appear to regulate different pools of cAMP 
within the cell which may be cell type specific. For example in HEK 293 and 
RASFs, Apremilast seems to induce significantly higher levels of cAMP compared 
to Roflumilast in the cytoplasm. The opposite was found in Jurkat T cells where 
Roflumilast elevated higher levels of cAMP compared to Apremilast . Apremilast 
and Roflumilast also exert differential effects in the PKAR1 and PKAR11 which 
are associated with the cytoplasm and membrane compartments respectively. 
The most interesting difference revealed from these FRET experiments however, 
was that in the nucleus of RASFs, Roflumilast significantly elevates cAMP levels 
whereas Apremilast seems to have little or no effect. This could perhaps lead to 
Roflumilast having a distinct biological effect from that of Apremilast,  as it is 
able to enter the nucleus in these cells and elevate cAMP which could perhaps 
elicit different downstream PKA signalling effects from that of Apremilast, which 
is seemingly unable to affect cAMP in the nucleus in these cells at least. Perhaps 
Roflumilast has nuclear penetrating ability and gets into nucleus to increase 
cAMP and activate PKA to produce different signals from Apremilast in the 
cytosol or membrane compartment, as it has been shown that some nuclear 
localised GPCRs produce different cell signals from that localised in the cell 
membrane (Yu, Zhong et al. 2013)  
 
The “super cAMP” elevation that (Schafer, Parton et al. 2014) found could 
perhaps be explained then by the possibilty that there may be more cAMP 
specific PDEs in the nucleus of that cell type (PBMCs) leading to this larger 
increase in cAMP elevation compared to Apremilast, Rolipram and Cilomilast .  
The “super cAMP elevation” caused by roflumilast may also be caused by off-
target effects, such as agonism or antagonism of a G-protein coupled receptor 
(adenosine, adrenergic, histamine, etc.), direct activation of adenylyl cyclase, 
or other non-PDE4 effects. Data recenlty published by (Schafer, Parton et al. 
2014) has shown that Apremilast doesn’t significantly inhibit any other PDEs, 
kinases, enzymes or receptors and mediates it’s effects in monocytes and T cells 
via PKA and NF-κB pathways. Therefore the only known molecular targets at this 
point for Apremilast  are the PDE4 family of enzymes. 
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It is known that Roflumilast inhibits Lipopolysaccharide (LPS)-induced 
inflammatory mediators via the suppression of Nuclear Factor-κB, p38 Mitogen-
activated protein kinase, and C jun NH2-terminal kinase activation (Kwak, Song 
et al. 2005).Roflumilast inhibits production of of several inflammatory mediators 
such as NO, TNF-α and IL-1β in RAW264.7 cells via the inhibition of NF-κB 
activation and SAPK/JNK and p38 MAP kinase pathways . Kwak and collegues 
(Kwak, Song et al. 2005) found that besides Roflumilast inhibiting NF-κB, 
Roflumilast may inhibit proinflammatory gene expression via an additional 
mechanism of JNK and p38 MAP kinase inactivation in RAW 264.7 macrophages.  
 
Gene chip analysis has also recently been published by (Schafer, Parton et al. 
2014) where clear differences in gene expression were noted between 
Apremilast, Roflumilast and Cilomilast. It identified the top gene sets regulated 
by all three PDE4 inhibitors as belonging to the immune response, inflammatory 
response and, cytokine activity, chemokine signalling and stress response 
biogroups. See table 3-1 and 3-2. However there were numerous gene sets that 
were regulated by Roflumilast and Cilomilast but not by Apremilast. The main 
gene set differences found between the three PDE inhibitors belonged to the 
cytoplasmic ribosome, peptide chain elongation, ribosome, protein complex 
disasembly and viral infectious cycle biogroups. Therefore it was noted that 
while Apremilast gene regulation was focused on the inflammatory and immune 
response, cytokine and chemokine pathways and stress response genes, 
cilomilast and Roflumilast exhibited a wider pattern of gene regulation that 
included ribosomal genes, protein translation and disassembly, and the viral 
response genes. Specific targets of gene regulation by Apremilast identified in 
this paper by (Schafer, Parton et al. 2014) included the inhibition of many 
chemokines, chemokine receptors and Th1 cytokine genes, as well as the 
enhancement of the genes encoding the anti-inflammatory factor SOCS-3, which 
is an inhibitor of the cytokine receptor/JAK-STAT pathway and was previously 
reported to be induced by cAMP elevation via the activation of Epac1 (Williams 
and Palmer 2012). So, Apremilast may be able to suppress cytokine signalling 
through IL-6 and other class 1 cytokine receptors via the activation of Epac 1, 
expression of SOCs-3 and by the inhibition of  JAK-STAT signalling. 
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Table 3-1 Top scoring gene transcript biogroups regulated concordantly by 
PDE4 inhibitors in LPS-stimulated monocytes (Schafer, Parton et al. 2014). 
 
 
Table 3-2 Top-scoring transcript biogroups regulated discordantly by 
Apremilast versus other PDE4 inhbitors in LPS-stimulated monocytes 
(Schafer, Parton et al. 2014). 
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cAMP signalling in the nucleus remains largely unresearched, however several 
papers have noted PKA and AKAP signalling routes to the nucleus (Okamoto, 
Takemori et al. 2004, Haj Slimane, Bedioune et al. 2014).  
While most PKA substrates are phosphorylated by PKA anchored by an AKAP in 
close vicinity to the substrate, PKA signalling to the nucleus involves nuclear 
entry of the free C subunit, due to size exclusion preventing the entry of the PKA 
holoenzyme. The classical view of nuclear PKA signalling is where cAMP binds to 
PKA outside the nucleus where the C subunits dissociate from the R subunits and 
then cross the nuclear envelope by passive diffusion, a slow process 
(Harootunian, Adams et al. 1993). However, recent evidence revealed that in 
HEK293 cells, a nuclear resident pool of PKA exists which is isolated from cAMP 
that is generated in the plasma membrane by AKAP anchored PDE4 (Sample, 
DiPilato et al. 2012). This research  revealed that PDE4D played an important 
role in controlling nuclear PKA activity in HEK293 cells as PDE4 inhibition 
dramatically accelerated the nuclear PKA response  to a chronic Forskolin 
treatment, (Sample, DiPilato et al. 2012) However, another group(Haj Slimane, 
Bedioune et al. 2014) revealed a different arrangement in cardiac myocytes, 
when they found that there was no acceleration of nuclear PKA activation upon 
inhibtion of PDE4  and suggested that perhaps in cardiac myocytes a different 
arrangement of components may exist  with PDE4 being located at the nuclear 
envelope (Lugnier, Keravis et al. 1999, Dodge, Khouangsathiene et al. 2001). 
Here the PDE4 pool would control the extent of C subunits released upon β-
adrenergic stimulation and gate the  transfer of C subunits into the nucleus from 
an extra-nuclear pool of PKA holoenzyme.  
 
In cardiac myocytes, it has been reported that muscle AKAP (mAKAP) targets PKA 
to multiple locations including the nucleus (Yang, Drazba et al. 1998) and the 
nuclear membrane (Kapiloff, Jackson et al. 2001). mAKAP is known to bind 
PDE4D3, a cAMP specific PDE isoform that may control cAMP levels in this 
compartment and therefore modulate the release of PKA C subunits into the 
nucleus or the nuclear membrane. The pool of PKA that delivers the C subunit 
for diffusion into the nucleus is thought to be located in the cytoplasm. 
Interestingly, disruption of anchored PKA complexes by overexpression of soluble 
AKAP fragments affects cAMP signalling to the nucleus and gene regulation 
measured for example CREB phosphorylation (Feliciello, Giuliano et al. 1996) 
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Furthermore, targetting of PKA via AKAP75/79/150 associated with the 
cytoskeleton enhances signalling to the nucleus by delivering the C subunit to 
the nucleus (Feliciello, Li et al. 1997). Anchoring of PKA11 in actin cortical 
cytoskelaton increases the rate, magnitude and sensitivity of cAMP signalling in 
the nucleus also (Feliciello, Li et al. 1997). 
 
A study by (Haj Slimane, Bedioune et al. 2014) used FRET probes targeted to the 
cytoplasm and nucleus to study spatiotemporal dynamics of nuclear cAMP and 
PKA activity in adult cardiac myocytes and revealed a differential integration of 
cytoplasmic and nuclear PKA responses to β-AR stimulation. β-AR stimulation 
activates a GTP-binding protein (Gs), which stimulates adenylyl cyclase to 
produce cAMP, which in turn activates PKA. PKA is well characterised in various 
subcellular compartments of adult cardiac myocytes, its regulation in the 
nucleus, however, is unknown. PKA regulates many effetors in cardiac myocytes 
including CREB and class 11 histone diacetylase (HDAC 4 and 5) in the nucleus 
(Muller, Neumann et al. 2000, Ha, Kim et al. 2010, Backs, Worst et al. 2011, 
Chang, Lee et al. 2013). 
Hence, it is possible that distinct PDEs and AKAPs are tethered to nuclear 
compartments and Roflumilast is able to inhibit these PDEs and activate PKA in 
the nucleus, which could lead to different physiological outputs for Roflumilast 
compared to Apremilast. PDE4D3 is known to bind mAKAP at the nuclear 
membrane, mAKAP is expressed in myocytes,skeletal muscle and the brain. In 
COPD, in addition to pulmonary manifestations, patients develop systemic 
problems, including skeletal muscle and other organ specific dysfunctions. Could 
Roflumilast be targetting PDEs tethered to this mAKAP in skeletal muscle, 
increasing cAMP and increasing anti inflammatory mediators in this vicinity, 
helping to alleviate symptoms? 
 
Another interesting study, (Yang, Polanowska-Grabowska et al. 2014) found that 
nuclear PKA activity in myocytes is not regulated by nuclear cAMP 
compartmentation but rather by direct compartmentation of the PKA catalytic 
subunit and that the nucleus may constitute a PKA signalling domain distinct 
from the cytosol.They observed that cytosolic and  nuclear PKA exhibit different 
sensitivities to β-adrenergic stimulation which suggested that the nucleus 
contains an independant PKA signalling microdomain. This PKA 
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compartmentation drove differential activation of PKA substrates associated 
with contractility and hypertrophy. This data suggests that Roflumilast induced 
cAMP increases in the nucleus of RASF could result in different physiological 
responses from those driven by Apremilast. Perhaps an increase in nuclear cAMP 
by Roflumilast  will cause a differential phosphorylation of PKA substrates 
compared to those in the cytosol. It has also been suggested that some nuclear 
localised GPCRs produce different cell signals from that localised on the cell 
membrane (Yu, Zhong et al. 2013). Perhaps nuclear PKA signalling could lead to 
different physiological outcomes in different cell types and this could unveil PKA 
signalling differences between Apremilast and Roflumilast with Apremilast 
seemingly unable to affect cAMP in the nucleus in these cells at least. 
 
In light of the information discussed above and the data revealing that there is 
selectivity of action between Apremilast and Roflumilast in regulating specific 
cAMP pools in cells, which therefore will be likely to then result in a unique set 
of phentotypic outputs. The following chapters of this thesis therefore will try to 
elucidate any differential signalling events triggered by each of these PDE4 
inhibitors. 
 
 
 
 
 
 
4 Profiling Signalling differences between 
Apremilast and Roflumilast.  
 
4.1 Comparing effects of Apremilast and Roflumilast on 
PKA phosphorylation states in cells 
4.1.1 Introduction  
In the presence of inflammatory extracellular signals, G-protein coupled 
receptors bind with a number of ligands such as leukotrienes, prostaglandins, 
chemokines and histamines which activate adenylyl cyclase and promote 
increased production of cAMP (Serezani, Ballinger et al. 2008). cAMP mediates a 
myriad of cellular responses and biological functions via the activation of a 
limited number of effectors including the cAMP-dependent protein kinase A  
(PKA), the exchange proteins directly activated by cAMP (Epac 1 and 2) and the 
cAMP-gated ion channels (CNG).  cAMP interacts with PKA and Epac to elicit 
changes in protein expression (Zambon, Zhang et al. 2005).The 
phosphodiesterase 4 inhibitors Apremilast and Roflumilast are known to mediate 
their effects in monocytes and T cells via PKA and NF-κB pathways (Kwak, Song 
et al. 2005, Schafer, Parton et al. 2014). PKA is anchored to specific sub cellular 
targets by its interaction with AKAPs, therefore only particular pools of PKA are 
exposed to activating concentrations of cAMP at any one time (Baillie 2009). 
Therefore, because of the discrete compartmentalisation of signalling proteins, 
signals from one second messenger (in this case cAMP) can result in the 
activation of distinct signal transduction pathways, and diverse physiological 
responses (Buxton and Brunton 1983). Hundreds of cytosolic and nuclear proteins 
have been identified as substrates for PKA (Tasken, Skalhegg et al. 1997). 
Regulation of transcription by PKA is mainly achieved by direct phosphorylation 
of the cAMP-responsive binding element family of transcription factors, including 
cAMP response (CRE)-binding protein (CREB) and activating transcription factor -
1 (ATF-1), while inhibiting the activity of other promoters such as the nuclear 
factor kappa B (NF-κB) (Ollivier, Parry et al. 1996, Schafer 2012). CREB is 
involved in numerous physiological processes and regulates gene expression in a 
phosphorylation dependent fashion (Brindle, Linke et al. 1993, Mayr and 
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Montminy 2001). Ser 133 is the major phosphorylation site of CREB that is 
phosphorylated by PKA (Gonzalez, Yamamoto et al. 1989). The phosphorylation 
of Serine residues alters the affinity of CREB to CREB-binding protein and p300, 
and results in a change in transcription efficiency (Chrivia, Kwok et al. 1993, 
Lundblad, Kwok et al. 1995, Mayr and Montminy 2001). Effects of 
phosphorylation of PKA on CREB , ATF-1 and NF-κB cause decreased mRNA 
expression of cytokines and other inflammatory mediators as well as increased 
expression of anti-inflammatory signals (Jimenez, Punzon et al. 2001, Serezani, 
Ballinger et al. 2008). In this chapter I will employ a number of different 
techniques to try and elucidate signalling differences between Apremilast and 
Roflumilast.  
4.1.2 Specific aims 
Spatially distinct pools of cAMP control particular PKA sub-populations able to 
phosphorylate distinct substrate cohorts (Baillie 2009). Insight into this can be 
gained by the use of phospho-antibodies to proteins that are phosphorylated by 
PKA and also by antisera raised to the PKA target motif ‘RRxS’ that are able to 
detect a variety of PKA substrates. I exploited this powerful technology to 
complement the FRET studies in chapter 3 in order to assess whether Apremilast 
and Roflumilast cause differential effects on the PKA phosphorylation state of 
proteins in cells. I have specifically evaluated (i) selectivity of phosphorylation  
of a defined set of proteins; (ii) differences in the magnitude of phosphorylation 
of particular proteins (iii) differential temporal phosphorylation of a defined set 
of proteins and (iv) the effect of both drugs under basal conditions or at high 
cAMP following activation of adenylate cyclase. I studied the effects of 
Apremilast and Roflumilast in a range of cell types, HEK 293, Jurkat T cell 
leukemia and U937 monocytic cells. Cells were treated with 0.1, 1 and 10 µM 
Apremilast and 0.01, 0.1 and 1 µM Roflumilast with and without forskolin at 10 
µM for 30 mins and then western blot analysis was performed using specific 
antibodies for known PKA substrates.  
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4.1.3 Results 
The effects of Apremilast and Roflumilast on CREB phosphorylation at Ser 133 
was studied in HEK293, Jurkat T and U937 cells. The results in (figure 4-1) show 
that there were little differences between Apremilast and Roflumilast on CREB 
phosphorylation in any of the cell lines. Apremilast 10µM with and without 
forskolin 10µM, significantly induced CREB phosphorylation at Ser133 in Jurkat T 
cells (C) whereas Roflumilast application alone did not have a significant 
increase in CREB phosphorylation, but did when co-treated with Forskolin 10µM. 
In HEK 293 cells (B) Apremilast shows a trend in increased CREB phosphorylation 
but this increase is not statistically significant, however when treated with 
Forskolin 10µM, Apremilast does show a statistically significant increase in CREB 
Ser133 phosphorylation. In U937 cells (A) however, both Apremilast (10µM) and 
Roflumilast (1µM) significantly increase CREB phosphorylation at Ser133 when 
they are added along with 10µM forskolin. Neither induce a statistically 
significant increase when applied alone, however there does look to be a trend 
in increased phosphorylation with both inhibitors, which is indicative of PKA 
activation. 
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Figure 4-1  Effect of Apremilast and Roflumilast on CREB phosphorylation. A-C Western 
blot analysis of CREB protein Ser133 phosphorylation in A) U937 cells B) HEK 293 cells and 
C) Jurkat T cells. A representative Western blot is presented with each graph. All treatment 
groups were compared with DMSO by one-way ANOVA followed by Dunn’s Multiple 
Comparison Post- Test (n=3. No statistically significant differences were observed between 
Apremilast and Roflumilast. *p<0.05 versus DMSO, **p<0.01 versus DMSO, 30-minute 
stimulation with drug. 
 
Detection of ‘pan’ PKA phosphorylated proteins (PKA phospho-proteome) using a 
PKA substrate antiserum  raised against a phosphorylated PKA target motif (R-X-
X-pS/T) that is able to detect a variety of PKA substrates  was then used to 
evaluate the effects of Apremilast and Roflumilast. Jurkat T cells were treated 
as before which is described in the materials and methods section. The results 
showed (figure 4-2) that although there was not a statistically different increase 
in the phosphorylation of PKA substrates in Jurkat T cells with either inhibitor 
there does look to be a trend in increased phosphorylation of PKA substrates 
with the consensus motif R-X-X-pS/T when treated together with Forskolin 
(10µM).  
109 
 
109 
 
 
Figure 4-2 Effect of Apremilast and Roflumilast on PKA phosphorylation. Western blot 
analysis of PKA substrate phosphorylation (R-X-X-p S/T) in Jurkat T cells. A representative 
Western blot is presented with graph. All treatment groups were compared with DMSO by 
one-way ANOVA followed by Dunn’s Multiple Comparison Post- Test (n=3). No statistically 
significant differences were observed between Apremilast and Roflumilast. 30-minute 
stimulation with drug.  
 
Members of the vasodilator-stimulated phosphoprotein (VASP) family are 
important regulators of actin cytoskeletal dynamics whose functions and protein-
protein interactions are regulated by (PKA) at serine 157 (Butt, Abel et al. 1994). 
Therefore, the effects of Apremilast and Roflumilast on the phosphorylation of 
this well defined PKA substrate was studied (figure 4-3) in both HEK 293 and 
U937 cells. The results show that in U937 cells neither Apremilast or Roflumilast 
increase the phosphorylation of VASP at ser 157 on their own however they both 
significantly increase VASP phosphorylation at (10µM) Apremilast and (1µM) 
Roflumilast when added with Forskolin (10µM). The opposite is seen in HEK 293 
cells however, where only Apremilast (10µM) with Forskolin (10µM) significantly 
increases the phosphorylation of VASP at Ser133 whereas Roflumilast has no 
effect on VASP phosphorylation in these cells. 
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Figure 4-3 Effect of Apremilast and Roflumilast on the phosphorylation of VASP at Ser157. 
A-B Western blot analysis of VASP phosphorylation in A) U937 cells and B) HEK 293 cells. A 
representative Western blot is presented with each graph. All treatment groups were 
compared with DMSO by one-way ANOVA followed by Dunn’s Multiple Comparison Post- 
Test (n=3). No statistically significant differences were observed between Apremilast and 
Roflumilast in U937 cells. *p<0.05 versus DMSO, **p<0.01 versus DMSO ***p<0.001 versus 
DMSO, 30-minute stimulation with drug. 
 
 
 
 
4.1.4 Discussion 
The data presented shows that Apremilast and Roflumilast both significantly 
increase CREB phosphorylation in Jurkat T cells and U937 cells in the presence of 
Forskolin which is consistent with reports that Apremilast and Roflumilast 
activate the PKA pathway as it is known that PDE4 inhibitors increase 
intracellular cAMP which leads to the phosphorylation and activation of PKA 
(Schafer, Parton et al. 2010), which results in the up regulation of CREB and 
down regulation of NFκB-dependent genes (Houslay, Schafer et al. 2005, 
Schafer, Parton et al. 2010). Apremilast along with forskolin treatment in HEK 
cells increases the phosphorylation of CREB but not Roflumilast in these cells. 
There does seem to be cell type differences in whether the inhibitors induce 
CREB phosphorylation or not.  
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U937 and Jurkat T cell data in figure 4-1 is consistent with a recent paper by 
(Schafer, Parton et al. 2014) that showed Apremilast activates the PKA-
CREB/ATF-1 pathway in Jurkat T and THP-1 monocytic cells, which results in 
enhancement of CRE-driven gene transcription and inhibition of NFκB- driven 
gene transcription. In addition to this it has been shown that Apremilast inhibits 
NF-Κb transcriptional activity, which normally drives expression of genes such as 
TNFα (Schafer, Parton et al. 2010). 
In human peripheral blood mononuclear cells, cAMP elevation caused by 
forskolin or treatment with the PKA activator dibutyryl cAMP inhibits NF-κB-
dependent gene transcription (Ollivier, Parry et al. 1996). This effect is not 
dependent on nuclear translocation or phosphorylation of the NF-κB subunits 
p65, p50, or c-Rel, but rather by direct inhibition of NF-κB transcriptional 
activity (Ollivier, Parry et al. 1996) . In TNF-α-stimulated Jurkat T cells, 
forskolin or db-cAMP inhibit NF-κB luciferase activity, but interestingly, not IκBα 
degradation or NF-κB DNA binding activity (Takahashi, Tetsuka et al. 2002). 
Rolipram has been shown to inhibit NF-κB and NFAT activation in Jurkat and 
primary T cells (Navarro, Punzon et al. 1998) and to inhibit LPS-induced NF-κB 
luciferase activity in alcohol-exposed RAW264.7 cells (Gobejishvili, Barve et al. 
2008). These studies suggest that the inhibition of NF-κB is only at the level of 
transcriptional activity. However, it has also been shown that roflumilast inhibits 
LPS-induced NF-κB DNA binding, IκBα phosphorylation, and IκBα degradation in 
RAW264.7 cells (Kwak, Song et al. 2005). Therefore the mechanism action of 
roflumilast may be somewhat different from that of rolipram. 
The positive effects on CREB induced by PDE4 inhibitors and the negative effects 
on NF-κB are manifested in modulation of gene expression. Hence, CREB-
dependent gene expression tends to be augmented, with two examples being IL-
10 and IL-6, which bear CRE sites within their promoters.  Expression of the anti-
inflammatory cytokine IL-10 is enhanced by PDE4 inhibitors in a PKA-dependent 
manner (Eigler, Siegmund et al. 1998). The mechanism of this enhancement 
involves multiple CRE elements within the IL-10 promoter and enhancer, which 
recruit the CRE binding proteins CREB and ATF-1, both of which are substrates of 
PKA (Platzer, Fritsch et al. 1999). A thorough analysis of the CREB regulation has 
revealed many genes; including SOCS, SOCS1, and TGF-β2 are regulated in this 
way (Impey, McCorkle et al. 2004). Conversely, NF-κB-dependent gene 
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transcription tends to be inhibited by cAMP-elevating agents. A review by 
(Barnes and Adcock 1998) discussed in detail the relative roles for NF-κB, CREB, 
and other transcription factors in the regulation of pro-inflammatory mediator 
expression. The interplay between CREB-dependent and non-CREB-dependent 
gene transcription thus defines the relative sensitivity of individual promoters to 
the effects of PDE4 inhibition.  Inhibition of TNF-α, IFN-γ, IL-12A, and IL-23A by 
Apremilast was found to occur through suppression of mRNA expression (Schafer, 
Parton et al. 2010), which is consistent with the evidence in the literature 
described above that cAMP-elevating agents regulate expression of genes at the 
transcriptional level. Expression of the common IL-12 and IL-23 p40 subunit, 
encoded by the IL-12B gene, is known to be NF-κB-dependent (Ma, Zhang et al. 
2004) and inhibited by the cAMP analog 8-Br-cAMP(Feng, Wang et al. 2002). 
However, suppression of the IL-12A (p35) and IL-23A (p19) subunits by a PDE4 
inhibitor was previously unreported. The inhibition of IL-12 gene expression is 
reflected in the decreased IL-12 p70 protein levels (Schafer, Parton et al. 2010). 
Inhibition of IL-12 and IL-23 could be an important aspect of psoriasis therapy, 
supported by the significant efficacy of ustekinumab, an anti-IL-12/IL-23 p40 
monoclonal antibody which is in development for the treatment of patients with 
chronic moderate to severe plaque psoriasis (Chien, Elder et al. 2009). In 
contrast to inhibition of IP-10, IFN-γ, MIG, TNF-α, IL-12p70, MIP-1α, MCP-1, and 
GM-CSF, Apremilast enhanced LPS-stimulated IL-10 production (with significant 
elevation at 1 μM), and to a lesser extent, IL-6 production (with significant 
elevation only at 10 μM) (Schafer, Parton et al. 2010). 
My data is consistent with the above findings as it confirms that the Apremilast 
and Roflumilast act via the PKA pathway to increase the phosphorylation of CREB 
and thereby should inhibit NFκB activation and increase the production of anti 
inflammatory cytokines. Further downstream effects and whether Apremilast 
and Roflumilast will cause differential phosphorylation of other proteins will be 
investigated further in this chapter. 
In addition to data in figure 4-1 showing that Apremilast and Roflumilast 
increase the phosphorylation of CREB at Ser 133 in U937 and Jurkat T cells, and 
Apremilast only in HEK 293 cells, Figure 4-2 shows that although not significant, 
there does look to be an increase in the phosphorylation of PKA substrates.  
Figure 4-3 revealed that both inhibitors increase the phosphorylation of VASP at 
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Ser157 in the presence of forskolin in U937 cells, however in HEK cells only 
Apremilast in the presence of forskolin increases VASP phosphorylation 
significantly at Ser157. This could be interesting as VASP phosphorylation has 
been implicated in a number of diseases such as Asthma and colon cancer 
(Hastie, Wu et al. 2006, Kohler, Birk et al. 2011, Ali, Rogers et al. 2015). 
Vasodilator-stimulated phosphoprotein (VASP) phosphorylation occurs on two 
serine and one threonine (Ser 157, Ser 239 and Thr 278) through cAMP and cGMP 
dependent protein kinases A and G (Butt, Abel et al. 1994). Phosphorylation by 
cAMP protein kinase preferentially occurs at Ser 157 (Butt, Abel et al. 1994). 
Attachment and migration of airway epithelial cells is an important aspect of 
repair of injury induced by allergens and other agents in asthma. VASP mediates 
focal adhesion, actin filament binding and polymerization in a variety of cells, 
thereby inhibiting cell movement (Krause, Dent et al. 2003). Phosphorylation of 
VASP via cAMP and cGMP dependent protein kinases releases this "brake" on cell 
motility and it is thought that phosphorylation of VASP may be necessary for 
epithelial cell repair of damage from allergen-induced inflammation (Hastie, Wu 
et al. 2006). Hastie et al found that decreased VASP phosphorylation was 
observed in epithelial cells of asthmatics compared to non-asthmatic individuals, 
despite response to β-agonist. The observed decrease in VASP phosphorylation 
suggested greater inhibition of actin reorganization which is necessary for 
altering attachment and migration required during epithelial repair.  
Phosphorylation of VASP has also been found to be involved in inflammatory 
tissue injury repair by (Kohler, Birk et al. 2011) who found it to dampen Hepatic 
Ischemia-Reperfusion Injury. This study examined the role of differential VASP 
Ser phosphorylation in regulating cell survival and apoptosis in human colon 
carcinoma cells.  It found that in human colon carcinoma cells suppression of 
VASP Ser157 phosphorylation reduced F-actin content and survival and increased 
apoptosis, while inhibition of VASP Ser239 phosphorylation increased F-actin 
content and survival and reduced cell death. Also, while 8Br-cAMP induced VASP 
Ser157 phosphorylation and reduced cell death, treatments with 8CPT-cGMP 
elevated VASP Ser239 phosphorylation and promoted apoptosis. 
Therefore, since both Apremilast and Roflumilast increase the phosphorylation 
of VASP at Ser157 in U937 cells and Apremilast only in HEK 293 cells, perhaps 
pharmacological manipulation of VASP Ser phosphorylation could be exploited to 
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affect the malignant actin cytoskeleton and induce apoptosis in colorectal 
cancer cells. This could perhaps present a use for PDE4 inhibitors as a 
therapeutic target of controlling cell survival and death behaviour in colon 
cancer via VASP phosphorylation. Further studies would have to be done to 
assess the effects of PDE4 inhibition on VASP phosphorylation in more detail and 
in appropriate cells. Some of the results in this chapter could be limited by low n 
numbers which could be addressed in the future. 
 
 
 
 
 
 
 
 
4.2 CelluSpots™ - Kinase Substrate Arrays to potentially 
identify signalling differences 
Most signalling networks are regulated by reversible protein phosphorylation. 
The specificity of this regulation depends on the capacity of protein kinases to 
recognize and efficiently phosphorylate particular sequence motifs in their 
substrates. Therefore, in a bid to further attempt to profile signalling 
differences between Apremilast and Roflumilast, I employed the use of peptide 
substrate arrays to try and identify whether Apremilast and Roflumilast have 
differentiating effects on any kinase substrates which will perhaps unveil PKA 
signalling differences. For this I used CelluSpots™ Y-kinase substrate arrays 
(figure 4-4). The arrays consist of a series of peptides derived from sequences of 
tyrosine kinase substrates as well as consensus sequences of some other kinases, 
generated as peptide-cellulose conjugates, and spotted on glass slides. Each spot 
is a known 15-mer peptide bound to cellulose via the C-terminus and with an 
acetylated N-terminus with Tyr found at the 7th position of the peptides. 
Rheumatoid arthritis synovial fibroblast (RASF) cells were used in these 
experiments.   
Slides were incubated with protein lysates from RASFs, untreated and treated 
with either inhibitor at 10µM as described in materials and methods section. 
They were then probed with an anti phospho-tyrosine antibody which was 
detected by ECL. Each black spot on the array corresponds to a known peptide 
sequence that has been phosphorylated by kinases present in the lysate. Non 
phosphorylated sequences appear as negative (no visible spot).  Densitometry 
analysis was then performed and the results did reveal some interesting hits 
although no significant differences between inhibitors were found. 
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Figure 4-4  CelluSpots™ - Kinase Substrate Arrays illustration. Ready to screen kinase 
arrays with tyrosine- and serine/threonine-kinase substrates from annotated 
phosphorylation sites. (Intavis Bioanalytical Instruments)   
 
4.2.1 Results 
CelluSpots™ Y-kinase substrate array experiments (figure 4-5) revealed that 
treatment of RASFs with both Apremilast and Roflumilast led to some significant 
increases in several different kinase substrates. Densitometry analysis of the 
arrays show a few significant differences between untreated RASFs and RASFs 
treated with either of the inhibitors, table 4-1 shows the phosphorylated peptide 
sequences following treatment with the inhibitors. Interestingly, Apremilast and 
Roflumilast treatment significantly increased the phosphorylation of a member 
of Src family kinases, Src, when compared with control lysate. Analysis also 
showed that only Apremilast significantly induced the phosphorylation of Fyn, a 
tyrosine specific phosphotransferase that also belongs to the Src family of 
tyrosine kinases.  
This increase in phosphorylation of Src by Apremilast and Roflumilast and Fyn by 
Apremilast is interesting as it has previously been shown that PDE 4 binds to both 
of these tyrosine specific phosphotransferases and inhibits PKA phosphorylation 
(McPhee, Yarwood et al. 1999). They found that PDE4A4 selectively binds SH3 
domains of SRC family tyrosyl kinases. Fyn is primarily located in the cytoplasmic 
leaflet of the plasma membrane and it is known to play a role in the immune 
response and in the control of cell growth. Several aspects of Fyn function are of 
clinical interest. Fyn is involved in keratinocyte development, and it is thought 
alteration of Fyn levels may aid in treatment of skin disorders (Resh 1998).   
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Figure 4-5 CelluSpots™ Tyrosine Kinase Substrate Arrays. A) N=1-3 tyrosine kinase 
substrate arrays overlaid with  lysates from RASF cells either untreated or treated with 
Apremilast 10µM or Roflumilast 10µM includes an antibody only control.  Each black spot 
corresponds to a known peptide sequence that has been phosphorylated by kinases in the 
lysate. Non-phosphorylated sequences appear as negative (no spot) B) Densitometry 
analysis of the arrays normalised to antibody only control. Data is shown as SEM for three 
experiments * P <0.05 and ** p<0.01. 
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Table 4-1 Peptide sequence information of phosphorylated peptides on Tyrosine Kinase 
Substrate Arrays followed by treatment of Apremilast and Roflumilast in Rheumatoid 
arthritis synovial fibroblasts. 
 
Western blot analysis was performed (Figure 4-6) in RASFs treated with 
Apremilast and Roflumilast at 10µM to verify the data from the substrate arrays. 
Apremilast and Roflumilast both appear to significantly increase the 
phosphorylation of SRC substrates indicating a possible increase in Src 
phosphorylation. Results showed that Apremilast only, increases the 
phosphorylation of Fyn at Y530. It also appears that both inhibitors increase the 
phosphorylation of Src although this was not found to be statistically significant, 
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an increase in n numbers might unveil this which would again suggest an 
agreement with the kinase array data.  
 
 
Figure 4-6 Effect of Apremilast and Roflumilast on the phosphorylation of Fyn at Y530 (A) 
and Src Y416 (B) in Rheumatoid Arthritis Synovial Fibroblasts (RASFs). A) Western blot 
analysis of Phosphorylation of Fyn (Y530) in RASF cells (n=4) and representative blot for 
graph. B) Western blot analysis of Phosphorylation of Src (Y416) (n=3) along with 
representative blot. Student’s t- test was used to compare treatments with the untreated 
cells. No statistically significant differences were observed between Untreated, Apremilast 
and Roflumilast on phosphorylation of Src (Y416) in RASFs. Statistical significant 
differences were found between untreated and Apremilast treated cells as well as a 
significant difference between Apremilast and Roflumilast in the phosphorylation of Fyn 
(Y530) *p<0.05.  30 minutes stimulation with 10 µM Apremilast or Roflumilast. 
 
 
4.2.2 Discussion 
The results from Kinase substrate arrays are interesting as it has shown that both 
Apremilast and Roflumilast significantly increase the phosphorylation of a 
number of tyrosine kinase substrates. For example, both inhibitors significantly 
increased the phosphorylation of a few Src substrates as well as a PKA consensus 
site motif in Src kinase itself. Only Apremilast significantly increased the 
phoshorylation of a Fyn kinase consensus sequence. This information was then 
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used to confirm via western blot that Apremilast does significantly increase the 
phosphorylation of Fyn at Tyr506 which would explain the increase in 
phosphorylation of the Fyn in the celluspot arrays.  Western blot analysis was 
also used to test the affect of the inhibitors on the phosphorylation of Src, 
however an increase in phosphorylation of Src was not found to be significant by 
either of the inhibitors in these cells. 
Fyn is a member of the Src family of non receptor tyrosine kinases with diverse 
biological functions including the regulation of mitogenic signalling and cell 
cycle entry, proliferation, integrin-mediated interactions, reproduction and 
fertilization, axonal guidance, and differentiation of oligodendrocytes and 
keratinocytes (Saito, Jensen et al. 2010). Fyn is primarily localized to the 
cytoplasmic leaflet of the plasma membrane, where it phosphorylates tyrosine 
residues on key targets involved in a variety of different signalling pathways. 
Importantly, though Fyn has extensively been described for its role in immune 
function. Fyn positively regulates mast cell responsiveness (Parravicini, Gadina 
et al. 2002) and is involved in the differentiation of natural killer cells (Gadue, 
Morton et al. 1999). ). It is also known that functionally, the loss of Fyn in mast 
cells impairs mast cell degranulation and cytokine production (Parravicini, 
Gadina et al. 2002, Gomez, Gonzalez-Espinosa et al. 2005). Fyn primarily 
functions to positively regulate mast cell responsiveness (Gilfillan and Rivera 
2009). The fact then, that Fyn  positively regulates mast cell responses could be 
interesting as increasing evidence indicates that mast cells are critical for the 
pathogenesis of inflammatory diseases (Theoharides 1996, Theoharides and 
Cochrane 2004), such as arthritis (Woolley 2003), atopic dermatitis, psoriasis 
(Harvima, Viinamaki et al. 1993, Ozdamar, Seckin et al. 1996),and multiple 
sclerosis (Theoharides 1990). Mast cell-related atopic dermatitis (AD) and 
psoriasis are triggered or exacerbated by stress through mast cell activation 
(Church and Clough 1999, Katsarou-Katsari, Filippou et al. 1999). Psoriasis is 
characterized by keratinocyte proliferation and inflammation, as well as mast 
cell accumulation and activation (Harvima, Viinamaki et al. 1993, Harvima, 
Nilsson et al. 2008). Mast cells have also been found to be increased in lesional 
psoriatic skin (Harvima, Viinamaki et al. 1993, Ozdamar, Seckin et al. 1996). 
Since Apremilast increases the phosphorylation of Fyn in RASFs, could this 
perhaps be a reason for its success in the treatment of psoriasis? 
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Multiple signalling pathways have been identified to modulate Fyn activity (yaka 
etal 2003, Maksumova et al 2005) of which PKA plays a critical and special role in 
inflammatory pain (Malmberg, Brandon et al. 1997). Fyn is involved in 
inflammatory responses and in this context, it is interesting that PKA specifically 
activated Fyn Kinase in spinal dorsal horn to evoke pain hypersensitivity (Yang, 
Yang et al. 2011). Evidence indicated that PKA appears to play a unique role in 
inflammatory pain, as genetic knockout of PKA regulatory subunit R1β 
selectively inhibits pain hypersensitivity induced by peripheral inflammation 
rather than nerve injury (Malmberg, Brandon et al. 1997). This could be quite 
interesting to follow up as in our lab it has been previously been shown that 
PDE4 binds directly to Fyn and inhibits PKA (McPhee, Yarwood et al. 1999).  Fyn 
has multiple phosphorylation sites which can affect its kinase activity, and it has 
been reported that S21 phosphorylation of Fyn by PKA can enhance its activity 
(Yeo, Oh et al. 2011). Therefore it is possible to say that perhaps Apremilast 
while inhibiting PDE4 is activating Fyn via the phosphorylation of PKA and 
influencing the inflammatory response. 
 
4.3 Reverse Phase Protein Array 
Reverse phase protein array (RPPA) is a high-throughput antibody-based 
technique with the procedures similar to that of Western blots. Proteins are 
extracted from cultured cells and denatured by SDS. The Protein lysates are 
then arrayed as micro spots on nitrocellulose- coated glass slides and probed 
with highly specific antibodies that have been validated for RPPA. At least 200 
antibodies are currently validated to monitor protein levels and post 
translational modifications. Each micro spot contains the whole proteome 
repertoire of the cell.  Therefore the protein array allows measurement of 
protein expression levels and their modification by phosphorylation in a large 
number of biological samples simultaneously in a quantitative manner using 
high-quality validated antibodies. Reverse Phase Protein Arrays have emerged 
over the last 10 years as a powerful functional proteomics tool for high 
throughput signalling pathway analysis. Therefore I decided to employ RPPA 
analysis of lysates from Rheumatoid arthritis synovial fibroblasts treated with 
10µM Apremilast and Roflumilast, which was performed at the Edinburgh Cancer 
122 
 
122 
Research Centre by Dr Bryan Serrels, to do some further pathway analysis of 
Apremilast and Roflumilast. Figure 4-5 shows the RPPA set up used for these 
experiments. 
 
 
 
Figure 4-7 Schematic representation of Reverse Phase Protein Array platform. Cell lysates 
are arrayed onto nitrocellulose-coated slides and subsequently incubated with primary and 
secondary validated antibodies. The slides are then scanned and analysed on a Licor 
Oddyssey Scanner. 
 
4.3.1 Results 
The results from RPPA analysis showed a number of interesting hits, where 
Apremilast and Roflumilast seem to increase the phosphorylation or expression 
of different proteins, shown in figure 4-8. Among these hits are several proteins 
that are involved in the inflammatory response for example Src which showed up 
in the kinase arrays, the protein kinase Akt at threonine 308, mTor pSER 248, S6 
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ribosomal protein and several others. CREB Ser133 was used as a control for 
these experiments since we know that both Apremilast and Roflumilast increase 
the phosphorylation of this protein. Accompanying images (figure 4-9) from the 
arrays are presented along with the graphs (formed from the analysis of the 
images). One of the more interesting images with most striking difference 
between untreated cells as well as between Apremilast and Roflumilast was the 
total and phospho S6 ribosomal protein at Ser240/244 (figure 4-9) as well as 
phospho Akt  at Thr308 and Ser473, although there doesn’t look to be a 
difference between the inhibitors here. 
 
Figure 4-8 Reverse Phase Protein Array. A-B show all hits from RPPA, Over 150 antibodies 
were tested (See materials and method section). Arrays were scanned on Licor Oddyssey 
scanner and intensities of spots were quantified (Bryan Serrels Edinburgh Cancer Research 
Centre). 
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Figure 4-9 Reverse Phase Protein Array Images. Selection of images of interesting RPPA 
hits including, S6 Ribosomal protein, S6 Ribosomal protein pS240/244, Phospho-Akt 
Ser473, Phospho-Akt T308 and Phospho-PKC. Images obtained from Oddyssey® scanning 
system. 
 
To evaluate the observations made by RPPA, selected antibodies were used to 
test RASF lysates treated with 10µM Apremilast or Roflumilast and analysed by 
Western blot. Total S6 ribosomal protein and S6 ribosomal pSer240/244 as well 
as Akt Thr 308 and Ser 473 antibodies were selected (figure 4-10 and 4-11). 
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Figure 4-10 Effect of Apremilast and Roflumilast on the phosphorylation of Akt at Thr 308 
and Ser 473 in Rheumatoid Arthritis Synovial Fibroblasts (RASF). A-B Western blot analysis 
of Akt phosphorylation in RASF cells A) pAkt (Thr308) B)pAkt (ser473). C) Representative 
Western blots for each graph. Student’s t- test was used to compare treatments with the 
untreated cells. No statistically significant differences were observed between Apremilast 
and Roflumilast on phosphorylation of Akt (Ser473) in RASFcells. *p<0.05.  30 minutes 
stimulation with 10 µM Apremilast or Roflumilast. 
 
 
Results from figure 4-10 show that both Apremilast and Roflumilast increased 
the phosphorylation of Akt at Thr308 in RASFs, which confirms the findings from 
RPPA however there were no significant differences between PDE4 inhibitors. 
There was, however, no significant increase in the phosphorylation of Akt at Ser 
473, which is in disagreement  with the RPPA data. Interestingly, the 
PI3K/Akt/mTOR pathway is thought to be involved in positively regulating the 
immune response (Weichhart and Saemann 2008) as well as the phosphorylation 
of Akt being known to mediate anti inflammatory activity (Vo, Lee et al. 2014). 
I then probed (by western blot) for Ribosomal S6 (rpS6) phosphorylation as the 
RPPA data looked positive. rpS6 has been found to be hyper activated and 
differentially phosphorylated in epidermal lesions of patients with psoriasis and 
atopic dermatitis (Ruf, Andreoli et al. 2014) as well as rpS6 pSer 240/244  said to 
be expressed in lesional skin from patients with autoimmune skin blistering 
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diseases (Abreu-Velez, Googe et al. 2013). The western blot data in figure 4-11 
below backs up the RPPA data for this protein as it appears that Apremilast 
significantly increases the phosphorylation of the rpS6 at Ser240/244 in RASFs 
whereas Roflumilast does not show a significant increase in these cells. Total 
rpS6 expression does also look to be enhanced by Apremilast, again agreeing 
with the RPPA data although this was not shown to be significant. 
 
 
 
Figure 4-11 Effect of Apremilast and Roflumilast on rpS6 in RASF cells. A-B Western blot  
analysis of A) phosphorylation of S6 ribosomal protein at Ser 240/244 B) Total rpS6. C) 
Representative western blots for each graph. Student’s t-test was used to compare 
treatments with untreated cells (n=3) Significant differences were found between Apremilast 
and Roflumilast on the phosphorylation of rpS6 Ser240/244. * p<0.05 
 
Therefore the kinase substrate array, RPPA and western blot data prompted me 
to investigate the S6 ribosomal protein (rpS6) pathway as it appears clear that 
treatment of RASFs with Apremilast leads to an increased phosphorylation of the 
S6 Ribosomal protein at Ser 240/244 as well as leading to increased 
phosphorylation of Fyn protein in these cells, whereas Roflumilast doesn’t seem 
to significantly increase the phosphorylation of either of these proteins in these 
cells. A paper by (Salmond, Emery et al. 2009) has described a signalling event 
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where T cell receptor pathways lead to ribosomal protein rpS6 phosphorylation 
and this acts as a point of convergence for multiple TCR-induced signalling 
pathways. The paper also showed that Fyn contributes to the induction of rpS6 
phosphorylation via the activation of mTOR – and MAPK-dependent pathways. 
Figure 4-12 explains this pathway. I wanted to try and investigate where in this 
pathway PKA may contribute and what effect the inhibitors have on each point 
since it is known that Apremilast and Roflumilast increase the activation of PKA. 
It is possible that an increase in PKA phosphorylation of Fyn following Apremilast 
treatment is activating Fyn directly. It is also possible that an increase in PKA 
activity triggered by the inhibitors results in a phosphorylation of rpS6, as there 
is evidence that suggests that PKA may be a third in vivo Ribosomal S6 kinase in 
pancreatic β-cells (Moore, Xie et al. 2009). 
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Figure 4-12 TCR signalling pathways leading to ribosomal rpS6 phosphorylation (Salmond, 
Emery et al. 2009). A) TCR induced activation of Lck and Fyn results in downstream 
activation of MEK and PI3K, and uptake of amino acids (AA) from the extracellular 
environment. MEK activates its downstream effector ERK that in turn activates RSK. PI3K 
and AA signalling facilitates activation of mTOR. mTOR is critical for phophorylation of S6K 
at residue T389, whereas both Mtor and MEK – dependent signals are required for 
phosphorylation of S6K T421/S424. RSK and S6K both contribute to maximal 
phosphorylation of rpS6 at residues Ser235/236. B) Upstream signals required for rpS6 Ser 
240/244 phosphorylation are similar for rpS6 Ser 235/236 as described in A. However RSK 
plays a minor role in Ser240/244 and mTOR-dependent S6K activity is dominant for 
rpS6240/244 phoshorylation. Furthermore, MEK may also be an inhibitory pathway, 
decreasing rpS6 phosphorylation. 
 
Below is a model which I based my pathway analysis on and shows the 
pharmacological inhibitors available for each point in the pathway, some of 
which I have used in my experiments (figures 4-14-16). Unfortunately due to 
time constraints, all of the inhibitors were unable to be tested and so a 
complete analysis of this pathway was not performed. 
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Figure 4-13 TCR signalling pathway leading to rpS6 phosphorylation. Indicated points of 
inhibition shown on the pathway by available pharmacological inhibitors. Adapted from 
(Salmond, Emery et al. 2009). 
 
Hek 293 cells were used for these experiments due to ease of cell culture and 
the ability to produce lots of protein for western blot analysis quickly and easily, 
compared to the more difficult propagation and time consuming nature of 
primary RASFs. Ideally RASFs would have been used but due to lack of available 
time this was not possible. Figure 4-14 below shows the results for western blot 
analysis using the PKA inhibitor H-89 +/- Apremilast or Roflumilast. The 
phosphorylation of rpS6 was then assessed using phospho-specific antibodies for 
rpS6 at Ser240/244 and Ser235/236. The phosphorylation of rpS6 at ser 235/236 
was a hit in the RPPA analysis although there appeared to be no differences 
between the inhibitors here. In addition the following kinases and proteins 
upstream of rpS6 were monitored: S6 kinase p70 (T421/S424), PI3K p85 and at 
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Fyn Y506. The data showed that rpS6 phosphorylation at Ser 240/244 and 
235/236 was significantly reduced with H-89 treatment which suggests that PKA 
is involved here; however treatment with either of the inhibitors after H-89 
treatment had no effect. Similarly in RASFs, rpS6 phosphorylation was 
significantly increased in HEK 293 cells, whereas Roflumilast was not. There was 
no significant difference between Apremilast and Roflumilast treatments in HEK 
cells though. Interestingly, Apremilast and Roflumilast both significantly 
increased the phosphorylation of P70 S6 kinase T421, however Apremilast seems 
to significantly increase the phosphorylation of this protein above that of 
Roflumilast as there is a significant difference between the two inhibitors here. 
Again, H-89 significantly reduces the phosphorylation of this protein. Total rpS6 
expression appears to be mainly unchanged by H-89 treatment although it looks 
to be decreased slightly this is not significant. Phosphorylation of PI3K is 
unchanged by H-89 treatment, although it is not significant, Apremilast appears 
to increase the phosphorylation of PI3K. Mirroring the situation in RASFs, 
Apremilast increases the phosphorylation of Fyn in HEK cells. H-89 treatment 
does significantly reduce Fyn phosphorylation although this reduction is not 
significant when either Apremilast or Roflumilast is added; suggesting perhaps 
that Fyn phosphorylation induced by Apremilast is via PKA.  
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Figure 4-14 Effect of inhibition of PKA before stimulation with  Apremilast and Roflumilast 
on the S6 ribosomal pathway. Hek 293 cells were pretreated with +/- H-89 for 30 mins before 
stimulation with Apremilast and Roflumilast 10µM for 30 mins. A-F) Western blot analysis of 
phosphorylation of rpS6 Ser240/244, Ser235/236, total rpS6, S6 kinase p70 (T421/S424), PI3K 
p85 and Fyn Y506. G) Representative blots and loading control. Values represent the mean 
of 3 experiments, error bars represent SE. *p<0.05,***p<0.001. 
 
 
 
The next inhibitor in the pathway studied was the mTOR inhibitor Rapamycin 
(figure 4-15). Data showed that phosphorylation of P70 S6 Kinase was 
significantly blocked by rapamycin as was the phosphorylation of rpS6 240/244. 
Total rpS6 and total P70 S6 kinase were largely unchanged by mTOR inhibition. 
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Figure 4-15 Effect of inhibition of mTOR before stimulation with Apremilast and Roflumilast 
on the S6 ribosomal pathway.  Hek 293 cells were pre-treated with +/- H-89 for 30 mins 
before stimulation with Apremilast and Roflumilast 10µM for 30 mins. A-D) Western blot 
analysis of phosphorylation of rpS6 Ser240/244, S6 kinase p70 T421/S424, Total rpS6 and 
Total S6 Kinase p70. E) Representative blots and loading control. Values represent the 
mean of 3 experiments, error bars represent SE. *p<0.05. 
 
The MEK inhibitor U0126 was the next pharmacological inhibitor to be tested 
(figure 4-16). This inhibitor appeared to have a small inhibitory effect on the 
phosphorylation of rpS6 240/244. Interestingly, I observed that both Apremilast 
and Roflumilast significantly induce the phosphorylation of rpS6 at Ser235/236. 
Could the inhibitors differentially phosphorylate different residues on rpS6 by 
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acting on different PKA pools that affect this pathway? Since Apremilast only 
appears to increase the phosphorylation of rpS6 at Ser240/244 whereas both 
inhibitors increase the phosphorylation of rpS6 at Ser235/236. Perhaps 
Apremilast increases the phosphorylation of Fyn upstream of rpS6 resulting in 
rpS6 phosphorylation at ser240/244. Could they be regulating different pools of 
PKA, as PKA is thought to exclusively phosphorylate rpS6 at Ser235/236 in 
pancreatic β-cells (Moore, Xie et al. 2009). Apremilast-induced phosphorylation 
of rpS6 at Ser240/244 may lead to different physiological outcomes from that of 
Ser235/236 phosphorylation for example, and therefore might produce different 
biological effects than Roflumilast.  For example, an up-regulation of human 
ribosomal protein S6-p240 has been documented in psoriasis and it has also been 
found to be expressed in lesional skin areas of skin biopsies from patients with 
autoimmune skin blistering diseases (Abreu-Velez, Googe et al. 2013). If rpS6 is 
activated for protein synthesis needed to repair lesional skin in these disorders, 
this could then explain the success of Apremilast in the treatment of psoriasis 
patients (Papp, Kaufmann et al. 2013).  
Both Apremilast and Roflumilast significantly increase the phosphorylation of 
p44/42 MAPK or ERK1/2 in this pathway (figure 4-16). Expectedly, this increase 
was completely inhibited by the MEK inhibitor U0126. Apremilast and Roflumilast 
had no effect on total or phospho p90 RSK, which is interesting as this suggests 
they are exerting their affects on rpS6 phosphorylation via both MEK and mTOR. 
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Figure 4-16 Effect of inhibition of MEK1/2 before stimulation of Apremilast and Roflumilast 
on  the S6 ribosomal pathway. Hek 293 cells were pretreated with +/- H-89 for 30 mins before 
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stimulation with Apremilast and Roflumilast 10µM for 30 mins. A-F) Western blot analysis of 
phosphorylation of rpS6 Ser240/244, Ser235/236, p90 RSK, total rpS6 and total p90 RSK. G) 
Representative blots and loading control. Values represent the mean of 3 experiments, error 
bars represent SE. *p<0.05. 
 
 
4.3.2 Discussion 
Collectively the results from RPPA and western blot analysis of the rpS6 pathway 
have shown that Apremilast alone increases the phosphorylation of rpS6 at 
Ser240/244 whereas Roflumilast does not significantly increase the 
phosphorylation of this site in RASFs or HEK cells. Analysis of the rpS6 pathway 
has shown that both inhibitors do increase the phosphorylation of S6 Kinase p70 
and MAPK both which lead to phosphorylation of rpS6 and that rapamycin 
treatment blocked the phosphorylation of both of these proteins. However, 
there was little effect when stimulated with Apremilast or Roflumilast following 
pre-treatment with rapamycin. 
Apremilast also increases the phosphorylation of Fyn Y506, which is upstream of 
both MAPK and S6 kinase in this pathway.  It was shown by (Salmond, Emery et 
al. 2009) that Fyn can transduce TCR signals via the MAPK and PI3K pathway 
(Lovatt, Filby et al. 2006, Salmond, Filby et al. 2009), both of which likely 
contribute to Fyn dependent rpS6 phosphorylation. So it is likely that 
Apremilast-induced increases in the phosphorylation of Fyn, is contributing to 
the phosphorylation of rpS6 at Ser240/244 as this is found downstream of Fyn in 
this pathway. Perhaps Apremilast is affecting a different pool of PKA from that 
of Roflumilast as both Apremilast and Roflumilast increase the phosphorylation 
of rpS6 at Ser235/236, which is known to be phosphorylated by PKA directly at 
this residue (Moore, Xie et al. 2009). 
It is important to note that cAMP can activate PKB (Filippa, Sable et al. 1999, 
Brennesvik, Ktori et al. 2005), which can in turn stimulate S6K1/2 via the 
activation of Tsc1/Tsc2 and a subsequent increase in mTORC1 activity (Manning, 
Tee et al. 2002). In addition, cAMP can also activate the Erk signalling pathway 
(Stork and Schmitt 2002) which via RSK can directly phosphorylate rpS6 at 
235/236 (Roux, Shahbazian et al. 2007). In addition, the ERK pathway can 
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stimulate the activity of S6K1/2 via the activation of mTORC1. Therefore rps6 
phosphorylation is likely mediated via S6K, however rpS6 phosphorylation was 
inhibited by H89 so we know PKA is involved here. It is possible that rpS6 
phosphorylation by Apremilast is mediated by PKA and could this lead to a 
distinct biological role of rpS6 Sr240/244 compared to ser 235/236, as a number 
of ribosomal proteins have been known to have extra ribosomal functions (Wool 
1996). 
Unfortunately experiments were not completed with the use of PI3K inhibitor 
LY294002, PP2 (inhibits Fyn) or B1-D870 (RSK inhibitor) to assess their affects 
and subsequent treatment with Apremilast or Roflumilast.  It has been shown 
(Salmond, Emery et al. 2009) that rpS6 phosphorylation at Ser240/244 is blocked 
by this inhibitor since it is downstream in the pathway. However, western blot 
data didn’t show an increase in phosphorylation of PI3k with either inhibitor in 
my experiments. This could possibly be a cell specific effect as different cells 
were used in each study. 
Ribosomal protein S6 is a component of the 40S ribosomal subunit.  The 
regulated phosphorylation of ribosomal protein rpS6, which occurs in response to 
a  wide variety of stimuli, takes place on five conserved serine residues — 
Ser235, Ser236, Ser240, Ser244, and Ser247 (Krieg, Olivier et al. 1988). This 
signalling event has attracted much attention since its discovery in 1974, yet its 
physiological role has remained obscure. Studies have shown that it is involved in 
the regulation of cell size, cell proliferation, and glucose homeostasis (Ruvinsky, 
Sharon et al. 2005). It is thought the protein may contribute to the control of 
cell growth and proliferation through the selective translation of particular 
classes of mRNA. rpS6 phosphorylation is tightly controlled by the pathway of 
mammalian target of rapamycin complex 1 (mTORC1)/p70 ribosomal protein S6 
kinases 1 and 2 (p70S6K1/2) (Meyuhas 2008), as well as by ERK (Sturgill, Ray et 
al. 1988, Roux, Shahbazian et al. 2007), casein kinase 1(Hutchinson, Shanware et 
al. 2011), PKC (House, Wettenhall et al. 1987, Ohtsubo, Yamada et al. 2014), 
and cAMP-dependent protein kinase (PKA) (Moore, Xie et al. 2009, Valjent, 
Bertran-Gonzalez et al. 2011, Ohtsubo, Yamada et al. 2014) signalling cascades. 
This is confirmed in my experiments as Rapamycin an mTOR inhibitor ablates the 
phosphorylation of rpS6 at Ser240/244.  Upstream mechanisms of regulation of 
rpS6 are poorly studied and its role in protein synthesis remains largely debated 
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and the exact molecular mechanisms regulating rpS6 and the function of 
phosphorylated rpS6 remain poorly understood. 
One study has shown (Ruvinsky, Sharon et al. 2005) that ribosomal protein S6 
phosphorylation is a determinant of cell size and glucose homeostasis as the 
rates of global protein synthesis and accumulation are increased in rpS6P-/- MEFs. 
This observation implies that protein synthesis, at least in this cell type, is 
down-regulated by rpS6 phosphorylation. Conversely rpS6-pS240 is found to be 
expressed in lesional areas of skin biopsies from patients (Abreu-Velez, Googe et 
al. 2013). It is thought that perhaps that rpS6-pS240 may be influencing protein 
synthesis and/or with the inflammatory/anti-inflammatory immune response in 
patients affects by skin diseases.  The phosphorylation of ribosomal protein S6 
correlates with an increase in mRNAs that encode for proteins involved in cell 
cycle progression and therefore controlling mammalian cell growth and 
proliferation. This protein could then be activated for protein synthesis needed 
to repair lesional skin in these disorders. Perhaps the combination of Apremilast 
triggered increases in phosphorylation of rpS6 Ser240 along with the known 
increase in anti-inflammatory mediators is the reason that Apremilast has been 
so successful in psoriasis trials (Papp, Kaufmann et al. 2013). 
Recent data has suggested a surprising new function for rpS6 phosphorylation in 
cancer biology (Khalaileh, Dreazen et al. 2013).  rpS6 phosphorylation protects 
against DNA damage induced by mutant Kras, a gene mutated in many cancers. 
Work suggests that phosphorylated rpS6 could in principle act to reduce the 
formation of reactive oxygen species (ROS), a known inducer of DNA 
damage(Tanaka, Halicka et al. 2006), or alternatively to reduce oncogene-
induced replication stress and consequent DNA damage (Halazonetis, Gorgoulis 
et al. 2008). This opens up a possible repositioning space for Apremilast in the 
future. 
 
 
 
5 Phage Display 
5.1 Introduction 
In the final part of my studies Phage display technology was employed to 
discover new linear motifs as binding partners for PDE4. Phage display is a 
versatile in vitro technology that allows expression of exogenous (poly) peptides 
on the surface of phage particles.  It can be used as a tool for mapping novel 
protein-protein interactions. Using randomly generated DNA sequences and 
molecular biology techniques, large diverse peptide libraries can be displayed on 
the phage surface. The phage library can be incubated with a target of interest 
and the phage which binds can be isolated and sequenced to reveal the 
displayed peptides’ primary structure. The filamentous phage M13 is the most 
commonly used vector to create random peptide display libraries (Hamzeh-
Mivehroud, Alizadeh et al. 2013). The rapid isolation of specific ligands by phage 
display is advantageous for many applications including selection of inhibitors for 
the active and allosteric sites of enzymes, receptor agonists and antagonists, 
and G-protein binding modulatory peptides.   Consequently, the phage display 
technique has been extensively employed for the identification of novel in 
vitro and in vivo ligands in different areas such as cancer, vaccine development, 
and epitope mapping. From increasing number of phage display collections, 
numerous new applications have also emerged. For example , selections from a 
variety of different libraries have been used to identify peptide agonists and 
antagonists for receptors (Sidhu 2000), determine binding specificity of domains 
(Sparks, Rider et al. 1996) (Linn, Ermekova et al. 1997), map carbohydrates and 
protein functional epitopes (Sidhu 2000), select antibodies that recognise post-
translational modifications  (Kehoe, Velappan et al. 2006), identifying targets for 
the inhibition of tumour-specific angiogenesis (Zurita, Arap et al. 2003) as well 
as vaccine development (Lidqvist, Nilsson et al. 2008). Most recently however, 
there has been a move towards the use of phage display for the production of 
humanised antibodies and development of new therapeutics, and recently phage 
display has been a driver for the development of clinically useful peptides and 
peptidomimetics  (Brissette, Prendergast et al. 2006). A few selected peptides 
and proteins are in clinical or preclinical stages of development and some are 
reaching the market (Rothe, Hosse et al. 2006).  
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The most common screening method for identifying and isolating ligands that 
bind to the target of interest is based on enriching the phage clones with binding 
affinity for the target by a process called bio panning (Smith and Petrenko 1997, 
Christensen, Gottlin et al. 2001, Pande, Szewczyk et al. 2010).  Bio panning 
involves the following steps: i) Target immobilisation: the purified target of 
interest is immobilised on plates. ii) Phage binding: the phage library is added 
and allowed to bind to the target in conditions suitable for binding. iii) Washing: 
the unbound phages are removed. (iv) Phage elution: due to the high stability of 
filamentous phage, a wide variety of methods can be applied to elute the bound 
phage. Common methods for recovering bound phage are disruption of the 
interaction between the displayed ligand and the target by changing the pH or 
adding a competing ligand, denaturant or protease (e.g. because a protease-
cleavage site has been engineered between the displayed protein/peptide at the 
N-terminus and the coat protein itself). (v) Increasing stringency: the eluted 
phage is then amplified in bacterial cells and bio panning repeated for several 
rounds (usually 3–5). This tends to select against phage with low affinity/ non-
specific binding to the target of interest. (vi) Identification of selectants using 
DNA sequencing. See figure 5-1 below. 
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Figure 5-1 Biopanning. The process for affinity selection of phage-displayed peptide or 
protein: Step 1, target is immobilized and phage library is added.Step 2,washing to remove 
unbound phage. Step 3, elution of bound phage as the result of conformational changes to 
the binding site caused by pH change or other means which disrupts the interaction 
between displayed ligand and the target. Step 4, amplification of eluted phage for next 
round of biopanning.  
 
Random peptide libraries can be constructed using degenerate oligonucleotides 
introduced into the phage genome. Peptide libraries can be generated with 
lengths of the displayed peptides varying from 6 to 30 residues. It is usually 
difficult to predict the optimum length required for the randomized displayed 
peptides as this depends on a number of factors including the folding properties 
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of the displayed peptide, the characteristics of the target, and the purpose of 
investigation (Noren and Noren 2001). The construction of the library is a key 
step because the probability of being able to select ligands that bind the target 
is highly dependent on library diversity and sequence length.  
In this chapter Phage display technology was employed in order to identify any 
novel binding motifs that associate with PDE4. Specifically, we were interested 
in the binding cohort of peptides that were changed by the association of 
Apremilast or Roflumilast to the active site of full length, purified PDE4. Our aim 
was to identify sequences that were differentially regulated by the inhibitors in 
an attempt to find binding motifs that may exist in previously characterised 
signalling proteins. Such information may explain the differences in signalling 
and cAMP generation induced by the different inhibitors. 
Phage display experiments presented in this chapter were kindly performed by 
Tedd Hupp at Edinburgh Cancer research centre. Peptide phage display was 
carried out through three rounds on captured PDE4A4 alone and PDE4A4 with 
either Apremilast or Roflumilast bound using an in-house generated 12-mer 
peptide library. Results were analysed initially by the Tedd Hup group. Over 
5000 peptides bound to PDE4A4 alone and the number of times a peptide 
sequence bound was either increased or decreased when Apremilast or 
Roflumilast was bound to PDE4a4. I analysed the results of the 1st 1000 hits and 
looked for any differences between the inhibitors and whether they increased or 
decreased the number of times each peptide bound to PDE4A4. Figure 5-1 below 
shows an example of some of the peptide sequences identified to either increase 
or decrease binding with inhibitors bound. Peptide arrays were then produced 
(Ruth Macleod, Baillie Lab) using the sequences I identified to validate these 
binding peptides. The peptides were synthesised on continuous cellulose 
membrane supports on Whatman 50 cellulose membranes by Ruth Macleod 
(Baillie lab) using Fmoc ( 9- fluorenylmethyloxycarbonyl) chemistry with the 
AutoSpot-Robot ASS222 (Intavis Bioanalytical Instruments, Berlin).This technique 
has been used extensively by the Baillie lab in the past to map the interfaces 
between interacting proteins such as PDE4D5-barrestin (Sachs, Baillie et al. 
2007), Epac-barrestin(Berthouze-Duquesnes, Lucas et al. 2013) , RACK1-
PDE4D530, PDE8A-RAF131,PDE4-Hsp2032, JNK-barrestin(Li, MacLeod et al. 2009).  
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Figure 5-2 Identification of 12mer peptide sequences that bound PDE 4A4 alone or in its 
ligand bound state with either Apremilast or Roflumilast. Selection of some of the 
sequences identified, where binding affinity was either increased or decreased when 
Apremilast or Roflumilast was bound to PDE4A4 and any differences noted between the 
inihibitors.  
 
478 sequences were identified where there appeared to be differences in 
binding when Apremilast or Roflumilast is bound to PDE4a4. Peptide arrays were 
produced containing these peptide sequences (described in materials and 
methods section) to validate PDE4a4 binding to these sequences. Purified 
PDE4a4 tagged with MBP (Maltose binding Protein) was overlaid on the array 
(described in materials and methods section) as well as an MBP only control and 
then probed using an anti- MBP antibody. The results of the peptide array and 
subsequent densitometry analysis in figure 5-3 confirm the binding of many of 
these peptide sequences to PDE4a4.  
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Figure 5-3 Peptide array containing phage display sequences identified from analysis. A) 
Peptide array was overlaid with either purified PDE4a4-MBP protein or as a control MBP 
only and probed using anti-MBP antibody. Positively interacting peptides generate dark 
spots on the array. B) Bar chart represents densitometry analysis of array shown as % of 
the maximum spot density. 
 
Densitometry analysis was performed on the arrays and spots that were 
identified as over 80% of the maximum spot density were chosen and processed 
using Protein Blast search programme to identify targets in the human proteome 
that may match to these sequences (Altschul, Madden et al. 1997). The results 
for this are in table 5-1 below and show a number of interesting hits where 
Apremilast and Roflumilast may increase or decrease the binding of PDE4a4 to 
certain sequences that are present in proteins. 
 
 
Table 5-1 Blast search results from selected binding spots from Phage array data. The 
number of times each particular sequence is bound to PDE4a4 alone or PDE4a4 bound to 
Apremilast or Roflumilast is shown in the left hand columns. 
 
There are a number of interesting results from the blast searches, one example 
being that sequence DAACSSLGCDLG only appears to bind to PDE4a4 in the 
presence of Apremilast. One of the blast hits from this for example is a Keratin 
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associated protein. Keratin belongs to a family of fibrous structural proteins and 
is the protein that protects epithelial cells from damage or stress. Studies have 
shown that it is expressed aberrantly in the suprabasal keratinocytes of psoriatic 
lesions, compared to in normal epidermis (Fu and Wang 2012). 
More interestingly however, some of the blast hits were proteins found in the 
Ubiquitin protease system, for example TRIM1 (an U3 Ubiquitin ligase) and USP42 
(Ubiquitin specific protease 42) as well as some F box proteins which form part 
of the SCF ubiquitin ligase complex. This is interesting as some F-box proteins 
are known to be up regulated in some cancers.  
As an additional screen, based on a second set of analysis of phage peptide hits 
binding to PDE4a4 was screened for evidence of the top 10 consensus site motifs 
using an online consensus motif tool known as MEME or Multiple Em for Motif 
Elicitation  (Bailey, Boden et al. 2009)  MEME discovers novel, ungapped motifs 
(recurring, fixed-length patterns) in nucleotide or protein sequences. 
MEME splits variable-length patterns into two or more separate motifs.  The first 
1000 peptides were sorted and entered into the online tool (figure5-4). Once 
identified each motif sequence was then synthesised on peptide array as before 
courtesy of Ruth Macleod (Baillie lab) (figure5-5). Subsequently, any hits from 
the peptide arrays were then entered into  protein Blast search tool to identify 
any targets in the human proteome (Altschul, Madden et al. 1997). An example 
of some of the blast results are shown in table 5-2.   The motifs found were 
again associated with some Ubiquitin proteins. For example being HERC2 which 
is an E3 Ubiquitin protein ligase and Cul7, a component of an E3 ubiquitin ligase 
complex.  This is interesting as peptide array has been used by the Baillie lab to 
successfully identify ubiquitination sites on PDE4D5 (Li, Baillie et al. 2009). 
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Figure 5-4 Identification of consensus site motifs (a) 1000 peptides that were identified as 
binding to PDE4a4 were processed using  MEME (B) to identify  consensus motifs 
(http://meme.nbcr.net/meme/cgi-bin/meme.cgi). The panel in A) represents data from the 
one of the core motifs identified from the 12mer peptide library as GYMPVVS which is also 
shown in B). Example of a consensus site motif that can be developed from the deep 
Sequencing using MEME.  
 
 
Figure 5-5 PDE4a4 binding to peptide arrays consisting of peptide spots containing 
identified motifs. Positively interacting peptides generate dark spots, while those that do 
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not interact leave blank spots. Positive interactions were identified on motifs 1,2,4,7 and 8 
on the array.  
 
 
 
Table 5-2  Blast results from identified binding motifs.  
 
5.2 Discussion 
The data in this chapter has led to the discovery of novel binding motifs that 
associate with PDE4A4, some of which seem to differentially regulated by 
Apremilast and Roflumilast (Table 5-1). The most interesting discovery was that 
many of the motifs are found in proteins that are known to participate in the 
Ubiquitin Proteosome System (UPS). 
The Ubiquitin Proteasome System (UPS) is the main route for targeted 
destruction of cellular proteins by the proteasome (Hershko 2005) (Ciechanover 
2005).  It plays a role in protein synthesis and turnover, cell cycle progression, 
protein localisation, trafficking,  DNA repair, sodium channel function, 
regulating immune and inflammatory responses as well as cellular response to 
stress (Ciechanover 1998, Ciechanover 2006) (Malik, Price et al. 2006). 
Ubiquitination marks proteins for ATP-dependent degradation by the 26S 
proteasome. Aberration of this system can lead to the dysregulation of cellular 
homeostasis and the development of multiple diseases such as cancer (Adams, 
Palombella et al. 2000, Hideshima, Bradner et al. 2005, Spano, Bay et al. 2005), 
neurodegenerative diseases (Ciechanover and Brundin 2003), cardiovascular 
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disease (Herrmann, Ciechanover et al. 2004, Versari, Herrmann et al. 2006, Zolk, 
Schenke et al. 2006) as well as inflammatory and autoimmune diseases (Mountz 
2002, Colmegna, Sainz et al. 2005).  Therefore the UPS provides a rich source of 
targets for intervention for disease. 
The UPS is thought to be involved in the development of inflammatory and 
autoimmune diseases through multiple pathways, including MHC-mediated 
antigen presentation, cytokine and cell cycle regulation, and apoptosis 
(Colmegna, Sainz et al. 2005) and is thought to play a role in inflammatory 
arthritis, psoriasis,  asthma, inflammatory bowel disease and autoimmune 
thyroiditis (Elliott, Zollner et al. 2003).  Therefore the UPS has the potential to 
be an exciting novel therapeutic target for the treatment of inflammatory and 
autoimmune diseases and perhaps PDE4 inhibitors such as Apremilast might be 
useful in this sphere as PDE4s are known to be ubiquitinated.  (Li, Baillie et al. 
2009) found that PDE4D5 is ubiquitinated, via the discovery of a Ubiquitin 
interacting motif (UIF) present in the C- terminal portion of PDE4D5. It was also 
found that the β-arrestin-sequestered E3 ligase, Mdm2 was critical for this 
ubiquitination.  These UIMs have an important role in directing the 
ubiquitination of many substrate proteins (Hoeller, Hecker et al. 2007) (Li, 
Vadrevu et al. 2010).  
It is interesting that the ubiquitin/proteasome pathway can be regulated via 
cAMP-signaling. For example, studies have shown that in vitro and in vivo 
elevation of cAMP in rodent skeletal muscle decreased proteasome activity, 
ubiquitin-protein conjugates, and the levels of atrogin-1, an E3 ubiquitin-ligase 
that plays a role in muscle atrophy (Goncalves, Lira et al. 2009). Furthermore, 
inhibition of PDE4 with rolipram, down regulated proteasome activity and 
suppressed up-regulation of the E3 ubiquitin-ligases atrogin-1 and MuRF-1, 
induced in rat skeletal muscle by fasting (Lira, Goncalves et al. 2011) . The use 
of cAMP-PKA signalling to reduce proteasome activity as well as the levels of the 
two a forementioned E3 ubiquitin-ligases may constitute a novel potential 
therapeutic approach to treat skeletal muscle atrophy (Lira, Goncalves et al. 
2011).  
Apremilast and Roflumilast treatments reduce binding of PDE4A4 to a TRIM1 
peptide (figure 5-1). TRIM1is an E3 ubiquitin ligase. The link between PDE4 is 
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exciting because the E3-ligase TRIM family of proteins are known to regulate 
signalling pathways triggered by innate immune pattern-recognition receptors. 
(Versteeg, Rajsbaum et al. 2013) demonstrated that many TRIM proteins are 
important regulators of the innate immune response and that regulatory TRIMs 
are likely to act at different steps during the induction of IFN and pro-
inflammatory cytokines.  
One of the other motifs found via the MEME programme that interacts with 
PDE4A4 belongs to HERC2, another E3 Ligase. This is interesting as it has been 
shown that HERC2 targets BRCA1, a breast cancer suppressor, for ubiquitination 
and degradation. HERC2 expression has also been found in breast epithelial cells 
and breast carcinomas which suggests that it may play a role in breast 
carcinogenesis (Versteeg, Rajsbaum et al. 2013) . Perhaps, there is a yet to be 
discovered input from the cAMP signalling system in the function of HERC2 in 
cancer and if so, Apremilast and Roflumilast may also be useful in the future for 
treatment for certain cancers via this signalling axis. 
A rising theory in the protein science field has been the concept that the 
majority of amino acid sequences in higher eukaryotes are intrinsically 
disordered and this allows for specific and rapid adaptation to signalling change 
required for complex multi-cellular metazoan life (Tompa 2012). It is now 
recognized that a large proportion of protein-protein interactions are not driven 
necessarily just through globular domains. There is increasing understanding that 
protein-protein interaction can be driven through small peptide motifs that form 
critical interfaces in signalling proteins and that these high affinity protein-
protein interactions can be disrupted by small molecules or peptide mimetics 
(Jubb, Higueruelo et al. 2012). Low throughput peptide phage libraries have in 
fact given rise to novel peptides that bind with a high affinity to a target protein 
(Stevens, Lin et al. 2009, Phan, Li et al. 2010).  
The data presented in this chapter has provided evidence that Apremilast and 
Roflumilast can either enhance or decrease the binding of PDE4A4 to specific 
peptide sequences or motifs that are found in a variety of proteins in the human 
proteome, most interestingly Ubiquitin-related proteins. The information 
presented here is preliminary but may be used in the discovery of a novel 
binding partners for PDE4 or a new role for PDE inhibition in disease. The Baillie 
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lab has optimized an assay workflow to discover disruptor peptides and have two 
patents on such agents. Firstly N and C truncations are used to define the 
“minimum” core binding motif. Each residue in the “core motif” is sequentially 
substituted with each of the twenty naturally occurring amino acids or a range of 
apt synthetic non-native replacements. Iterative rounds of substitution of amino 
acids in key positions that demonstrate enhanced binding, eventually results in a 
disruptor peptide that has a higher affinity for the protein of interest than does 
its protein partner in the complex. The final stage is to chemically “cap” the 
disruptor peptide to further enhance affinity and stability. The peptides can be 
rendered cell permeable (for experiments involving cell, tissue or animals) by 
addition of a stearate group at the N-terminal site. Amino acid substitution scan 
and truncation mutagenesis can be used to optimize the binding of aptamers to 
each protein of interest. 
Phage display therefore, represents an important approach in the development 
of peptides and peptidomimetics for therapeutics in the future. The information 
gathered in this chapter therefore will be useful for further study and could lead 
to the possible development of a new peptidomimetic for use in disease 
treatment and perhaps further information that could lead to the repositioning 
of Apremilast to other diseases such as cancer.
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6 Final Discussion and Future Perspectives 
cAMP signalling  plays a critical role in a variety of biologic responses within cells 
such as inflammation, apoptosis and lipid metabolism (Tasken and Aandahl 
2004). In the presence of extracellular inflammatory signals, G protein coupled 
receptors bind to a variety of ligands and activate adenlyl cyclase, which 
promotes the production of cAMP (Serezani, Ballinger et al. 2008).  CAMP 
interacts with effector proteins such as PKA and Epac to induce changes in gene 
expression (Zambon, Zhang et al. 2005) and promote downstream physiological 
events. Activation of PKA results in the phosphorylation of CREB and ATF-1, with 
concomitant inhibition of the activity of other promoters such as NFκB (Schafer 
2012). Effects on CREB, ATF-1 and NFκB lead to decreased expression of 
cytokines and other inflammatory mediators as well as the increased expression 
of anti-inflammatory mediators (Jimenez, Punzon et al. 2001, Serezani, Ballinger 
et al. 2008). Therefore, cAMP helps to maintain immune homeostasis by 
modulating the production of pro and anti- inflammatory mediators. On balance, 
increased cAMP levels leads to a reduction in inflammatory signalling.  
Intracellular levels of cAMP are controlled partly by production via adenylyl 
cyclase, and partly by degradation via cyclic nucleotide phosphodiesterases 
(PDEs), which are the only enzymes that degrade cAMP (Conti and Beavo 2007). 
Twenty one genes encoding PDEs have been identified in the human genome, 
and these have been grouped into 11 PDE families based on their amino acid 
sequence, structure, enzyme kinetics, modes of regulation and tissue 
distribution (Conti and Beavo 2007, Houslay 2010). Thus, as central regulators of 
the intracellular levels of cAMP, several PDEs have been targeted for therapeutic 
intervention in  diseases such as congenital heart failure (Uretsky, Generalovich 
et al. 1983), erectile dysfunction (Boolell, Gepi-Attee et al. 1996), depression 
and schizophrenia (Siuciak 2008, Zhang 2009) and in particular, PDE4, for its role 
in inflammatory disease. 
PDE4 plays a particularly important role in inflammatory and immunomodulatory 
cells and is ubiquitously found in inflammatory cells including mast cells, 
eosinophils, neutrophils, T cells, macrophages as well as structural cells such as 
sensory nerves, epithelial , smooth muscle cells and keratinocytes (Torphy 1998) 
PDE4 has been implicated in a number of inflammatory diseases, including 
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Psoriasis, psoriatic arthritis, Ankylosing spondylitis, Chronic Obstructive 
Pulmonary disease (COPD) and Rheumatoid Arthritis (Lipworth 2005, McCann, 
Palfreeman et al. 2010). PDE4 inhibition elevates intracellular levels of cAMP 
which then results in the down regulation of inflammatory responses by reducing 
the expression of TNFα, IL-23 and other pro inflammatory cytokines, whilst 
increasing anti-inflammatory cytokines such as IL-10 (Houslay, Schafer et al. 
2005, Schafer 2012). Therefore PDE4 is of interest as a therapeutic target and a 
significant number of PDE4 inhibitors have been developed and are currently 
being investigated for their use in inflammatory disorders such as asthma, 
chronic obstructive pulmonary disease (COPD), psoriasis, inflammatory bowel 
disease and rheumatoid arthritis (Souness, Aldous et al. 2000, Page and Spina 
2011). Currently marketed PDE4 inhibitors include Apremilast (Otezla®, Celgene 
corporation)(2014) approved in the United States for treatment of patients with  
Psoriatic Arthritis (PsA) and Roflumilast (Daliresp®, Forest Pharmaceuticals) for 
the treatment of Chronic obstructive pulmonary disease (COPD). 
The studies in this thesis were conducted to directly compare Apremilast with 
Roflumilast, in order to substantiate the differences observed in the molecular 
and cellular effects of these compounds, and to search for mechanisms that 
underpin differentiating effects. 
cAMP is a freely diffusible molecule, and could potentially flood the interior of 
the cell, leading  to the indiscriminate activation of multiple downstream 
effectors (Houslay, Baillie et al. 2007). It is now accepted that this situation is 
avoided by the compartmentalisation of cAMP signals. Discrete micro domains of 
cAMP, created by the actions of phosphodiesterases, have been directly 
visualised in live cells using genetically encoded cAMP sensors (Zaccolo and 
Pozzan 2002). PKA is anchored to specific sub cellular targets by its interaction 
with AKAPs, therefore only particular pools of PKA are exposed to activating 
concentrations of cAMP at any one time (Baillie 2009). Therefore, signals from a 
single second messenger can result in the activation of distinct signal 
transduction pathways, and diverse physiological responses (Buxton and Brunton 
1983). 
 
154 
 
154 
 FRET-based cAMP sensors have given considerable insight into the 
compartmentalisation of cAMP and proteins involved in cAMP signalling 
(Smith,Langeberg et al. 2006; Baillie 2009; Houslay 2010).  
In the first part of my thesis (Chapter 3) I used genetically encoded, FRET-based 
cAMP sensors to assess dynamic changes in cAMP levels in living cells as a 
consequence of challenge with Apremilast and Roflumilast to determine whether 
Apremilast and Roflumilast triggered similar cAMP changes at multiple cellular 
locations. The data provided a unique opportunity of determining whether there 
is any selectivity of action between Apremilast and Roflumilast in regulating 
specific cAMP pools in cells. The data showed for the first time that Apremilast 
and Roflumilast do appear to regulate different pools of cAMP within the cell, 
which may cell type specific. For example, my data showed that in HEK 293 and 
RASFs, Apremilast seems to induce significantly higher levels of cAMP compared 
to Roflumilast in the cytoplasm. The opposite was found in Jurkat T cells where 
Roflumilast elevated higher levels of cAMP compared to Apremilast. Apremilast 
and Roflumilast also exert differential effects in the PKAR1 and PKAR11 which 
are associated with the cytoplasm and membrane compartments respectively. 
The most interesting difference revealed from the FRET experiments however, 
was that in the nucleus of RASFs, Roflumilast significantly elevates cAMP levels 
whereas Apremilast seems to have little or no effect.  
It is clear that cAMP signalling in the nucleus is largely under researched. 
However, PKA signalling in the nucleus is known to produce distinct biological 
effects from that of other cellular compartments, for example a study by (Haj 
Slimane, Bedioune et al. 2014) used FRET probes targeted to the cytoplasm and 
nucleus to study spatiotemporal dynamics of nuclear cAMP and PKA activity in 
adult cardiac myocytes and revealed a differential integration of cytoplasmic 
and nuclear PKA responses to β-AR stimulation. Therefore, the specific elevation 
of cAMP by Apremilast and Roflumilast in different cell types may lead to 
different biological outcomes. An illustratioin of this was shown recently when 
clear differences in gene expression were noted following treatment with 
Apremilast and Roflumilast (Schafer, Parton et al. 2014). Gene chip analysis 
identified that numerous gene sets were regulated by Roflumilast but not 
Apremilast. It was noted that while Apremilast gene regulation was focused on 
the inflammatory and immune response, cytokine and chemokine pathways and 
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stress response genes, Roflumilast exhibited a wider pattern of gene regulation 
that included ribosomal genes, protein translation and disassembly, and the viral 
response gene. 
Data also showed that Apremilast and Roflumilast exerted differential effects in 
the PKAR1 (cytoplasm) and PKAR11 (membrane) compartments of RASFs. This 
was expected due to the differential binding of these inhibitors to the ‘high’ and 
‘low’ affinity forms of PDE4A4. However other insights into this phenomenon will 
be provided in the future from molecular modeling of PD4A4 with each inhibitor 
bound in the active site (PH Schafer, personal communication).  It appears 
Apremilast occupies a different space within the binding pocket to Roflumilast. 
Apremilast influences the position of  Y274, T278, and F279 of the UCR domain 
of PDE4A4 whereas Roflumilast does not. This could explain why Roflumilast 
binds more tightly to the high affinity conformer of PDE4A4, but Apremilast 
binds more tightly to the low affinity conformer. The membrane vs cytosolic 
distribution could then explain these cAMP compartmentalisation differences. 
This discrepancy in ligand binding may also contribute to mechanistic 
differences. During my studies I made PDE4A4 constructs with residues Y274, 
T278 and F279 mutated to alanine. However, I was unable to do further studies 
with these mutants due to lack of time. The next step for these studies then, 
would be to use  these mutants along with wild type PDE4A4 to perform 
phosphodiesterase activity assays, which is a two step radioactive assay of cAMP 
hydrolysis, previously described by (Marchmont and Houslay 1980). These assays 
could be used to test the wild type and mutant PDE4A4s in both the membrane 
and cytosolic fractions of cells to see if this selectivity difference in the high and 
low affinity conformers would disappear, and perhaps then explain 
compartmentalisation differences. 
Apremilast and Roflumilast are known to mediate their effects in monocytes and 
T cells via PKA and NF-κB pathways (Kwak, Song et al. 2005, Schafer, Parton et 
al. 2014). In the second part of the thesis (Chapter 4), I focused on study of the 
signalling differences caused by Apremilast and Roflumilast by using a number of 
different biochemical techniques. I found that Apremilast increases the 
phosphorylation of a number of distinct PKA substrates suggesting possible 
signalling differences compared to Roflumilast. 
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In the first part of this chapter I found that Apremilast and Roflumilast both 
significantly increase CREB phosphorylation in a cell type specific manner. For 
example, Apremilast and Roflumilast both significantly increase CREB 
phosphorylation in Jurkat T cells and U937 cells in the presence of forskolin. 
Whereas, Apremilast along with forskolin treatment in HEK cells increases the 
phosphorylation of CREB but not Roflumilast in these cells suggesting CREB 
phosphorylation induced by these inhibitors is cell type specific. I also found that 
both inhibitors increase the phosphorylation of VASP at Ser157 (a known PKA 
substrate) in U937 cells in the presence of forskolin.  However, in HEK cells only 
Apremilast in the presence of forskolin increases VASP phosphorylation 
significantly at Ser157.  
This data is consistent with reports that Apremilast and Roflumilast activate the 
PKA pathway as it is known that PDE4 inhibitors increase intracellular cAMP 
which leads to the phosphorylation and activation of PKA (Schafer, Parton et al. 
2010), which results in the up regulation of CREB and down regulation of NFκB-
dependent genes (Houslay, Schafer et al. 2005, Schafer, Parton et al. 2010).  
Collectively data from Kinase substrate and Reverse Phase protein arrays showed 
that only Apremilast increases the phosphorylation of Fyn Y530 and rpS6 
Ser240/244 in RASFs and HEK 293 cells, whereas Roflumilast does not 
significantly increase the phosphorylation of either of these proteins.  Analysis 
performed on the S6 Ribosomal Pathway in HEK 293 cells confirmed this finding 
by showing that both inhibitors increase the phosphorylation of S6 Kinase p70 
and MAPK both which lead to phosphorylation of rpS6.  
Further analysis of the rpS6 pathway using pharmacological inhibitors led to the 
hypothesis that Apremilast and Roflumilast may be regulating different pools of 
PKA as Apremilast only increases the phosphorylation of rpS6 Ser240/244 
significantly, which was found to be mediated via PKA. While both Apremilast 
and Roflumilast increase the phosphorylation of rpS6 at Ser235/236, which is 
known to be phosphorylated by PKA directly at this site (Moore, Xie et al. 2009). 
It is likely that Apremilast-induced increases in the phosphorylation of Fyn, is 
contributing to the phosphorylation of rpS6 at Ser240/244 as this is found 
downstream of Fyn in this pathway.  
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This finding could be significant as rpS6-pS240 is found to be expressed in 
lesional areas of skin biopsies from patients (Abreu-Velez, Googe et al. 2013) 
and rpS6-pS240 is thought to influence protein synthesis and/or with the 
inflammatory/anti-inflammatory immune response in patients affects by skin 
diseases (Abreu-Velez, Googe et al. 2013).  
The combination of Apremilast triggered increases in phosphorylation of rpS6 
Ser240 along with the known increases in anti-inflammatory mediators is perhaps 
the reason that Apremilast has been so successful in psoriasis trials (Papp, 
Kaufmann et al. 2013). This information along with recent data suggesting a new 
function for rpS6 phosphorylation in cancer biology (Khalaileh, Dreazen et al. 
2013) opens up a possible repositioning space for Apremilast in the future.  
A paper recently published by PH Schafer et al (Schafer, Parton et al. 2014) 
studied the pharmacodynamic properties of Apremilast and it showed that 
Apremilast had no other identified binding targets other than PDE4. The paper 
also confirmed that Apremilast mediates its effect in monocytes and T cells via 
PKA and NF-κB pathways. It modulates gene expression in monocytes, reduces 
interferon-α production induced by TLR9 signalling in dendritic cells and inhibits 
cytokine production in T cells. 
In the final chapter in my thesis I employed the use Phage Display and the data 
presented provided evidence that Apremilast and Roflumilast can either enhance 
or decrease the binding of PDE4A4 to specific peptide sequences or motifs that 
are found in a variety of proteins in the human proteome, most interestingly 
Ubiquitin-related proteins. The data is preliminary but may be used in the 
discovery of a novel binding partner for PDE4 or a new role for PDE inhibition in 
disease.  
6.1 Final Conclusion 
Apremilast and Roflumilast are both PDE inhibitors with a high specificity and 
similar affinity for PDE4 (vs the other 10 PDE families).  Work has shown that 
both drugs do not show a preference for any of the 25 or so isoforms of PDE4, 
and hence should work in a similar fashion. Studies looking at cAMP production 
following treatment of both compounds highlighted the fact that there is a 
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differential cAMP response that may impinge on downstream signalling events. 
Using cutting-edge biochemical techniques, I set out to investigate the 
molecular nature of this difference, and my thesis supports the notion that there 
are not only differences in cAMP dynamics but this also leads to differential PKA 
substrate phosphorylation and a possible change in PDE4-binding partner profile. 
These variances are likely due to small but specific differences in binding mode 
between the two isoforms. My work has provided a unique snapshot of the 
complexity of the cAMP signalling system and is the first to directly compare 
action of the two approved PDE4 inhibitors in a detailed way. The work 
contained in this thesis should act as a stepping-stone for other work that seeks 
to better investigate the link to PDE4s and the UPS and to better define the 
significance of rpS6 Ser240/244 phosphorylation induced specifically by 
Apremilast 
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